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Abstract  
Muscle atrophy is a feature of many chronic diseases and contributes to both 
morbidity and mortality, emphasising the importance of understanding the 
molecular pathways involved. Zinc finger protein 216 (ZNF216) is an atrogene, a 
gene which is up-regulated during and directly mediates skeletal muscle atrophy, 
and encodes the ubiquitin (Ub) receptor protein ZNF216. Herein it is 
demonstrated that ZNF216 mRNA levels increase in the extensor digitorum 
longus (EDL) in a lipopolysaccharide (LPS)-infusion rat model of muscle atrophy, 
relative to saline control. However, combined administration of low level 
dexamethasone (Dex) with LPS, although sparing muscles from atrophy, did not 
blunt ZNF216 expression which parallels previous observations for the atrogenes 
muscle atrophy F-box protein (MAFbx) and muscle RING-finger 1 (MuRF1). 
ZNF216 expression levels were further elevated in biceps femoris muscle in rats 
dosed with the statin drug simvastatin (in which severe muscle damage and 
atrophy occurs), relative to control rats. The ZNF216 ǯUb-binding ability 
and its reported association with the 26S proteasome indicates it may shuttle 
proteins targeted for degradation to the proteasome as part of the atrophy 
programme. We utilised immobilised recombinant ZNF216 protein and its Ub-
binding Znf_A20 domain alone to capture Ub-modified proteins from rat skeletal 
muscle that may 	 ? ? ?ǯ. Bound proteins specifically 
eluted by deubiquitination were identified via liquid chromatography tandem 
mass spectrometry (LC-MS/MS) and included adenylate kinase 1 (AK1) and actin, 
both previously proposed as substrates of MuRF1. However, ion scores for all 
candidates were below the accepted threshold of significance and 
immunoblotting failed to validate LC-MS/MS data. This approach also revealed an 
increase in a low molecular weight Ub-positive protein from EDL muscle after 
24hrs of LPS infusion. Retrospective analysis revealed this Ub-positive protein 
was consistently captured in other experiments and confirmed by protein MS and 
immunoblotting to represent an unmodified and unanchored (i.e. not attached to 
a substrate) K48-linked Ub dimer. Subsequent capture of the Ub dimer using the 
Znf_UBP domain of isopeptidase T (isoT), a Ub-binding domain selective for the 
free C-terminus of Ub, confirmed the dimer was unanchored and also revealed a 
ladder of longer endogenous unanchored poly-Ub chains. Optimised affinity 
capture conditions has afforded the first opportunity to purify longer free poly-
Ub chains and perform the initial molecular analyses of endogenous unanchored 
poly-Ub purified from in vivo sources. 
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CHAPTER 1 
General Introduction 
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1.1. Introduction 
Skeletal muscle atrophy describes a reduction in muscle size that often 
accompanies other disease states; associated weakness and reduced muscular 
function makes this a debilitating condition. This introduction highlights the 
importance of understanding the molecular mechanisms which underline 
skeletal muscle atrophy, and describes the current understanding of the proteins 
and pathways involved. One such protein that has recently been identified for its 
role in muscle atrophy is zinc finger protein 216 (ZNF216). We note strategies 
that have been previously employed to proteomically analyse ubiquitinated 
proteins, and conclude with current information on ZNF216, the ubiquitin 
receptor we have characterised within this thesis via its expression and 
interactions. 
 
1.2. Clinical importance of skeletal muscle atrophy 
The onset of skeletal muscle atrophy in combination with life threatening 
diseases, such as cancer and AIDS, is associated with longer recovery time and 
increased mortality [1, 2]. Pajak et al. 2008 state that almost a third of all cancer 
deaths are due to muscle cachexia, which causes cardiac and respiratory failure 
[3]. Muscle wasting may also be induced by catabolic states such as sepsis [4-6], 
denervation [7-10] and immobilisation or disuse [11-13], illustrating the various 
triggers of atrophy. Hasselgren et al. 2005 reviews various aspects of muscle 
atrophy initiated by sepsis, and briefly reviews the clinical implications, which 
include loss of ambulation and pulmonary complications [14]. Disuse induced 
muscle atrophy may also be relevant to astronauts, who suffer muscle loss during 
space flight due to the lack of gravity, or more commonly is experienced by 
3 
  
inactive patients who are hospitalised [15]. Loss of muscle strength and mass is ǡǲǳ
detail elsewhere [16, 17]. Sarcopenia differs from other atrophy types as multiple 
factors induce this condition, through largely unknown mechanisms, which have 
been suggested to, in part, involve apoptosis, as reviewed in more depth by 
Marzetti et al. 2010 [17].  
 
Muscle wasting has traditionally been recognised by reduced muscle size, 
induced by increased levels of protein degradation, coupled with down-regulated 
protein synthesis. In the case of fasting induced skeletal muscle atrophy, protein 
degradation into individual amino acids has been suggested as an advantage for 
providing a source of energy when carbohydrates and fats are at low levels. The 
reason for muscle atrophy onset under other conditions is unclear, as no 
apparent physiological advantage is evident. The muscle atrophy-inducing effect 
of immobilisation has been reversed by exercise, but this cannot be applied to 
muscle wasting caused by other triggers [18] and to date no drug has been 
produced that specifically inhibits atrophy onset.  
 
Studies have previously focused on cytokines released that trigger muscle cells to 
shrink, but clearly there can be a number of upstream pathways that result in 
muscle wasting. Biochemical and genetic studies have revealed that muscle 
atrophy is not a random chaotic event, but that specific proteins are upregulated ǲǳǡ ?Ǥ ?Ǥ
the initial biochemical pathways have been relatively well characterised, the 
downstream events, which multiple modes of skeletal muscle atrophy may share 
in common, are yet to be fully elucidated. By clearly characterising these 
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pathways, and identifying specific targets required for muscle atrophy under all 
conditions, potential drug targets may be identified that could ultimately improve 
the prognosis of patients affected by muscle wasting. 
 
1.3. Models of skeletal muscle atrophy 
Ultimately, we are interested to understand modes of human skeletal muscle 
atrophy. However, while human studies involving immobilisation can be 
performed, atrophy triggers such as cancer and sepsis cannot be induced in 
humans. Samples from patients with cancer or from patients in intensive care are 
useful for validating potential mediators of skeletal muscle atrophy [19], but 
there can by multiple factors that vary between patients. Thus, animal models are 
of importance because these factors can be controlled for, as muscle atrophy can 
be induced, something that is ethically impossible to do in humans. The 
drawbacks of animal models arise as there are some differences in physiology 
between species. In addition there is some debate over the age of rats used for 
models, as juveniles may respond differently to atrophy stimuli.  
 
Tumours can be introduced in animals for cachexia models, including C26-B 
adenocarcinoma implantation in mice [20] and Yoshida AH-130 ascites hepatoma 
inoculation in rats [21]. Models of sepsis in animals vary from infecting animals 
with live bacteria via cecal ligation and puncture (CLP) or by intravenously 
infusing animals with lipopolysaccharide (LPS), collected from Gram-negative 
bacteria that express LPS. LPS is recognised by a core tri-molecular complex of 
cluster of differentiation 14/toll-like receptor 4/MD2 (CD14/TLR4/MD2) in 
mammalian macrophage cells and induces anti-bacterial responses. Similarly, 
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studies into LPS-induced atrophy in C2C12 (mouse myoblast cell line) myotubes 
indicate that LPS is recognised by TLR4 and mediates downstream events [22]. 
The molecular events surrounding LPS recognition involve a number of protein-
protein interactions, contrary to initial theories which regarded innate immune 
responses, such as LPS recognition, to be less complex than the acquired immune 
response, as discussed in more detail in Triantafilou & Triantafilou 2005 [23]. 
Sarcopenia models have primarily been based on Caenorhabtidis elegans [24, 25], 
a well established and useful model, based on its short life cycle, low 
maintenance costs and small size (1mm in length). Additionally, C. elegans 
genome is relatively small and fully characterised and shares considerable 
homology with that of mammals, allowing identification of sarcopenia related 
genes through RNA interference (RNAi) in worms [26]. However, one group 
published findings supporting the suitability of the Rhesus monkey as a non-
human primate model of sarcopenia [27], which has subsequently been utilised 
and produced data that suggested caloric restriction lessened age-related 
changes in Type II muscle fibres and fibre cross-sectional area in aging rhesus 
monkeys [28].  
 
Diminished or ablated signalling from the nervous system to muscle triggers 
atrophy, thus animal models of denervation involve interrupting signalling to 
skeletal muscle via severing of the sciatic nerve. Animal models allow controls to 
be introduced and can reveal genes and proteins that are upregulated or required 
in different modes of atrophy. The human homologs of these candidates can then 
be assessed for their involvement in patients with muscle atrophy, to validate 
them in a human situation [19]. 
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1.4. Sensitivity to muscle atrophy is dependent on muscle type and 
species 
Skeletal muscle, which can be consciously controlled and is sometimes referred ǲǳǡǲ-ǳǲ-ǳ
muscle, containing type I or type II fibres, respectively. As the names suggests, 
slow-twitch muscle contracts slowly, metabolising aerobically and thus requiring 
a rich blood supply, hence its characteristic red appearance. Slow-twitch muscle 
contains numerous mitochondria for aerobic respiration, thus requiring large 
numbers of capillaries to deliver enough blood to meet the high oxygen demand. 
Fast-twitch muscle contracts rapidly and can produce a greater force than that of 
slow-twitch muscle. Fast-twitch muscle contains further subtypes IIa, IIb and IIx. 
Subtype IIa is similar to slow-twitch muscle in having a rich blood supply and 
large numbers of mitochondria and thus metabolising aerobically, but contracts 
more quickly than type I fibres. However, this subtype is rare in humans, in which 
the fastest fibre is type IIx. Unlike type I/type IIa fibres, this subtype metabolises 
anaerobically utilising glycolysis [29], contracting at a faster rate but exhausting 
sooner. Type IIb fibres similarly respire anaerobically, and are the major 
constituent of rodent skeletal muscle. Type IIx and IIb have considerably less 
mitochondria than types I and IIa, thus requiring less blood and having a paler 
appearance.  
 
Severity of muscle atrophy is predominantly measured by percentage muscle 
loss. An alternative method for measuring the extent of muscle atrophy is by 
calculating changes in protein-to-DNA ratio, as a method for determining protein 
catabolism [30-32]. However, this ratio is less frequently measured than 
percentage muscle weight loss.  
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The severity of muscle wasting, as occurs in different modes of skeletal muscle 
atrophy, varies depending on muscle type. In a fasting-induced model of atrophy 
in rats, the authors noted a difference in the severity of wasting between muscle 
types, measured by weight loss in fast-twitch plantaris muscle (primarily type 
IIa) relative to slow-twitch soleus muscle (type I) [33]. Plantaris muscle was 
more sensitive to wasting relative to soleus, the former exhibiting increasing 
weight loss from one to three days of fasting, whilst weight loss of soleus muscle 
was first observed on the third day and to a lesser extent than that of plantaris 
muscle. This was attributed to a difference in autophagy signalling between 
different muscle types. The lysosomal based catabolic process autophagy 
contributes to some modes of muscle atrophy, as discussed later in Section 1.7. 
Conversely, a group utilising a denervation induced atrophy model in rats (in 
which the sciatic nerve was crushed), observed that slow-twitch soleus muscle 
was more sensitive to wasting than fast-twitch extensor digitorum longus (EDL) 
muscle (type IIb), when comparing muscle loss in denervated/innervated limbs 
[34]. This study was designed to measure the sparing effect of the proteasome 
inhibitor Velcade in a denervation model of atrophy, and the authors noted 
greater sparing of slow-twitch muscle upon Velcade treatment relative to fast-
twitch muscle, implicating the involvement of the ubiquitin proteasome system 
(UPS) during denervation induced atrophy, primarily in soleus over EDL muscle. 
The UPS is one of the cells major processes responsible for degradation of 
cellular proteins (further details on the UPS later). A similar observation was 
made in a rat unloading model of muscle atrophy, in which soleus muscle was 
more severely wasted upon unloading relative to unloaded EDL muscle [35]. The 
authors also noted that unloaded soleus muscle had significantly higher ubiquitin 
levels relative to control, but no significant difference was observed in unloaded 
EDL muscle relative to control.  
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It would appear, from these models, that muscle atrophy involving the UPS 
affects slow-twitch muscle preferentially to fast-twitch muscle. However, earlier 
studies on a CLP induced sepsis model of muscle atrophy in rats provided 
evidence of UPS involvement in this mode of atrophy specifically in fast-twitch 
EDL relative to slow-twitch soleus, in which ubiquitin mRNA levels and energy-
dependent protein breakdown were observed to increase only in the former [6]. 
This highlights the differences between different models of skeletal muscle 
atrophy, and emphasises the importance of studying multiple modes of wasting 
to clarify their different molecular regulation. Some muscles contain mixed fibre 
type, containing both fast-twitch and slow-twitch fibres, such as gastrocnemius 
(contains type I, IIa, IIx and IIb). Similarly to observations in other muscles, 
denervation induced muscle atrophy led to increases in ubiquitin-protein 
conjugates and ATP-dependent proteolysis in gastrocnemius muscle [36]. 
 
Skeletal muscle atrophy studies heavily rely on rodent models of atrophy. The 
differences in muscle fibre types between humans and rodents complicates the 
use of these animals in skeletal muscle atrophy models; as noted earlier, rodents 
predominantly contain type IIb skeletal muscle, whilst the fastest contracting 
human fast-twitch muscle is type IIx. Murton et al. 2008 reviews the involvement 
of the UPS during human skeletal muscle atrophy, and discusses differences 
between animal models and observations in humans [37]. The authors note 
differences between the physiology of rodents and humans, and the differences 
in severity of animal models and human studies, in which the former are more 
severe conditions that may induce stronger responses than that observed in 
humans. This emphasises the importance of validating the role of human 
homologs of atrophy related genes in rodent models, and vice versa. 
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1.5. Understanding molecular mechanisms that instigate muscle 
wasting 
The onset of skeletal muscle atrophy may be triggered by multiple stimuli, which 
may directly initiate atrophy signalling pathways in skeletal muscle, or 
alternatively stimulate immune cells, including macrophages, to release cytokines 
that subsequently induce an atrophy response in muscle cells. As extensively 
reviewed in Pajak et al. 2008, multiple inflammatory cytokines may promote 
downstream muscle atrophy signalling, including tumour necrosis factor alpha 
(TNF  and interleukin-1 (IL-1), which they note may be released from immune 
cells in response to a tumour, or from the tumour itself [3]. The authors review a 
number of papers with conflicting observations, in which TNF  has been 
observed to be sufficient to activate downstream atrophy signalling, whereas 
others noted the requirement of additional cytokines to facilitate TNF  
signalling, including IL-1 , interleukin-6 (IL-6) and interferon-gamma (IFN- ). 
They noted that TNF  , IL-1  and IL-6 can be produced and secreted from muscle 
fibres themselves. Li et al. 2009 observed that both IL-1  and IL-1  could directly 
signal to C2C12 cells, stimulating p38 mitogen-activated protein kinase (p38 
MAPK) phosphorylation and nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF- B) signalling, that resulted in significant shrinking of 
myotubes after 48 hours of stimulation [38]. NF- B signalling is discussed in 
further detail in Section 1.9.1.5. Thus IL-1  and IL-1  alone were sufficient to 
trigger an atrophy response in C2C12 myotubes.  
 
As noted earlier in Section 1.3, LPS-induced atrophy in C2C12 cells stimulates 
TLR4 activation [22]. Similarly to observations in IL-1  and IL-1  stimulated 
cells, Doyle et al. 2011 observed TLR4 signalling was propagated via p38 MAPK 
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activation, which mediated downstream atrophy events, and the authors 
demonstrated that TLR4 knockout or inhibition of p38 MAPK abolished myotube 
atrophy. Cachectic factors such as TNF  thus have a role in skeletal atrophy in 
stimulating downstream signalling to increase protein degradation, in part via 
increased activity of the UPS (see Section 1.7.) However, muscle size is 
determined by both catabolic signals and anabolic signalling, which is 
comprehensively described in Sandri et al. 2008 [39]. Anabolic signalling is 
regulated by growth factors, including insulin-like growth factor 1 (IGF1), which 
stimulates PI3-kinase (PI3K) generation of phosphatidylinositol-3,4,5-
triphosphates, that subsequently activates Akt. IGF1 both induces muscle growth, 
also termed hypertrophy, by increasing protein synthesis and suppresses muscle 
protein breakdown (further information in Section 1.6) [40]. Under basal 
conditions, Akt inhibits the transcription factor forkhead box, class O (FoxO) by 
phosphorylating it and thus sequestering it in the cytoplasm. Upon 
dephosphorylation, FoxO can enter the nucleus and transcribe targeted atrophy 
related genes, suggesting a possible link between atrophy and hypertrophy 
signalling that might allow precise regulation of muscle size. Supporting this, a 
FoxO mutant resistant to Akt mediated phosphorylation prevented Akt mediated 
inhibition of downstream FoxO signalling targets [41]. Additionally, reduced 
circulating IGF-1 levels were observed in a rat model of sepsis [42] and in 
children diagnosed with cancer [43]. Conversely, mice bearing the C26 colon 
adenocarcinoma exhibited the same loss of muscle mass upon hyperexpression 
of IGF-1 [44] and whilst IGF-1 is down-regulated in a cancer cachexia in rats 
bearing the AH-130 hepatoma, muscle IGF-1 receptor increases [45]. Together, 
this suggests that the relationship between IGF-1/Akt signalling and muscle 
atrophy is yet to be fully elucidated and may be more complex than originally 
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considered. Figure 1.1, from Sandri et al. 2008, illustrates some of the pathways 
associated with muscle hypertrophy and atrophy that affect muscle fibre size. 
 
Ultimately, muscle atrophy can be attributed to simultaneous decreased protein 
synthesis coupled with upregulated protein degradation via specific pathways in 
a co-ordinated manner, known as the atrophy programme. The relative 
contribution of depressed synthetic and promoted catabolic pathways differs 
between different modes of atrophy. Cancer induced atrophy was once believed 
to occur as a result of reduced protein synthesis rates [46], but more recent 
studies have identified a role for both depressed synthetic rates coupled with 
increased protein degradation during cancer cachexia [47]. Down-regulation of 
IGF-1 was noted in a sepsis model of atrophy in rats, causing a reduction in 
protein synthesis [48]. This supports the notion that atrophy may be induced by 
inverse regulation of the mediators of hypertrophy [49]. However, sepsis has 
been observed to also increase expression of genes required for protein 
degradation by the UPS [50, 51], and proteasome inhibitors inhibited sepsis-
induced muscle proteolysis, strongly implicating the importance of protein 
degradation during muscle atrophy [52]. Upstream pathways, such as the release 
of cytokines and recognition of LPS to induce muscle atrophy signalling pathways 
have been extensively reviewed, although there is less information available 
about the downstream pathways. Evidence has emerged that while an decrease 
in protein synthesis, such as by IGF-1/Akt signalling is apparent, protein 
degradation is also upregulated. The common downstream pathways shared 
between different modes of muscle atrophy are unclear and studies have been 
performed to look for common genes/proteins that are upregulated across all 
models of muscle atrophy. 
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Figure 1.1 
 
   
Figure 1.1 Signalling pathways linked to hypertrophy and atrophy pathways that 
regulate muscle fibre size, taken from Sandri et al. 2008 [39]. 
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1.6. Atrogenes 
To address the question of whether there are common features of muscle 
atrophy, there has been investigation into the existence of atrophy related genes 
that are upregulated across multiple models of wasting. Whilst a number of 
transcripts are upregulated in response to a single model of atrophy, Bodine et al. 
2001 identified transcripts upregulated in multiple rodent models, which 
included denervation, immobilisation and unweighting models [53]. Two 
transcripts were observed to be upregulated across all studied models 
(denervation, unweighting and immobilisation models); UPS components MAFbx 
and MuRF1, that are discussed in more detail in 1.8.1.1 and 1.8.1.2, respectively. 
To validate candidates, the authors utilised two further rats models of skeletal 
muscle atrophy, in which rodents were treated with either the cytokine IL-1 or a 
high dose of the glucocorticoid dexamethasone (Dex), in which both MAFbx and 
MuRF1 gene expression was upregulated over 10-fold. MAFbx and MuRF1 
knockout in mice conferred resistance to denervation induced atrophy, further 
substantiating the importance of these proteins during atrophy. In recent 
knockout studies, in a mouse fasting model of muscle atrophy, small hairpin RNA 
(shRNA)-mediated MAFbx silencing reduced fasting-induced muscle loss [54]. 
Gomes et al. 2001 independently identified upregulation of a transcript in a 
fasting model of atrophy in mice using cDNA microarrays, which consistent with 
the observations of Bodine et al., was identified to be MAFbx. This group 
validated MAFbx as a key component of the atrophy programme by confirming 
its increased expression in rodent models of fasting, diabetes, cancer and renal ǡǲǳǡ
atrophy-related genes [40, 55]. MAFbx and MuRF1 are connected to the UPS, 
both being characterised as E3 ubiquitin ligases (see Section 1.9).  
14 
  
The concept of an atrophy programme, in which specific genes are up- or down-
regulated was further evidenced by later cDNA microarray analysis of multiple 
models of muscle atrophy, again noting MAFbx and MuRF1 increased expression, 
as well as components of the UPS (see Section 1.7), and observing down-
regulation of growth-related mRNAs, including IGF1-binding protein 5 (IGF1-
BP5) [55]. More recently in 2006, a further protein ZNF216 was first studied for 
its involvement in denervation and fasting models of atrophy. Not only was 
ZNF216 mRNA and protein expression upregulated in these models, but ZNF216 
knockout mice exhibited resistance to denervation-induced muscle atrophy. This 
implicated ZNF216 to be another key protein involved in the atrophy 
programme, which similarly to MAFbx and MuRF1 has a role in the UPS, and 
highlighted ZNF216 as a novel atrogene [56].  
 
1.7. Skeletal muscle atrophy up-regulates components of the 
ubiquitin proteasome system (UPS) 
Skeletal muscle atrophy is associated with suppressed protein synthesis coupled 
with increased protein degradation, the latter of which is mediated by a number 
of different processes. Two of the main intracellular pathways for protein 
degradation are autophagy and the UPS. Autophagy is a mechanism that allows 
degradation of cellular proteins, including protein aggregates and damaged 
organelles, by forming a double membrane around the target that matures into 
an autophagosome upon fusion with lysosomes. Lysosomal cysteine proteases 
cathepsins B, D and L degrade the sequestered contents, the products of which 
are then recycled. Autophagy has been linked to fasting-induced atrophy (see 
Section 1.4), in which the difference in sensitivity between fast- and slow-twitch 
muscles was attributed to a difference in autophagy signalling [33]. Increased 
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autophagy has also been associated with denervation [57] and disuse [58] 
models of atrophy, in addition to upregulated UPS components and activity. 
Sandri 2010 comprehensively reviews the role of autophagy in skeletal muscle 
and notes that while it does have a role in several modes of muscle wasting, 
autophagy suppression may actually trigger muscle atrophy [59-61]. 
Interestingly, autophagy is activated under starvation conditions to prevent cell 
death, but excessive autophagic activity leads to this outcome, in a process 
distinct from apoptosis induced cell death. Maiuri et al. 2007 discusses the 
complex crosstalk between autophagy and apoptosis [62]. Autophagosome 
formation requires a number of autophagy-related (Atg) genes, including Atg5.  
 
Interestingly, apoptosis has been associated with calpain-mediated cleavage of 
Atg5, in which truncated Atg5 localises with mitochondria and promotes 
apoptotic events via caspase activation [63]. Calpains and caspases are cysteine 
proteases associated with cell death, but have also been implicated having a 
potential role in disuse and sepsis induced muscle atrophy [64, 65], possibly by 
disrupting the sarcomere to allow degradation by the UPS. While autophagy 
clearly plays a role in skeletal muscle atrophy, ablation of this process is 
detrimental as it has a role in maintaining muscle mass, whereas proteasomal 
inhibition during denervation can reduce the severity of muscle wasting [34], 
suggesting that components of the UPS may be a more viable drug target for 
reducing the severity of muscle atrophy. Jagoe & Goldberg 2001 also suggest that 
muscle loss in cachexia is primarily due to increased UPS activity [66] and 
Donohoe et al. 2011 suggest that the UPS is the primary mechanism of protein 
degradation in cachexia [67]. 
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The UPS targets proteins for degradation via the conjugation of a polyubiquitin 
tag, which is recognised by the 26S proteasome; further details are in Section 1.9. 
Earlier in this Chapter, multiple studies are cited in which UPS components have 
been observed to increase during muscle atrophy. Ubiquitin mRNA levels 
increase between 1.2-19-fold in denervation, sepsis, fasting, cancer, uremia and 
diabetes models of muscle atrophy in rodents and humans [6, 34, 50, 51, 55], as 
does proteasomal subunit mRNA expression between 1.5-5-fold [51, 55].  
 
However, changes in UPS activity are not only associated with conditions such as 
muscle atrophy, but aberrant components of the UPS result in diseases such as ǯ. The ability of ubiquitin to conjugate to other proteins, 
including other ubiquitin moieties, is vital for its function. A ubiquitin frameshift 
mutation is produced from misreading of mRNA for the human Ub-B gene, in 
which the reading frame is adjusted +1, and results in loss of the C-terminal 
Gly76 residue, essential for ubiquitin conjugation (see Section 1.9.1.5), which is 
replaced by a 20 amino acid nonsense extension sequence. This frameshift 
mutant is termed Ubb+1, which wild type ubiquitin is still able to conjugate to, and 
thus the Ubb+1 mutanǲǳǡts conjugation to Ǥǲ	ǳǡȋ+1), have previously 
been observed to inhibit 26S proteasomal degradation of ubiquitinated 
substrates in vitro [68], and Ubb+1 capped chains were shown to similarly inhibit 
the proteasome [69]. These in vitro studies in combination with evidence that 
Ubb+1 capped polyubiquitin chains accumulate in patients with Alzheiǯ
disease suggest this frameshift mutant may contribute to the aetiology of this 
disease [69-71]. 
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1.8. The importance of the ubiquitin proteasome system (UPS) during 
normal cellular function 
As mentioned previously, intracellular protein degradation may be carried out by 
a number of pathways, which includes the UPS. Components of the UPS may be 
upregulated or perturbed during disease, but protein degradation is also of 
fundamental importance for protein homeostasis during normal cellular function. 
Imai et al. 2003 reviews the link between molecular chaperones and the UPS in 
determining the fate of unfolded proteins [72]. The authors note that over a third 
of cellular proteins fold incorrectly when newly synthesised and that even 
correctly folded proteins are susceptible to damage. Chaperones can recognise 
unfolded/damaged proteins, for example by exposed stretches of hydrophobic 
residues, and cooperate with co-chaperones to refold proteins correctly. 
Conversely, the UPS can recognise misfolded/damaged proteins and 
proteolytically destroy them, to prevent protein aggregation, which is associated 
with a number of neurodegenerative diseases [73, 74]. Protein aggregates may be 
sequestered from other cellular components by the formation of aggresomes 
[75], which may fuse with lysosomes and be degraded via autophagy pathways 
[76, 77]. Kraft et al. 2010 discuss the pathways that link the autophagy system 
and the UPS, both of which utilise ubiquitin and ubiquitin-binding proteins [78]. 
For example, ubiquitin binding protein p62 is required for autophagy-mediated 
degradation of protein aggregates [79]. 
 
Imai et al. 2003 note that there is little known about how the fate of proteins, to 
be refolded or degraded, is determined. Ravid & Hochstrasser 2008 review the 
various mechanisms by which proteins are recognised for proteasomal 
degradation, and note that some proteins that do not fold correctly, termed 
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ȋȌǡǲǳȋ
signals) that target them directly from the site of folding (often the endoplasmic 
reticulum (ER)) to the proteasome for degradation [80]Ǥǲ-ǳ
amongst the other degrons described by this review, which was discussed in 
further detail recently by Varshavsky 2011; the N-end rule describes 
observations that for certain proteins, their half-life in vivo is highly dependent 
on the identity of its N-terminal residue [80, 81]. N-terminal degrons, or 
destabilizing residues, include type I (basic) or type II (hydrophobic) residues. In 
eukaryotes, the N-end rule affects protein degradation via ubiquitin-dependent 
degradation, but interestingly similar observations are observed in prokaryotes 
which lack a UPS, reviewed in Mogk et al. 2007 [82]. Both eukaryotic and 
prokaryotic systems require recognition of the N-terminal residue of proteins by 
E3-ligase N-recognin or bacterial adaptor protein ClpS, respectively. Eukaryotic 
N-recognin mediates ubiquitination of the target, for proteasomal degradation 
(further details of UPS enzymes in Section 1.9.), while bacterial Clps delivers the 
substrate to bacterial ClpAP protease complex [80, 82].  
 
While ubiquitin is fundamental in general protein turnover for both UPS-
mediated degradation and selective autophagy, ubiquitin is a protein that is also 
essential for signalling events and a host of non-degradative processes (see 
1.9.1.5. for further details). 
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1.9. Components of UPS 
 
1.9.1. Enzymes required for polyubiquitination 
Ubiquitin conjugation to a substrate, via the C-terminal glycine residue of 
ubiquitin, is primarily controlled by 3 enzymes; classed as E1, E2 and E3 enzymes 
[83] (see Figure 1.2). A single ubiquitin may be conjugated, or alternatively 
multiple ubiquitin ǲǳǢ
number of attached ubiquitin proteins and isopeptide linkage determines the fate 
of the attached protein (see Section 1.9.1.5). The first event during ubiquitin 
conjugation is ATP-driven, in which an E1 ubiquitin-activating enzyme forms a 
thioester bond with ubiquitin. ATP is hydrolysed, and pyrophosphate is released 
upon AMP binding to the terminal carboxylate group of ubiquitin. Subsequently, 
ubiquitin is conjugated to a key cysteine residue within the E1 enzyme, via a 
sulfhydryl group. Thiǲǳ
sulfhydryl of an E2 conjugating enzyme.  
 
E3 ubiquitin ligase enzymes then mediate transfer of ubiquitin to the -amino 
group of a lysine residue within a substrate, forming an isopeptide bond. 
Interestingly, ubiquitin may occasionally be conjugated to the -amino group 
within the N-terminal residue of substrates [84]. E3 ligases, in combination with 
different E2 enzymes, confer substrate selectivity. It has been widely noted that 
while mammalian cells appear to have only two E1 enzymes, the enzymes 
responsible for specificity have been identified in greater numbers; 20-40 E2 
enzymes and 500-1000 E3 ubiquitin ligases. The mode of ubiquitin transfer to a 
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Figure 1.2 
 
 
 
 
Figure 1.2 Ubiquitin conjugation to a target protein. Ubiquitin is adenylated by an E1 
activating enzyme and forms a thioester bond, via a key cysteine residue in the E1 
enzyme. Ubiquitin is conjugated to an E2 conjugating enzyme, before an E3 ligase 
mediated transfer to a target protein, forming an isopeptide bond between ubiquitin and 
the target. 
21 
  
substrate varies depending on the E3 ligase involved, reviewed in more detail in 
Nagy & Dicik 2010 [85], and varies between the two major subtypes. HECT 
(homologous to the E6-AP carboxyl terminus)-type E3 ubiquitin ligases are one 
subtype of E3s, which contain catalytic activity and directly bind ubiquitin prior 
to transfer to a substrate. Nedd4 family members are included within this group, 
and mediate a number of physiological processes through ubiquitination, 
discussed in further detail in Rotin & Kumar 2009 [86]. The alternative major E3 
subtype are RING- (really interesting new gene)-finger domain E3 ligases, that 
bring E2-conjugated ubiquitin within close proximity of target protein to mediate 
direct transfer from the E2 to the target. MuRF1 is a single subunit RING-finger 
E3 ligase, discussed in more detail in Section 1.9.1.2. However, RING E3-ligases 
may also include multi-subunit ligases such as the Skp1ȂCul1ȂF-box protein 
(SCF) complex, reviewed in greater detail in Cardozo & Pagano 2004 [87]. F-box 
proteins within this complex are responsible for substrate recognition, and 
include MAFbx (see 1.9.1.1). RING-finger proteins contain zinc binding sites that 
support a finger-like structure (Figure 1.3). U-box E3 ligases have finger 
structures highly similar to RING E3 ligases, but lack zinc binding sites and 
stabilise the fold via hydrogen bonding [88] and are increasingly regarded as 
another major E3 ubiquitin ligase subtype [89, 90], although u-box ligases are 
predominantly associated with plants over other organisms [91]. 
 
Although not enzymes, a number of ubiquitin-binding proteins have been 
implicated in mediating translocation of ubiquitinated substrates to the Ǥǲǳǡ often 
having a ubiquitin-like domain and a ubiquitin-binding domain, presumably to 
allow simultaneous binding to the proteasome and to polyubiquitinated 
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Figure 1.3 
 
 
 
 
Figure 1.3 Schematic representation of a zinc finger domain, in which four cysteine 
residues within a polypeptide bind a zinc cation to produce a finger-like structure. These 
are found in RING finger E3 ligases, as well as other ubiquitin-binding proteins and a 
number of proteins involved in DNA-binding. 
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substrates. Yeast proteins Rad23 and Dsk2 were suggested to be shuttle factors 
based on their ability to bind polyubiquitin and interact with the proteasome [92, 
93]. Rad23 and Dsk2 mutants lacking ubiquitin-binding ability induced growth 
defects in yeast and provided evidence that shuttle factors play an important role 
in the UPS in yeast [92, 94]. However, shuttle proteins are not only present in 
yeast, as a mammalian shuttle factor valosin-containing protein (VCP)/p97 has 
been identified; reduced interaction of ubiquitinated substrates with this shuttle 
protein impairs proteolysis of the target, validating a role for shuttle proteins in 
the UPS in a mammalian context [95]. Zhang et al. 2009 suggested that shuttle 
factors preferentially associate with the proteasome when bound to a minimum 
ubiquitin chain length [96]. This was based on observations that ternary 
complexes involving yeast shuttle factor Dsk2 and proteasome subunit Rpn10 
varied greatly depending on ubiquitin chain length. The atrogene ZNF216 has 
also been proposed to act as a shuttle protein during muscle atrophy, and is 
discussed further in Section 1.10. 
  
MAFbx and MURF1 mRNA is predominantly expressed in skeletal muscle [53] 
and, as described in more detail in earlier sections, there is mounting evidence 
that these E3 ubiquitin ligases are both upregulated and required during multiple 
modes of muscle atrophy. This strongly implicates the importance of MAFbx and 
MuRF1 during skeletal muscle wasting, and prompted subsequent investigations 
into their biochemical roles and substrates.  
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1.9.1.1. MAFbx 
MAFbx was initially identified independently by two groups [53, 97], and was 
noted to contain an F-box domain that could bind to other components of the SCF 
complex, implicating its function as an E3 ligase. The ~40 residue domain was 
first identified in cyclin F [98], and accordingly later named the F-box domain by 
the same group [99]. Bai et al. 1996 noted that Skp1 was required for ubiquitin-
mediated proteolysis and bound cyclin F, and first associated F-box containing 
proteins with the UPS [99]. Human F-box proteins are divided into three 
subtypes, depending on the identity or presence of an additional domain; leucine-
rich repeats (LRRs)- and WD (Trp-Asp) repeats are the most common, and F-box 
proteins containing these domains are named FBXL and FBXW proteins, 
respectively [100-102]. N-	ǯ	-box domain are leucine zipper 
and leucine-charged residue-rich (LCD) domains. Like other F-box proteins that 
contain an alternative domain to that of the LRR or WD, or those that lack an 
additional domain, MAFbx is designated an FBXO protein; hence, MAFbx protein 
is derived from the FBXO32 gene. Like other F-box proteins, MAFbx provides 
substrate specificity during SCF-mediated ubiquitination. The MAFbx containing 
SCF complex also includes Skp1, Cul1, Rbx1 proteins. This complex forms a 
horseshoe shape in which substrate binding via MAFbx brings the target within 
close proximity of E2-conjugated ubiquitin, mediating ubiquitin transfer from the 
E2 enzyme to the substrate (Figure 1.4). Multiple rounds of ubiquitination 
generates a polyubiquitin chain, and targets the substrate for 26S proteasomal 
degradation (see Section 1.9.1.3.).  
 
Interestingly, another F-box protein, derived from FBXO25, shares high homology 
with MAFbx (see Chapter 3.2.), but expression is not induced during skeletal 
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Figure 1.4 
 
 
 
Figure 1.4 MAFbx-mediated polyubiquitination of a muscle atrophy substrate. The SCF 
complex comprises of MAFbx, Skp1, Cul1 and Rbx1, forming a horseshoe shape. This 
binds an E2-conjugating enzyme, and holds a MAFbx selected substrate within close 
proximity of ubiquitin- ?ǯǤ 
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muscle atrophy [103] and recent evidence implicates its involvement in targeting 
cardiac specific transcription factors [104]Ǥ	ǯ ?, and its 
requirement during muscle atrophy suggests that MAFbx substrates are amongst 
proteins specifically degraded under muscle atrophy conditions. One proposed 
MAFbx substrate is MyoD, a protein involved in myogenic differentiation [105]. 
Tintignac et al. 2005 identified that MAFbx LCD region is responsible for the 
MAFbx/MyoD interaction. The authors also observed reduced MyoD-induced 
differentiation upon MAFbx overexpression and provided evidence that a 
purified SCF complex containing MAFbx could ubiquitinate MyoD in vitro. Further 	ǯ
degradation, in which shRNA-mediated MAFbx down-regulation in fasted mice 
attenuated muscle loss was also associated with increased MyoD protein levels 
[54]. 
 
Skeletal muscle atrophy has been observed to not only result from increased 
protein degradation, but also reduced protein synthesis [47]. Indeed, there is 
evidence supporting theories of a link between muscle atrophy and hypertrophy 
molecular pathways [41]. Thus it was of great interest when Lagirand-
Cantaloube et al. 2008 identified a novel link between synthetic and proteolytic 
pathways, providing evidence that eukaryotic initiation factor 3 subunit F (eif3-f) 
is ubiquitinated by MAFbx [106]. Similar ǡ	ǯ
LCD domain mediates eif3-f binding and MAFbx down-regulation by shRNA in a 
C2C12 myotube model of atrophy prevents eif3-f degradation. The authors noted 
that this initiation factor can induce hypertrophy, by increasing levels of muscle 
structural proteins such as troponin T, desmin and myosin heavy chains and 
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suggest a novel mechanism where these two apparently distinct pathways are 
connected. 
 
1.9.1.2. MuRF1 
MuRF1 was initially identified as a protein binding to the giant myofibrillar 
protein titin by yeast two-hybrid screening [107]. MuRF1 was noted for its 
involvement in muscle atrophy within the same year it was identified binding to 
titin, and recombinant MuRF1 was confirmed to have E3 ligase activity in vitro 
[53]. MuRF2 and MuRF3 make up the other two family members and are close 
homologs of MuRF1; all three contain a tripartite RING:B-box:coiled coil domain. 
MuRF2 and MuRF3 appear to be involved in maintaining normal contractile 
function [108, 109]. Similarly to MuRF1, MuRF2 was observed to be part of a 
complex with titin, although binding was indirect via binding to the ubiquitin 
binding and autophagy associated protein p62, which in turn bound the titin-
binding zinc finger protein Nbr1 (next to BRCA1 gene 1) [110]. The authors 
hypothesised that titin, a protein that responds to mechanical load, may link 
sarcomere activity to downstream gene transcription. Lange et al. suggest that 
MuRF2 binding in this complex may sequester it from nuclear localisation, in 
which it may bind to the transactivation domain of transcription factor serum 
response factor (SRF) thus influencing SRF-mediate transcription, as opposed to 
functioning as an E3 ligase. MuRF1 is a RING-finger ligase, but monomeric as 
opposed functioning as part of a complex. However, similarly to MAFbx, MuRF1 
does not bind ubiquitin directly, but mediates ubiquitin transfer from an E2 
enzyme to a MuRF1-bound substrate. Yeast two-hybrid screens of skeletal 
muscle cDNA libraries identified eight myofibrillar proteins that interacted with 
MuRF1, but not all showed reduced levels in MuRF1 KO mice, suggesting they 
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may be regulators rather than substrates [109]. MuRF1 and MuRF3 have been 
suggested to ubiquitinate long lived sarcomeric proteins beta/slow myosin heavy 
chain (beta/slow MyHC) and MyHCIIa, in conjunction with E2 enzymes UbcH5a, -
b and Ȃc [108]. MyHC was observed to accumulate in MuRF1 and MuRF3 KO mice ǡ	 ?ǯ
depleted upon Dex treatment of myotubes, but spared by inhibiting MuRF1 in 
myotubes or in MuRF1 KO mice [111]. Correspondingly, a more recent study 
observed MuRF1-dependent MyHC ubiquitination upon denervation and fasting, 
although they observed that myosin-binding protein C (MyBP-C) and myosin 
light chains 1 and 2 (MyLC1 and MyLC2) were ubiquitinated and degraded prior 
to MyHC [112]. MyLC2 was one of the eight MuRF1-binding protein candidates 
reported by Witt et al. 2005[109], who also reported binding of troponin-I (TnI). 
Further evidence from another group supported TnI as a MuRF1 substrate [113]. 
However, this yeast two-hybrid screen identified cardiac TnI, having utilised a 
heart cDNA library, and a study that analysed a proteins that bound a catalytic 
MuRF1 mutant failed to capture TnI [112]. Clearly further work is required to 
validate TnI as a MuRF1 substrate during skeletal muscle atrophy, while in 
contrast MyHC is better validated as a target. Interestingly, a very recent study 
observed that GST-tagged MuRF1 could interact with and polyubiquitinate actin 
in vitro, and ubiquitinated actin could be detected in C2C12 myotubes, in healthy 
volunteers and cancer patients, implicating actin as a novel MuRF1 substrate 
[114]. 
 
Despite MAFbx and MuRF1 having different modes of ubiquitination and 
targeting different proteins, both act to conjugate polyubiquitin chains to a 
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substrate and thus target them for degradation by the 26S proteasome (further 
details on polyubiquitin chains in 1.9.1.5.2.) 
 
1.9.1.3. 26S Proteasome 
The 26S proteasome is an ATP-driven multisubunit complex consisting of the 20S 
proteasome, that contains proteolytic activity, and two 19S regulatory particles 
(see Figure 1.5). The 20S proteasome contains two alpha (  and two beta (  
rings stacked on top of each other, each ring containing seven subunits. The four 
rings form a barrel structure; the two inner rings are formed from  subunits, 
and the rings at the end of the barrel are formed from  subunits. The fourteen 
subunits required for 20S proteasome (two copies of each are required) are 
structurally homologous, but unlike subunits, some of the inner ring-forming 
subunits provide the proteolytic activity of the 20S proteasome.  subunits that 
have N-terminal threonine or serine residues provide the active sites of 
proteases, which are converted into nucleophiles that can attack the carbonyl 
groups in peptide bonds. Subunits 2 and 5 provide caspase-like, trypsin-
like and chymotrypsin-like catalytic activities, respectively [115, 116], and are 
contained within the 20S proteasome barrel structure. Proteins that enter the 
proteasome are digested into peptides seven to nine residues in length, which are 
subsequently broken down further by cellular proteases upon release into the 
cytoplasm, which reduce short peptides into individual amino acids.  
 
Substrate access to the proteasome for subsequent degradation is highly 
controlled to prevent non-specific proteolysis. The N-terminal residues of  
subunits in the outer rings block access to the 20S core and proteasomal entry is 
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Figure 1.5 
 
 
 
 
Figure 1.5 Composition of the 26S proteasome. The 20S proteasome comprises of four 
stacked rings, the two central and two outer rings made of seven subunits and  
subunits, respectively. The 19S regulatory particle is made of the 10 subunit base, and 9 
subunit lid. While the base is known to consist of 6 ATPase subunits (Rpt subunits), and 4 
non-ATPase subunits (Rpn subunits), the positions of subunits within the 19S regulatory 
particle are, to date, unknown.  
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tightly regulated by the 19S regulatory complex. The 19S regulatory particle 
contains 19 subunits, 10 of which form the 20S core-ǲǳǡ 9 ǲǳǤ
(Rpt1-6). The non-ATPase subunits, termed Rpn (regulatory particle non-
ATPase) subunits, include Rpn1, Rpn2, Rpn10 and Rpn13; the latter two of which 
have been associated with polyubiquitin binding [117, 118]. The ATPases are of 
the ATPase associated with various cellular activities (AAA) class, and has been 
suggested to have a number of roles, described in greater detail in a recent 
review by Bar-Nun & Glickman 2011 [119]. Globular proteins cannot enter the 
proteasome in their native structure, and require unfolding; ATPases in the 19S 
base produce a mechanical force that unfolds substrates. ATPases have also been 
associated with translocation of the targeted protein into the proteasome and 
this process has been coupled with unfolding activity. However, to date it is 
unclear whether unfolding drives translocation, or whether the reverse is true. ǲǳǡ-
terminal residues of subunits; gate opening is induced by a conformational 
change in the subunit ring, via a mechanism involving the C-terminus of 19S 
ATPase subunits (again, discussed further in Bar-Nun & Glickman 2011 [119]).  ? ?ǲǳǡ
deubiquitinating substrates via its Rpn11 subunit, which amputates the entire 
chain from substrates [120]. Deubiquitinating enzymes (DUBs) have enzymatic 
activities that reverse single ubiquitin (or ubiquitin-like) conjugation, or edit 
polyubiquitin (or ubiquitin-like) chains, thus regulating the fate of the target 
protein or potentially regulating a number of cellular processes [121]. 
Interestingly, a recent paper notes that proteasomal associated deubiquitinating 
enzymes ubiquitin C-terminal hydrolase 37 (Uch37) and ubiquitin specific  ? ?ȋ ? ?Ȍǲǳǡ
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be required for removal of Rpn11 amputated polyubiquitin chains that may 
otherwise remain associated with the proteasome and compete with 
polyubiquitinated substrates for binding [122]. Deubiquitination and 
proteasomal degradation are coupled, but further work is required to fully 
understand the effect of different deubiquitinating activities with proteolysis. 
While some ubiquitin is inevitably degraded, much of it is recycled and return to 
the cytosol intact for further rounds of conjugation, prior to its own proteolysis.  
 
However, a more complex mechanism for proteasomal recognition has emerged, 
in which a sequence within a substrate termed a proteasome initiation region, in 
combination to a polyubiquitin tag (proteasome binding tag), aids rapid 
proteasomal degradation [123-125]. Subsequent investigation revealed that 
presence of initiation region and proteasome binding tag on a target protein is 
not sufficient for degradation, but must be appropriately positioned and the 
initiation region be of a minimum length, to promote recognition by proteasomal 
receptors [126]. Further studies are required to understand proteasomal 
targeting.  
 
1.9.1.4. Deubiquitinating enzymes 
In addition to the 20-40 E2 enzymes and 500-1000 E3 ubiquitin ligases, nearly 
100 DUBs have been identified in the human genome. Protein degradation is, in 
part, regulated by deubiquitination. However, DUBs are not exclusively 
proteasomal associated (see 1.9.1.3), and alternatively localised DUBs also have a ǯǡ
other diverse cellular processes from generating active monoubiquitin from 
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precursors (see Section 1.9.1.5) to regulating cellular signalling [121, 127]. DUBs 
are divided into five families - UCH, USP, ovarian tumour (OTU), Josephin and 
Jab/MPN domain-associated metallopeptidase (JAMM) - and target a range of 
substrates, that may by mono- or polyubiquitinated, or alternatively conjugated 
to ubiquitin-like modifiers. The JAMM family are part of the zinc-dependent 
metalloprotease family, while the other four families are cysteine proteases; the 
latter family of DUBs can thus be irreversibly inactivated by reducing agents 
including N-ethylmaleimide (NEM) and iodoacetamide, which disrupt cysteine 
structures at the active site thiol group. 
 
Here, we will focus on the regulation of protein degradation via deubiquitination 
of polyubiquitinated proteins. One of the most established examples of 
deubiquitinating enzymes is USP7, alternatively named HAUSP (herpes simplex 
virus associated ubiquitin-specific protease). This cysteine protease binds to and 
deubiquitinates the tumour suppressor protein p53 [128], a tumour supressor 
protein that has a role regulating cellular stress response genes, including those 
involved in apoptosis, cell cycle arrest, senescence, DNA repair, cell metabolism 
and autophagy [129]. Removal of the polyubiquitin chain/proteasomal tag, 
increases p53 stability by reducing proteasomal degradation. In light of evidence 
that USP7 deubiquitinates polyubiquitinated p53, and that USP7 overexpression 
stabilised p53 [128], knock out of USP7 was predicted to destabilise p53 protein 
via increased proteasomal degradation. However, USP7 ablation via siRNA [130] 
or USP7 knock out by homologous recombination [131] also resulted in 
stabilisation of p53. It became evident that p53 stabilisation was more complex 
than initially thought. The E3 ubiquitin ligase murine double minute 2 (MDM2) 
both targets p53 and itself; the latter leading to destabilisation of MDM2 and its 
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subsequent degradation by the proteasome. The paradox that both USP7 knock 
down a ? ? ?ǯ
ability to deubiquitinate both MDM2 and its p53 target. 
DUBs may target a number of substrates, such as USP7 targeting MDM2 and p53; 
DUB activity may also be restricted to specific linkage polyubiquitin chains; for 
example, CYLD is a DUB associated with K63-linked polyubiquitin 
deubiquitination [132], while Otubain 1 (Otu1) preferentially cleaves K48-linked 
polyubiquitin [133]. Isopeptidase T (isoT) is a DUB that specifically recognises ǲǳǡǤǤ-terminus [134]. More 
detail is provided about unanchored polyubiquitin in Section 1.9.1.5.3.  
 
1.9.1.5. Ubiquitin  
Ubiquitin is a 76 amino acid globular protein, that has been observed to remain 
stable even at high temperatures, likely due to its compact structure. Ubiquitin is 
translated as a protein-precursor in both yeast and higher eukaryotes, where 
ubiquitin copies are conjugated head-to-tail (C-terminal glycine to N-terminal 
methionine) in a linear fusion, or a single copy is fused to a ribosomal protein. 
Ubiquitin precursors are subsequently deubiquitinated by cellular DUBs to 
produce mature ubiquitin monomers [135-137]. Mammals contain four ubiquitin 
genes, two as ribosomal fusions and two as polyubiquitin-encoding genes; Ubb 
and Ubc [138].  
 
Proteins may be post-translationally modified by the conjugation of ubiquitin, 
described in further detail below (Sections 1.9.1.5.1 and 1.9.1.5.2), but proteins 
may also bind ubiquitin non-covalently via at least one of 3 ubiquitin binding 
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surfaces. The key residues required for binding at these surfaces ; D58 [139], I44 
[140] and GG (at the C-terminus) [141]. Ubiquitin binding proteins are discussed 
in more detail in 1.9.1.5.4.  
NF- B is a family of transcription factors that regulate various cellular processes 
involved in immunity responses, inflammation, apoptosis, cell adhesion, and 
proliferation [142-145]. There are five family members in mammals, including 
p50/p105, p52/p100, RelA(p65), c-Rel and RelB; these form homo- and hetero-
dimers in different combinations to mediate gene transcription, but are mostly 
sequestered in the cytoplasm by binding of inhibitor of B family (I Bs) proteins 
under non-stimulated conditions. I Bs inhibit NF B dimers from entering the 
nucleus by masking the nuclear localisation signal (NLS), located at the N-
terminus of NF- B family members in the Rel homology domain (RHD). Liu & 
Chen 2011 comprehensively reviews ubiquitinǯs diverse roles in NF- B signalling 
[144], which may be regulated by post-translational modification of proteins 
involved in NF- B pathways by mono- and polyubiquitination (see Sections 
1.9.1.5.1 & 1.9.1.5.2, respectively), or even by unanchored polyubiquitin chains, 
that are not conjugated to a substrate (Section 1.9.1.5.3). An overview of NF- B 
signalling events described here are presented in Figure 1.6. 
 
1.9.1.5.1. Monoubiquitination 
Proteins may be monoubiquitinated; this modification is not associated with 
proteasomal degradation, but is connected to a number of other cellular 
processes, which includes protein degradation via an alternative pathway.  
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Figure 1.6 
 
Figure 1.6 Canonical NF- B pathways may by stimulated by LPS, IL-1 or TNF . TNF  and 
IL-1 induces RIP1 polyubiquitination or IRAK1/TRAF6/Ubc13-mediated synthesis of 
unanchored K63-linked polyubiquitin chains, respectively. Binding of TAK1 kinase via 
TAB2/TAB3 subunits, promotes self-activation and then phosphorylates IKK. IKK 
phosphorylates I B , which is polyubiquitinated and targeted for degradation by the 26S 
proteasome. Thus, the NLS of RelA within the RHD is unmasked, and promotes 
translocation of NF- B to the nucleus to mediate gene transcription. Non-canonical 
pathways induce NIK activation, which in turn phosphorylates the P100 NF- B precursor, 
inducing degradation of the ankryin repeat containing domain (ANK), unmasking the NLS 
of RelB and again allowing translocation to the nucleus. Transcriptional activation 
domains (TADs) allow binding of transcriptional co-activatiors/co-repressors. HTLV-1 
induces Tax expression, inducing IKK  phosphorylation and monoubiquitination. IKK  is 
translocated to autophagosomes and degraded, reducing NF- B mediated signalling. 
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Genomic DNA is packaged into chromatin, in which DNA is wrapped around 
histone proteins, and has been widely considered to inhibit gene transcription 
[146]. Post-translational modification of histone H2A by monoubiquitination was 
discovered over 30 years ago [147] but has only relatively recently been 
recognised for having a role in transcriptional repression and may be induced by 
DNA damage and have a role in DNA repair (reviewed in more detail in Zhou & 
Rosenfeld 2008 [148]).  
 
Interestingly, NF- B is widely assumed to be associated with polyubiquitin 
modification, but recent evidence indicates a minor role for monoubiquitination 
in NF- B signalling. For NF- B signalling to occur, the I B inhibitory protein must 
be removed; I B phosphorylation by IKK (I B kinase) induces its degradation 
(further details in 1.9.1.5.2). Cells infected with human T-cell leukaemia virus 
type 1 (HTLV-1) express the oncogene protein Tax, and were observed to induce 
constitutive phosphorylation and monoubiquitination of IKK  [149-151]. The 
monoubiquitination event was later associated with subcellular translocation of 
IKK  to autophagosomes for subsequent degradation, and induced down-
regulated NF- B signalling [152]. 
 
The link between monoubiquitination and protein translocation is well 
established, having a role in membrane protein trafficking, regulating 
endocytosis and endosomal sorting [153]. Signal-inducing receptors are amongst 
the proteins that have been observed to undergo internalisation into clathrin 
coated pits, which are transported via vesicles to endosomes termed multi-
vesicular bodies (MVB). Receptors may be recycled back to the cell surface, or 
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budding off from MVBs and fusion with lysosomes results in protein degradation 
in a proteasome-independent manner. Monoubiquitination of the receptor at the 
cytosolic domain has been observed to be sufficient for endocytosis to occur 
[154], which appears to be due to recruitment of ubiquitin-binding endocytic 
proteins (reviewed further in Mosesson & Yarden 2006 [153]). 
 
1.9.1.5.2. Polyubiquitinated substrates 
E3 ubiquitin ligase enzymes mediate transfer of ubiquitin to the -amino group of 
lysine residues or the -amino group of an N-terminal residue within a substrate; 
subsequently, further ubiquitin proteins may be conjugated to the substrate-
attached ubiquitin to form polyubiquitin chains, via one of 7 lysine residues (K6, 
K11, K27, K29, K33, K48 or K63) or at the N-terminal methionine (known as 
linear polyubiquitin chains). Traditionally, proteasomal recognition of 
polyubiquitinated substrates was associated with K48-linked polyubiquitin 
chains. However, it has become evident that, with the exception of K63-linked 
chains, all other polyubiquitin linkages can target proteins for proteasomal 
degradation [155]. Indeed, earlier in vitro studies noted that even heterogeneous 
polyubiquitin chains of mixed linkage were sufficient for binding to ubiquitin 
receptors as well as promoting proteasomal degradation [156]. Histone post-
translational modification and membrane protein trafficking requires a single 
ubiquitin, but it appears that tetraubiquitin is the minimum signal for 
proteasomal recognition [157].  
 
Polyubiquitination, as has been previously noted, has a major role in NF- B 
signalling. There are a number of pathways that ultimately lead to NF- B 
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activation, reviewed in greater detail in Perkins 2007 [145]. NF- B is mostly 
sequestered in the cytoplasm by binding of I B. A number of stimuli induce the 
canonical pathway, including bacterial LPS, and cytokines TNF  and IL-1. IKK 
contains three subunits; two catalytic subunits, IKK  and IKK  and one 
regulatory subunit IKK /NEMO (NF- B essential modifier). An example of the 
canonical pathway is the activation of IKK subunit IKK , which phosphorylates 
I B . This induces I B  ubiquitination with K48-linked polyubiquitin, targeting 
it for degradation by the 26S proteasome. This unmasks the NLS of NF- B 
subunit RelA, in a heterodimer complex with p50 (see Figure 1.6), allowing 
nuclear translocation and binding to various co-activators/co-repressors to 
mediate gene transcription. However, K48-linked polyubiquitination and 
degradation has another role during NF- B signalling, such as during the non-
canonical/alternative pathway. LPS may also trigger this pathway, as can 
stimulation of CD40 and lymphotoxin-  receptors. This pathway leads to IKK  
activation by NF- B-inducing kinase (NIK), which in turn phosphorylates the NF-
B precursor p100, of a p100/RelB dimer. Subunit p100 contains a C-terminal 
ankyrin repeat region, which acts similarly to I B inhibitors, masking the NLS of 
the adjacent RelB NF- B subunit. Phosphorylation of p100 induces K48-linked 
polyubiquitination, leading to proteasomal processing of p100 to p52. This 
unmasks the NLS and allowing entry of the p52/RelB NF- B dimer into the 
nucleus to mediate gene transcription. 
 
However, K48-linked polyubiquitin is not the only linkage important for NF-
B signalling. TNF  induced canonical NF- B signalling promotes the formation 
of a complex which includes RIP1 (receptor interacting protein 1) (see Figure 
1.6), which is polyubiquitinated with K63-linked polyubiquitin chains, which in 
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turn recruits TAK1 (tȾȂactivated kinase 1) and IKK 
complexes. TAK1 phosphorylates and activates IKK, again resulting in I B  
phosphorylation and degradation, and inducing nuclear localisation of the 
RelA/p50 dimer. TNF-receptor associated factor 6 (TRAF6) is a protein that is 
essential for IL-1 [158] and TLR- [159] mediated NF- B signalling. It was later 
found to be an E3 ubiquitin ligase, which functions with Ubc13/Uev1a to form 
K63-linked polyubiquitin chains [160]. There is conflicting data regarding TRAF6 
substrates and their role in NF- B signalling, described in further detail in Liu et 
al. 2010 [144]. Candidates for TRAF6-mediated ubiquitination include TRAF6 ǯNEMO, although further study is needed as 
K63-linked polyubiquitin is not the only linkage associated with NEMO (see 
below). There is recent evidence that TAK1 activation is not only via K63-
polyubiquitinated RIP1, and that TRAF6/Ubc13 synthesised unanchored K63-
polyubiquitin chains may also activate this kinase (see Section 1.9.1.5.3). 
 
Interestingly, linear polyubiquitin chains appear to also have a role in NF- B 
signalling [161-164]. Linear ubiquitin assembly complex (LUBAC), that forms 
linear polyubiquitin chains, has been found to activate canonical signalling by 
binding to NEMO and conjugating linear chains [165, 166] and more recently, 
genotoxic stress has been reported recently to induce NEMO linear 
ubiquitination, which is required for NF- B activation [164]. Alternatively, 
another group observed K27-polyubiquitination of NEMO during viral induced 
NF- B activation [167], indicating another potential polyubiquitin linkage 
involved in NF- B signalling. 
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Other polyubiquitin linkages have been associated with a number of roles other 
than proteasomal degradation and NF- B signalling; K6 with DNA repair [168] 
while K11-linked polyubiquitin has an emerging role in cell cycle control, 
reviewed in further detail in Bremm & Komander 2011 [169]. However, it is K63-
linked polyubiquitin chains that have been studied the most out of the non-
proteasomal related polyubiquitin linkages. DNA post-replication repair may be 
mediated by the RAD6 pathway and the DNA-polymerase sliding clamp PCNA 
(proliferating cell nuclear antigen) was identified a substrate in this pathway 
[170]. Hoege et al. 2002 noted PCNA could be modified at the same site by SUMO 
(small ubiquitin-related modifier), monoubiquitin, or K63-linked polyubiquitin 
chains. The authors suggested that DNA damage triggers monoubiquitination at 
this site, in preference to SUMOylation. Monoubiquitination then allows 
recruitment of enzymes that assemble K63-linked polyubiquitin which induces 
error-free DNA repair. K63-linked polyubiquitin mediated activation appears to 
be proteasome-independent, as it was shown that K63-polyubiquitinated PCNA 
was not subjected to proteasomal degradation [171], although the mechanism of 
activation remains unknown. 
 
Traditionally, polyubiquitin has been considered for its role as a ǲlinearǳ 
structure, but its ability to link via any of 7 lysine residues/N-terminal 
methionine opens the possibility of it forming branched structures. Indeed, E3 
ligase RING1B has been observed to auto-ubiquitinate and form branched 
ubiquitin chains for self-activation [172] and evidence suggests that branched 
polyubiquitin chains may inhibit protein degradation [173]. 
 
42 
  
In summary, polyubiquitination may be a very complex post-translational 
modification beyond the complexity of phosphorylation, even if only considering 
linkage, let al.one the vast number of possible conformations polyubiquitin can 
form. Multiple groups have performed quantitative analyses of polyubiquitin 
linkages present across different tissues and under different conditions [155, 
174-176]. Together, these studies revealed varied linkage compositions, that can 
be associated with multiple cellular processes from regulation of degradation to 
protein trafficking. 
 
1.9.1.5.3. Unanchored polyubiquitin 
Polyubiquitin has been largely studied for its role in regulating the proteins it 
post-translationally modifies. As was noted earlier, proteasomal associated DUBs 
act to remove polyubiquitin bound to the proteasome to allow subsequent 
binding of further polyubiquitinated proteins [122]. Indeed, earlier groups had 
observed the ability of unanchored polyubiquitin chains of tetraubiquitin and 
above to inhibit proteasome degradation in vitro [68], while deletion of the 
UBP14 DUB induced accumulation of free polyubiquitin chains that inhibited 
proteasomal degradation in yeast [134]. Unanchored polyubiquitin chains were 
further validated in a human context. Knockdown of isoT in human cells, a DUB 
that recognises and cleaves unanchored polyubiquitin, increased levels of free 
ubiquitin chains and competed with ubiquitinated p53 tumour suppressor 
protein for proteasomal binding; thus stabilising p53 by inhibiting its 
degradation [177].  
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A recent suggestion for the physiological role of unanchored polyubiquitin chains 
was as a source of monoubiquitin for the cell [178], but K63-linked unanchored 
polyubiquitin has also been implicated in having a role both activating kinases 
[179] and during innate immunity [180, 181]. TAK1, a kinase previously 
mentioned for its ability to phosphorylate and activate kinase IKK, is activated by 
unanchored K63-linked polyubiquitin; the model proposed a mechanism where 
multiple TAK1 kinases are brought within close proximity to activate each other, 
when binding to unanchored K63-linked chains via TAB2/3 (TAK1 binding 
protein 2/3) accessory proteins [179]. As previously noted, TRAF6/Ubc13 
mediate synthesis of unanchored K63-linked polyubiquitin chains upon IL-1 
pathway stimulation. Recruitment of myeloid differentiation primary gene 88 
(MyD88) at IL-1 receptors induces recruitment of two IL-1 receptor-associated 
kinases, IRAK4 and IRAK1. IRAK1 is activated and binds to TRAF6, which 
oligomerises and catalyses K63-polyubiquitination with Ubc13. Activated TAK1, 
induced by binding to TRAF6-synthesised unanchored K63-linked polyubiquitin 
chains, can subsequently activate IKK. This suggests that unanchored 
polyubiquitin is yet another ubiquitin species associated with NF- B signalling 
(see Figure 1.6) and that TRAF6 may be the source of these species. 
 
1.9.1.5.4. Ubiquitin binding proteins 
Non-covalent binding to ubiquitin is key to all ubiquitin-mediated processes, 
including deubiquitination, protein trafficking and autophagy. Ubiquitin binding 
proteins may bind via at least one of 3 binding surfaces, defined by key residues 
D58 [139], I44[140] or GG (at the C-terminus) [141]. Dikic et al. 2009 reviews the 
various ubiquitin-binding domains (UBDs) and how binding specificity for 
certain polyubiquitin chain lengths and linkages relates to their functions [182]. 
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The authors note that most UBDs bind at the I44 surface, a hydrophobic patch on 
the -sheet surface that is solvent exposed, but due to the multiple modes of 
binding at this surface I44 binding-UBDs are still structurally diverse. I44 binding 
proteins include ubiquitin conjugating enzyme UBCH5C [183], Alpha4 via a 
ubiquitin-interacting motif (UIM) (a protein that regulates protein 
serine/threonine phosphatase 2A catalytic subunit (PP2Ac) polyubiquitination) 
and p62 via its ubiquitin associated (UBA) domain, ubiquitin-binding mutants of ǯ[184].  
 
Alternatively, proteins may bind to ubiquitin at the polar surface of ubiquitin, 
centred around the D58 residue; for example, the Znf_A20 domain of RAB5 
guanine nucleotide exchange factor (RABEX5) [185]. Finally, isoT specifically 
deubiquitinates unanchored polyubiquitin, recognition of which has been 
attributed to the Znf_UBP/BUZ domain of isoT; this domain forms a pocket into 
which the free C-terminal tail of unanchored ubiquitin (the proximal ubiquitin) 
can enter [141].  
 
Radiation sensitivity abnormal 23 (RAD23) is a shuttle protein, that aids 
translocation of polyubiquitinated proteins to the proteasome via binding to the 
polyubiquitin tag and direct proteasome binding. Considering the association of 
K48-linked polyubiquitin to proteasome recognition, in favour of K63-linked 
chains, it is interesting to note that RAD23 showed preferential binding to K48- 
over K63-linked polyubiquitin [186]. Alternatively, the nuclear protein 
localization 4 ZnF (NZF) domain of TAB2, specifically binds K63-linked chains 
[187]; as was discussed in the previous Section. 
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1.9.1.5.5. Methods for purifying polyubiquitinated proteins 
Specific polyubiquitination of targets is key to a number of processes, as 
exemplified by NF- B signalling in which a specific inhibitor is degraded to allow 
NF- B entry to the nucleus, or during the regulation of polyubiquitinated 
proteins by DUBs like USP7 which mediate MDM2-catalysed auto- or p53-Ǥǲǳ
polyubiquitination of specific targets, and subsequently protein degradation is 
not a random process but aimed to remove particular substrates. The majority of 
muscle atrophy targets are yet to be catalogued. To fully understand the muscle 
atrophy process, these polyubiquitinated proteins need to be identified.  
 
Different methods have been employed for purifying polyubiquitinated 
substrates. Tagged ubiquitin has been expressed in yeast [188] and human cells 
[189] allowing purification via this tag, subsequent trypsinolysis and analysis by 
liquid chromatography tandem mass spectrometry (LC-MS/MS). Jeon et al. 2007 
generated a transgenic mouse that expressed tagged ubiquitin in the heart, and 
similarly purified and analysed ubiquitination substrates [190]. This has revealed 
a number of ubiquitin conjugation sites and substrates. An alternative strategy 
that has been employed is utilising the ubiquitin-binding S5a proteasomal 
subunit [191] or a ubiquitin-specific antibody [192]. 
 
Subsequently, tandem-repeated ubiquitin-binding entities (TUBEs) that are 
based on UBA domains were engineered in which multiple ubiquitin-binding 
domains are in close proximity, both promoting binding to polyubiquitin and 
protecting them from cellular enzymatic activities [193]. However, despite the 
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use of different UBA domains, it is unclear whether there is a level of selectivity 
using this method in terms of ubiquitin linkage. 
 
MS methods that have been employed to identify ubiquitination sites have taken 
advantage of trypsins inability to cleave after lysine residues in substrates that 
have ubiquitin attached [188]. This induces a mass shift of 114.1Da in the tryptic 
peptide derived from the linkage site, due to the isopeptide linked di-glycine stub 
remaining from the previously conjugated ubiquitin, aiding identification of 
substrates. As an alternative method for identifying ubiquitinated substrates, via 
binding to the S5a proteasomal subunit, but specifically eluting immobilised 
ubiquitinated proteins using USP2 catalytic core [194]. Eluted proteins were 
resolved by two-dimensional gel electrophoresis (2DE) and analysed by MS. 
More recently, a strategy was devised which utilised a monoclonal antibody that 
recognises the diglycine isopeptide on tryptic peptides; diglycine remains on 
ubiquitin-modified proteins after trypsinolysis [195]. This strategy allowed 
identification of around 19000 sites within 5000 human proteins that were 
diglycine modified, a method that can be used to assess ubiquitination-
modification quantitatively. Therefore, a number of different strategies have been 
employed to proteomically analyse ubiquitinated proteins in a range of cells and 
tissues, which may be utilised to address the unknown substrates of the atrophy 
programme. 
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1.10.  ZNF216 
 
1.10.1. Structure of ZNF216 
ZNF216 is a 213 residue protein (rat sequence), containing Znf_A20 and Znf_AN1 
domains at the N- and C- termini, respectively [196]. The N-terminal Znf_A20 
domain, located between amino acids 11-35, shares significant homology with 
the A20 protein, an inhibitor of TNF-induced NF- B signalling. This is the domain 
that has subsequently been associated with polyubiquitin binding [56]. The C-
terminal Znf_AN1 domain was named for its homology with a ubiquitin-like 
protein AN1 in Xenopus Laevis. ZNF216 protein exists in only one form, but two 
alternatively spliced transcripts exist in humans, as two different sequences exist 
upstream of the start ATG in exon [197]. However, no apparent difference in 
expression or regulation of these splice forms has been found to date. 
 
1.10.2. Biochemical function 
Initially, bioinformatic approaches were used to identify candidate genes 
responsible for hearing loss in humans, which mapped to the location of ZNF216 
[197]. Despite the position of ZNF216 on the human chromosome implicating a 
causal relationship to hearing loss, it could not be validated as a candidate. This 
was concluded when no disease causing mutations were identified in ZNF216, 
and transcripts were not observed to vary in length or abundance between 
control and deaf mice (dn) mice. 
 
48 
  
Huang et al. 2004 later identified ZNF216 as NEMO interacting protein via a yeast 
two-hybrid system [196]. Luciferase reporter assays indicated that ZNF216 
inhibits TNF-, IL1-, and TLR4-induced NF- B activation in a dose-dependent 
manner. More recently, ZNF216 was studied in the context of osteoclast 
differentiation [198]. Receptor and activator of NF-kappa B (RANK) and its ligand 
RANKL are known to be intimately involved in osteoclast differentiation. DNA 
microarray techniques showed that ZNF216 was upregulated as a result of 
RANKL stimulation in macrophages, and inhibited osteoclast formation (although 
not through the NF- B pathway). Hishiya et al. 2005 found no evidence that 
ZNF216 inhibits the NF- B pathway and in 2006 suggested that ZNF216 may not 
act directly on the NF- B pathway but act as a downstream effector as a 
component of the UPS [56]. Interestingly, AWP1 (protein associated with PRK1) 
is a protein highly homologous to ZNF216, having an N-terminal Znf_A20 domain 
that binds ubiquitin, and a C-terminal Znf_AN1 domain, and may be a regulator of 
NF- B signalling [199]. However, its role during NF- B signalling remains 
undefined to date. 
 
	 ? ? ?ǯǡet al. 2006 used yeast 
two-hybrid screening to identify binding partners and thus potential substrates 
of ZNF216 [56]. This yielded several clones of polyubiquitin C, binding ZNF216  ? ? ?Ǥ	 ? ? ?ǯ
localisation within the cell and was found to mostly be cytoplasmic. MS/MS was 
used to analyse proteins that co-immunoprecipitated with FLAG-tagged ZNF216 
and was found to associate 26S proteasome subunits. Interestingly, ubiquitin 
binding activity conferred by the A20 domain was not required for this 
association . 
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Hishiya et al. 2006 thus reasoned that ZNF216 may bind to polyubiquitinated 
substrates of the atrophy programme and shuttle targeted proteins to the 26S 
proteasome for degradation (Figure 1.7) [56]. Shuttle proteins may act to 
increase the efficiency of degradation by the 26S proteasome. Reduced 
interaction of the proteasome shuttle protein VCP leads to down-regulation of 
degradation of inactive ataxin-3, a deubiquitinating enzyme responsible for  
spinocerebellar ataxia type 3 [95]. Therefore shuttle proteins may play an 
important role in efficiently delivering substrates for degradation. Hishiya et al. 
2006 noted that although Dsk-2 has been identified as a shuttle protein in yeast, 
that similarly binds polyubiquitin and can associate with the proteasome, 
ZNF216 is not an orthologue [56]. The authors also inhibited COS-7 cell 
proteasomes with MG132, inducing accumulation of polyubiquitinated proteins 
that could not be degraded, aǮǯ[56]. The 
authors noted the association of ZNF216 with aggresomes, providing in vivo 
evidence of ZNF216 colocalising with polyubiquitinated proteins.  
 
Significant upregulation of ZNF216 mRNA levels was measured by Northern 
blotting in both a Dex induced myotube model and a fasting induced rat model of 
muscle atrophy [56]. Strikingly, ZNF216 knockout mice exhibited resistance to 
denervation induced atrophy, substantiating observations of increased ZNF216 
expression and accumulated ubiquitinated substrates in rats and myotubes 
under different atrophy stimuli. Together, these data implicated ZNF216 as 
having a critical role 	 ? ? ?ǯ
status as an atrogene. However, unlike the well established atrogenes MAFbx and 
MuRF1, further muscle atrophy models have yet to be analysed for the 
involvement of ZNF216, which may further validate it as a bona fide atrogene. 
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Figure 1.7 
 
 
 
Figure 1.7 Schematic of proposed function of ZNF216, which may bind polyubiquitinated 
proteins during skeletal muscle atrophy (such as those targeted by MAFbx), and shuttle 
them across to the 26S proteasome for degradation. ZNF216 may then continue to shuttle 
polyubiquitinated targets, and polyubiquitin is deubiquitinated and recycled for further 
rounds of conjugation. 
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1.11. Aims 
The atrogenes MAFbx and MuRF1 have been extensively researched in various 
models of skeletal muscle atrophy. Here, we aim to measure ZNF216 expression 
levels in different models of muscle atrophy, and compare to that of the 
established atrogenes MAFbx and MuRF1 to investigate ZNF216s role as an Ǥ	 ? ? ?ǯ
polyubiquitinated proteins via binding to the Znf_A20 domain. Considering its 
potential role as a shuttle protein that translocates atrophy substrates, ZNF216-
bound polyubiquitinated proteins may be muscle atrophy substrates. Thus we 
aim to purify and identify polyubiquitinated proteins from muscle that bind 
ZNF216, and potentially elucidate the elusive substrates degraded during skeletal 
muscle atrophy. 
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CHAPTER 2 
Materials and Methods 
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2.1. Experimental animals 
2.1.1. Intravenous endotoxin and chemical reagents 
1) lipopolysaccharide (LPS) (E. Coli, serotype 0127: B8, Sigma-Aldrich) 
2) thiobutabarbital sodium ((Inactin), Sigma-Aldrich) 
  
2.1.2. Protocol 
Chronically-instrumented male Sprague-Dawley Rats were continuously infused 
intravenously (i.v.) with either lipopolysaccharide (LPS) ( ? ?Ɋ-1 h-1; n=6) or 
saline (n=8) for 24 hr at 0.4ml h-1. 
 
The extensor digitorum longus (EDL) muscle was then removed and freeze-
clamped while the animals were under terminal anaesthesia, using 
thiobutabarbital sodium (80 mg kg ?1 i.v.). Muscles were stored in liquid nitrogen. 
Procedures were carried out by Julie March and Philip Kemp and were approved 
by the University of Nottingham Ethical Review Committee and were performed 
under Home Office Project and Personal license authority. 
  
2.2. Protein-to-DNA ratio 
2.2.1. Protein and DNA extraction 
2.2.1.1. Solutions 
1) perchloric acid: 0.2M, 0.1M and 1.2M PCA 
2) potassium hydroxide solution; 0.3M KOH 
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2.2.1.2. Protocol 
Alkaline soluble protein and DNA were extracted and quantified from EDL 
muscle from either saline or LPS-infused rats. Specifically, approximately 20mg 
of muscle was freeze-dried overnight and any visible blood and connective tissue 
was removed prior to powdering. 3 mg of powdered muscle was required for 
analysis. For precipitation of protein, 500 l of perchloric acid (0.2M PCA) was 
added to 3mg of muscle, and incubated in an ice-bath for 10 min. Samples were 
centrifuged at 3000 rcf for 15 min at 4oC. The remaining pellet was washed twice 
with 500 l PCA (0.2M) and the supernatant and washes were discarded. The 
precipitate was dissolved in 1ml potassium hydroxide (0.3M KOH) and incubated 
at 37oC for 1 hr, with gentle mixing. This solution was used to determine 
quantification of soluble protein and DNA by methods in Forsberg et al. 1991 
[200]. This allowed calculation of the protein-to-DNA ratio, a proposed method of 
calculating the magnitude of protein loss in muscle by Gamrin et al. 1996 [30]. 
Specifically, three 10 l aliquots of solution were extracted for protein 
quantification (see Section 2.2.2.) and the remaining solution was transferred to a 
glass tube. To precipitate DNA, 1ml of PCA (1.2M) was added to the remaining 
solution and was incubated in an ice-bath for 30 min. Samples were centrifuged 
at 3000 rcf for 15 min at 4oC. The pellet was washed twice with 500 l PCA 
(0.2M), and the supernatant, which contained the RNA, and washes were 
discarded. DNA was hydrolysed by incubating the pellet in 250 l PCA (1M) at 
70oC for 1 hr. Samples were centrifuged at 3000 rcf for 10 min at 4oC, and 200 l 
was required for DNA quantification (see Section 2.2.3.)  
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2.2.2. Protein quantification: Lowry method 
2.2.2.1. Solutions 
1) NaOH solution: 0.1M NaOH 
2) potassium hydroxide solution; 0.3M KOH 
3) NaOH and KOH solution: NaOH solution, KOH solution, mixed 9:1 
4) BSA standard: 1mg/ml, in NaOH and KOH solution 
5) sodium carbonate solution: 2% (w/v) Na2CO3 
6) sodium potassium tartrate solution: 2% (w/v) sodium potassium 
tartrate. 4H2O 
7) copper sulphate solution: 1% (w/v) CuSO4. 5H2O 
8) Lowry reagent: sodium carbonate solution, sodium potassium tartrate 
solution, copper sulphate solution, mixed 10:1:1 (v/v) 
9) Folin reagent: 10% ȋȀȌ	ǯ (Fisher 
Scientific), in NaOH solution 
 
2.2.2.2. Protocol 
Protein quantification was performed on samples from Section 2.2.2. Samples 
(10 l each) were diluted in NaOH solution (1:9). Similarly, BSA standards were 
used in triplicate in a range of 0-80 g. 100 l of samples were dispensed into a 96 
well plate, and samples/standards were made up to 200 l with NaOH, and 50 l 
of Lowry reagent was added. After 10 min incubation, 50 l of Folin reagent was 
added. The plate was incubated for 30 min at room temperature. Once colour had 
developed, the absorbance was measured using a plate reader (DYNEX 
technologies), and protein concentration was determined by comparing to the 
BSA protein standard curve. 
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2.2.3. DNA quantification 
2.2.3.1. Solutions 
1) perchloric acid: 1.7 M PCA 
2) diphenylamine solution: 4% (w/v), in glacial acetic acid 
3) acetaldehyde solution: 1.6mg/ml acetaldehyde 
4) DNA quantification reagent: diphenylamine, acetaldehyde, mixed 25:1 
(v/v) 
5) calf thymus DNA (Sigma-Aldrich; D4522): 45 g/ml, in 1M PCA 
 
2.2.3.2. Protocol 
To quantify DNA concentration, 50 l of PCA (1.7M) and 250 l of DNA 
quantification reagent were added to 200 l of the sample (see Section 2.2.2), and 
incubated overnight at 30oC. Absorbances were then analysed on a 
spectrophotometer (Spectramax® 190; Molecular Devices) at 595nm, in addition 
to a standard curve generated from calf thymus DNA that was treated identically 
to samples; the assay detected 0-11.25 g DNA. 
  
2.3. RNA extraction 
2.3.1. Solutions 
1) TRIzol® solution (Invitrogen) 
2) glycogen solution (10 g/ l), dissolved in TRIzol® solution 
3) CHCl3 (Sigma-Aldrich): iso-amyl alcohol (Sigma-Aldrich) (49:1) 
4) iso-propanol (Sigma-Aldrich) 
5) 75% EtOH 
6) RNase free water (Invitrogen) 
57 
  
2.3.2. Protocol 
Approximately 20-30mg of LPS (n=6) or control (n=8) EDL muscle was 
homogenised in 800 l of ice cold TRIzol solution, containing 5 l of glycogen 
solution. A polytron was used to homogenise the EDL muscle for approximately 
30s. Homogenate was incubated at room temperature for 5 min. To the 
homogenate, 160 l CHCl3 : iso-amyl (49:1) was added to the muscle extract and 
the tube then manually shaken followed by a 2s vortex. Incubation took place at 
room temperature for 2-3 min and was centrifuged at 12000 rcf for 15 min at 
4oC. The aqueous phase containing RNA was added to 400 l of ice-cold iso-
propanol, to have a 1:1 water phase:alcohol ratio and the organic phase and 
inter-phase were discarded. The samples were frozen at -20oC overnight to 
precipitate RNA, and the next day centrifuged at 12000 rcf for 15 min at 4oC. 
Pellets were washed in 800 l of 75% EtOH and were centrifuged again at 10000 
rcf for 10 min. RNA pellets were allowed to air-dry and then resuspended in 35 l 
of RNase free water. Resuspended RNA was quantified by measuring absorbance 
at 260nm and 280nm and was stored at -80oC (to undergo cDNA synthesis; see 
Section 2.4.) 
 
2.4. cDNA synthesis 
2.4.1. Solutions 
1) RNase free water (Invitrogen) 
2) random hexamer primers (Promega C1181) 
3) 10 x MMLV reverse transcriptase buffer 
4) 10mM dNTPs: 10mM dATP, 10mM dCTP, 10mM dTTP, 10mM dGTP, in 
RNase free water (Invitrogen) 
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5) RNA-ase inhibitor (Promega N2511) 
 
2.4.2. Protocol 
Reverse transcription was carried out using 1 g total RNA and 50ng of random 
hexamer primers was added to 15 l of diluted mRNA. An extra sample was made 
to act as a reverse transcription minus (-RT) control. Samples were incubated at 
70oC for 5 min to denature secondary structures and then placed on ice. To each 
sample was added 0.5 l of RNase inhibitor, 5 l 10 x MMLV reverse transcriptase 
buffer, 1.25 l of a pooled nucleotide mix and 1 l MMLV reverse transcriptase 
was added to each tube with the exception of the ȂRT sample, in which 1 l of 
RNase free water was added instead. Samples were made to a final volume of 
30 l and incubated at room temperature for 10 min, followed by a 42oC 
incubation for 1 hr. Reverse transcriptase enzyme was inactivated by heating 
samples at 70oC for 15 min. RNA-ase free water was added to samples to dilute 
them 1:3 (RNA:water), and stored at -80oC. 
 
2.5. TaqMan analysis 
2.5.1. Solutions 
1) PCR Universal Master Mix (Applied Biosystems) 
2) primer and FAM (6-carboxyl-fluorescin) probe sets (Applied 
Biosystems): HMBS (Cat # Rn00565886_m1), MAFbx (Cat # 
Rn00591730), MuRF1 (Cat # Rn00590197_m1), ZNF216 (Cat # 
Rn01479599_m1), Fbxo25 (Cat # Rn01478634_m1) 
3) primers: AWP1 (See Appendix I) 
4) probe: AWP1 (See Appendix I) 
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5) RNase free water (Invitrogen) 
6) cDNA samples from control and LPS tissue Ȃ diluted 1:3 with RNase free 
water 
 
2.5.2. Protocol 
Primer/probe sets for mRNA transcripts were shown to amplify with equal 
efficiency (data not shown; one example in Figure 3.2a), thus a comparative 
cycle-threshold (Ct) method was used for relative quantification of gene 
expression. Reactions were performed in the ABI Prism 7700 Sequence Detection 
System (Applied Biosystems) in MicroAmp 96-well reaction plates. Each well 
contained 12.5 l of master mix, 1.25 l primer and probe mix and 2 l of cDNA 
template in a reaction volume of 25 l in triplicate. Optimisation of AWP1 primers 
and probe was carried out to find conditions for the most efficient PCR. Wells 
measuring AWP1 contained 200nM probe, 900nM forward primer, 450nM 
reverse primer and again 12.5 l of master mix, and 2 l of cDNA template in a 
reaction volume of 25 l in triplicate. Cycling conditions were as follows: 50oC for 
2 min, 95oC for 10 min followed by 40 cycles of 95oC for 15s and 60oC for 1 min. 
Amplicons produced during cycling were analysed by DNA electrophoresis (on a 
4% agarose gel; see Section 2.6). The data from the LPS-treatment group was 
normalised to the average for the saline (control) group, using the 2 ?ȟȟ method. ȟȟt ȟt of LPS-treated samples and the ȟt of controls, following normalization of Ct values for the target gene to 
the Ct values of HMBS. The saline control group was given a value of 1, and fold 
changes in mRNA expression for the LPS-treated group were calculated, relative 
to the control group. 
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All data reported as means ±SEM. Comparisons between LPS and control tissue 
were performed by one-way analysis of variance (ANOVA). Significance was 
accepted at the 5% level. 
 
2.6. DNA electrophoresis 
2.6.1. Solutions 
1) Tris Ȃacetate-EDTA (TAE) buffer: 0.04M Tris-acetate 1mM EDTA, pH 8 
(HCl) 
2) ethidium bromide solution: 1% (w/v) water 
3) agarose gel solution: 1%/4% (w/v) agarose in TAE 
4) sample loading buffer: 5 x sample buffer (BioRad Cat 161-0767) 
  
2.6.2. Protocol 
Agarose gel solution was microwaved until the agarose had melted; either 1% or 
4% agarose was used, the latter required for separation of smaller gel products, 
including amplicons produced from TaqMan analysis in Section 2.5. The solution 
was mixed to ensure even temperature throughout. After cooling (but prior to 
setting), 1 l ethidium bromide solution was added and the mixture poured into a 
gel tank. Wells were formed by insertion of a comb before the gel set. The gel 
tank was filled with TAE buffer and sample loading buffer added to samples. 
Samples were loaded and the gel run at a constant voltage of 70V. DNA bands 
were detected on a UV transilluminator. 
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2.7. Plasmids 
The protein coding region of full length (FL) rat ZNF216 (residues 1-213) was 
produced previously in the lab from PCR amplified rat skeletal muscle cDNA. The 
PCR product was ligated in to the BamHI/XhoI sites of pGEX-4T-1 (GE 
Healthcare) to allow expression of N-terminal glutathione S-transferase (GST)-
tagged FL ZNF216 protein. This was provided as frozen (15% glycerol) stock, 
stored at -80oC. A mutant plasmid pGEX-4T-1-C30/33A-ZNF216 was generated 
via site-directed mutagenesis (see Section 2.9). The mutant encodes the same 
protein sequence as pGEX-4T-1-WT-ZNF216 but two conserved cysteine residues 
in the A20 domain have been substituted for alanines. The Znf_A20 construct was 
generated by introducing a premature stop codon after residue 60, also via site-
directed mutagenesis. Primers were later designed to clone the Znf_UBP (BUZ) 
domain (residues 163-291) of full-length human isopeptidase T (isoT). The 
Znf_UBP domain was cloned from human U20S cDNA (see Section 2.8) and 
ligated into the BamHI/XhoI sites of pGEX-4T-1. Constructs were verified using 
DNA sequencing.  
 
2.8. Cloning  
2.8.1. PCR amplification 
2.8.1.1. Solutions 
1) 5 x Green GoTaq® Flexi buffer (Promega) 
2) U20S cDNA (50ng/ l) 
3)  primers (10 M) (Appendix I)  Znf_UBP forward primer  
Znf_UBP reverse primer 
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4) 10mM dNTPs: 10mM dATP, 10mM dCTP, 10mM dTTP, 10mM dGTP, in 
deionised water 
5) deionised water 
6) GoTaq® DNA polymerase (5U/ l) (Promega) 
 
2.8.1.2. Protocol 
To clone the protein coding sequence of the Znf_UBP domain of iso T, 50ng 
human U20S cDNA (kindly donated by D. Foxler) was utilised as a template, and 
incubated with 1 l each of Znf_UBP forward/reverse primers, 0.5 l GoTaq, 4 l 5 
x Green GoTaq® Flexi buffer and 1 l dNTPs. A separate reaction was made up in 
the absence of GoTaq, and reaction mixtures were made up to 20 l with water. 
The cycling steps were as follows: 95oC for 1 min, followed by 40 cycles of 95oC 
for 1 min, 60oC for 1 min and 72oC for 1 min. Reactions were finally heated at 
72oC for 3 min for final extension, then held at 4oC. PCR reactions were separated 
by DNA electrophoresis on a 1% agarose gel (see Section 2.6); samples did not 
require the addition of sample buffer, as Green GoTaq Flexi buffer increases the 
density of samples to allow sinking to the bottom of the agarose gel well, and 
contains loading dye necessary for monitoring migration. The agarose gel 
purified PCR product was extracted using the QIAquick Gel Extraction Kit 
(QIAGEN), according to the manufacturerǯs instructions, and was double digested 
and ligated (see Section 2.8.2.) 
 
2.8.2. Restriction digest and ligation 
2.8.2.1. Solutions 
1) BamHI restriction enzyme (20U/ l) (NEB) 
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2) XhoI restriction enzyme (20U/ l) (NEB) 
3) NEBuffer 3 (10x) (NEB) 
4) T4 DNA ligase (3U/ l) (NEB) 
5) T4 DNA ligase reaction buffer (10x) (NEB) 
6) deionised water 
7) PCR product from Section 2.8.1. (Znf_UBP sequence) 
8) pGEX-4T-1 plasmid (100ng/ l) 
 
2.8.2.2. Protocol 
The PCR product purified from Section 2.8.1 was amplified to have BamHI and 
XhoI specific  ?ǯ ?ǯǡǤ16 l PCR product or 
5 l pGEX-4T-1 were double digested by the addition of 1 l BamHI, 1 l XhoI and 
2 l NEBuffer 3. The plasmid digestion was made up to a final volume of 20 l 
using deionised water. Digests were incubated for 2 hours at 37oC. Digested 
products were separated by DNA electrophoresis on a 1% agarose gel (see 
Section 2.6). The double digested PCR product or plasmid was extracted from 
agarose gel pieces using the QIAquick Gel Extraction Kit (QIAGEN), according to ǯǤ 
 
Purified double-digested products were quantified using a NanoDrop® ND-1000 
spectrophotometer (NanoDrop Technologies Inc., Wilmington, USA). The PCR 
product was ligated into the pGEX-4T-1 plasmid by incubating 50ng plasmid with 
between 3.5-10.5ng of double digested PCR product, together with 2.5 l T4 DNA 
ligase reaction buffer and 0.5 l T4 DNA ligase. Reactions were made up to a final 
volume of 25 l, and incubated overnight at 22oC, to allow ligation of the PCR 
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product into the pGEX-4T-1 plasmid. The ligation product was then put onto ice 
prior to transformation of the newly ligated plasmid into XL10-Gold bacteria.
 
2.9. Site-directed mutagenesis 
2.9.1. Solutions 
1) 10 x Pfu reaction buffer (Stratagene) 
2) plasmid   pGEX-4T-1-WT-rZNF216 (50ng/ l) 
3) primers (10 M) (Appendix I) ZNF216 C30/33A sense 
ZNF216 C30/33A antisense 
ZNF216 (1-60) sense (Znf_A20) 
ZNF216 (1-60) antisense (Znf_A20) 
4) dimethyl sulphoxide (DMSO) (Sigma-Aldrich D2650) 
5) 10mM dNTPs: 10mM dATP, 10mM dCTP, 10mM dTTP, 10mM dGTP, in 
deionised water 
6) deionised water 
7) Pfu DNA polymerase (2.5U/ l; Stratagene) 
8) Dpn1 restriction enzyme ( 20U/ l; NEB) 
 
2.9.2. Protocol 
This protocol follows instructions in QuikChange® Site-Directed Mutagenesis Kit 
(Stratagene.) Mutagenesis reactions were set up using the pGEX-4T-1-WT-
rZNF216 plasmid as a template, to generate a FL ZNF216 C30/33A mutant, and a 
truncated Znf_A20 construct. To each reaction, 5 l 10 x Pfu buffer, 1.25 l of sense 
and antisense primers and 1 l of 10mM dNTPs was added. Either 5ng, 20ng or 
50ng of plasmid was also added to each reaction, each in combination with either 
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0 l, 2.5 l or 5 l of DMSO. 1 l Pfu was added to each of these reactions at the 
denaturation step during cycling (see cycling information), with the exception of 
one reaction which contained 50ng plasmid and 0 l DMSO, and also lacked Pfu 
enzyme. The final reaction mixtures were made up to a final volume of 50 l. The 
cycling steps were; 95oC for 30s, after which Pfu was added to the necessary 
reactions, followed by 18 cycles of 95oC for 30s, 55oC for 1 min, 68oC for 6 min. 
Reactions were then held at 4oC. 
 
After site-directed mutagenesis, PCR products were treated with Dpn1 restriction 
enzyme to remove any non-mutated plasmid: 0.5 l Dpn1 was added to 25 l PCR 
products. The reaction was incubated at 37oC for 2 hours and put onto ice prior 
to transformation of the mutated plasmids into XL10-Gold bacteria. 
 
2.10. Transformation of E. coli with plasmid DNA 
2.10.1. Solutions 
1) XL10-Gold® ultracompetent cells (Stratagene) 
2) Luria Broth medium: 2.5% (w/v) LB (Sigma-Aldrich) Ȃ autoclaved to 
sterilise 
3) LB-agar ampicillin plates: 3.5% (w/v) LB-agar in H2O, 100 g/ml 
ampicillin 
 
2.10.2. Protocol 
Between 5 l-20 l of newly ligated plasmid (Section 2.8) or Dpn1-digested 
mutated plasmid (Section 2.9) was added to 100 l XL10-Gold competent cells 
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and incubated on ice for 30 min. Cells were heat shocked at 42oC for 30s before 
incubation on ice for 5 min. Cells and mutant plasmid were made up to 1ml with 
LB, and incubated at 37oC whilst shaking for 1 hr. Cells were plated out on agar 
ampicillin plates and incubated at 37oC overnight. pGEX-4T-1 plasmids confer 
ampicillin resistance, thus colonies that had grown after incubation are likely to 
contain intact plasmid. Single colonies were picked and used to inoculate 10ml 
LB overnight cultures. Plasmid preps using QIAprep® Spin Miniprep Kit (Cat # 
27104) were used to harvest plasmid from bacteria, and sequenced to identify 
successful mutagenesis and transformation. Glycerol stocks were made of 
successfully transformed cells. 
 
2.11. Glycerol stocks of E. coli 
2.11.1. Solutions 
1) 30% glycerol 
 
2.11.2. Protocol 
30% glycerol was filter sterilised, and 0.5ml added to 0.5ml bacterial culture. 
Glycerol stocks were then frozen at -80oC. 
 
2.12. GST-fusion protein overexpression 
2.12.1. Solutions 
1) Luria Broth: 2.5% LB (w/v) - autoclaved to sterilise 
2) ampicillin (100mg/ml) 
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3) 200mM isopropyl-1-thio- -D-galactopyranoside (IPTG) 
4) Tris-buffered saline (TBS)- Triton: 10mM Tris, 150mM sodium chloride, 
pH7.5 (HCl) 0.1% (v/v) Triton X-100 
 
2.12.2. Protocol 
Cells were obtained from glycerol stocks of XL10-Gold E. coli containing pGEX-
4T-1 plasmids with inserts that allow expression of GST-fused proteins. The 
plasmid confers ampicillin resistance to host cells, and cells either express 
recombinant GST-tagged WT ZNF216, C30/33A ZNF216, Znf_A20 or Znf_UBP 
proteins/constructs. These cells were grown overnight at 37oC whilst shaking in 
10ml LB amp (100 g/ml). The following day, cultures were diluted (1/100) in LB 
ampicillin (100 g/ml) contained in baffled flasks. Cells were grown whilst 
shaking at 37oC for 3 hours. Cultures were induced to overexpress protein by the 
addition of IPTG to a final concentration of 200 M and grown for a further 3 
hours while shaking at 37oC. These cultures were centrifuged in the Cellsep 
centrifuge at 4500 rcf, 4oC for 15 min, cell pellets resuspended in 10ml TBS 0.1% 
Triton X100 and stored at -20oC. 
 
2.13. Sodium dodecyl sulphate polyacrylamide-gel electrophoresis 
(SDS PAGE) 
2.13.1. Solutions 
1) 30% (w/v) acrylamide to bis-acrylamide 37.5:1 
2) 0.1% sodium dodecyl sulphate (SDS) 
3) buffer A: 1.1M Tris, 0.1% (w/v) SDS, 30% (w/v) glycerol, pH8.8(HCl) 
4) buffer B: 1.1M Tris, 0.1% (w/v) SDS, pH8.8(HCl) 
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5) stacking gel buffer: 0.14M Tris, 0.1% (w/v) SDS, pH6.8(HCl) 
6) ammonium persulphate (AMPS): 10% (w/v) ammonium persulphate 
7) deionised water 
8) tetramethylethylenediamine (TEMED): undiluted 
9) gel application buffer (GAB): 0.15M Tris, 8M urea, 2.5% (w/v) SDS, 20% 
(v/v) glycerol, 10% (w/v) 2-mercaptoethanol, 3% (w/v) DTT, 0.1% w/v 
bromophenol blue, pH6.8(HCl) 
10) electrode buffer: 0.025M Tris, 0.19M glycine, 0.1% w/v SDS 
11) Coomassie Blue stain: 50% (v/v) methanol, 20% (v/v) glacial acetic acid, 
0.12% (w/v) Coomassie Brilliant Blue R-250 
12) Coomassie Blue destain: 10% (v/v) methanol, 10% (v/v) glacial acetic 
acid 
 
2.13.2 Protocol 
5-20% polyacrylamide resolving gels were poured using a gradient caster, 
producing a continuous gradient. 100 l SDS was added to each resolving gel 
mixture, made to a total volume of 10ml with deionised water; the 5% 
polyacrylamide gel is composed of 1.67ml 30% acrylamide, 3.33ml buffer B and 
the 20% polyacrylamide gel contains 6.67ml 30% acrylamide, 3.33ml buffer A. 
Prior to pouring the gel, 100 l AMPS and 10 l TEMED were added to the gel 
mixtures to catalyse polymerisation. Water saturated butanol was used to cover 
the surface of the gradient gel. Subsequently, the 5% stacking gel was also 
polymerised using 100 l AMPS and 10 l TEMED (final concentration 0.12M Tris, 
0.1% SDS). GAB was added to protein samples, typically adding 20 l GAB to 50 l 
sample (containing around 5 g protein), which were heated to 90oC for 5 min. 
The gel was run at 40mA (E-C Apparatus Corporation). BIO-RAD All Blue 
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Precision Plus ProteinTM Standards were run on the gel in order to approximate 
the size of proteins within the samples. Gels were mostly either incubated for 1 
hr in Coomassie Blue stain and destained using Coomassie Blue destain solution, 
or proteins from the gel were transferred via Western blotting (see Section 2.15). 
Some gels were stained using Silver Staining Kit (GE Healthcare), according to the ǯǤ 
 
2.14. Two-dimensional gel electrophoresis (2DE) 
2.14.1. Solutions 
1) 30% (w/v) acrylamide to bis-acrylamide 37.5:1 
2) 0.1% sodium dodecyl sulphate (SDS) 
3) buffer A: 1.1M Tris, 0.1% (w/v) SDS, 30% (w/v) glycerol, pH8.8(HCl) 
4) buffer B: 1.1M Tris, 0.1% (w/v) SDS, pH8.8(HCl) 
5) ammonium persulphate (AMPS): 10% (w/v) ammonium persulphate 
6) tetramethylethylenediamine (TEMED): undiluted 
7) isoelectric focussing (IEF) sample buffer: DeStreak ?Rehydration 
Solution (GE Healthcare), 0.5% (v/v) pH 3 Ȃ 11NL ampholyte solution 
(GE Healthcare) 
8) mineral oil (BioRad) 
9) 70% EtOH 
10) equilibration buffer I (6M urea, 2% (w/v) SDS, 0.375M Tris-Cl, 2% (w/v) 
DTT, pH 8.8, 20% (v/v) glycerol) 
11) equilibration buffer II (6M urea, 2.5% (w/v) iodoacetamide, 0.375M Tris-
Cl, 2% (w/v) DTT, pH 8.8, 20% (v/v) glycerol) 
12) electrode buffer: 0.025M Tris, 0.19M glycine, 0.1% w/v SDS 
70 
  
13) agarose gel solution: 1% (w/v) agarose, 0.1% (w/v) bromophenol blue, 
in 1 x electrode buffer 
14) fixative: 40% (v/v) methanol, 10% (v/v) glacial acetic acid 
15) deionised water 
16) colloidal Coomassie Blue stain: 0.0125% (w/v) Coomassie G250, 3% 
(v/v) phosphoric acid, 8% (w/v) ammonium sulphate, 20% (v/v) ethanol 
 
2.14.2 Protocol 
5-20% polyacrylamide resolving gels were poured using a gradient caster, in a 
protocol identical to Section 2.13, except that the stacking gel was omitted, and 
GAB was not added to samples. Instead, 150 l isoelectric focussing (IEF) sample 
buffer was added to samples and incubated at room temperature for 15 min. 
Immobilised pH gradient (IPG) strips (11cm; pH 3-11NL) were actively 
rehydrated at 50V with the sample/IEF buffer, under 2ml mineral oil, overnight 
at 20oC. An 11cm focusing tray was washed with 70% ethanol, and dampened 
electrode wicks were placed on the electrodes. Excess mineral oil was drained 
from IPG strips, placed in the focusing tray and covered in 1ml mineral oil. To 
isoelectrically focus strips, the isoelectric focuser (BioRad) was set to a linear 
ramping programme (Step 1: 250V Ȃ 15 min; Step 2: 8000V Ȃ 2 hr 30 min; Step 3: 
8000V Ȃ 35000 Vh, Step 4: 500V Ȃ Hold).  
 
When focusing was complete, wicks were removed and mineral oil drained from 
IPG strips. Strips were washed 3 x 5 min with 1ml equilibration buffer I and 3 x 5 
min with 1ml equilibration buffer II. Finally, strips were mounted on the 5-20% 
gradient polyacrylamide gel, and a 1% agarose solution was pipetted onto the gel 
strip to monitor protein migration through the gel, and to seal the strip in 
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position. Gels were run at 40mA (E-C Apparatus Corporation). BIO-RAD All Blue 
Precision Plus ProteinTM Standards were run on the gel, adjacent to the IPG strip, 
in order to approximate the size of proteins within the samples. 
 
Proteins were either visualised by colloidal Coomassie staining, silver staining or 
were transferred via Western blotting (see Section 2.15). To colloidal Coomassie 
stain proteins, gels were fixed in fixative for one hr at room temperature with 
gentle rocking, prior to two 10 min washes with deionised water. Gels were then 
immersed in 100ml colloidal Coomassie Blue stain overnight with gentle rocking, 
and finally destained by further washes with deionised water. Some spots were 
excised and tryptically digested and analysed by peptide mass fingerprinting 
(PMF; Section 2.23). Gels were silver stained using Silver Staining Kit (GE 
Healthcare), ǯǤ 
 
2.15. Western blotting 
2.15.1. Solutions 
1) Western transfer buffer: 0.025M Tris, 0.192M glycine, 20% (v/v) 
methanol 
2) Ponceau S solution: 0.1% (w/v) Ponceau S, 10% (v/v) glacial acetic acid 
3) Renaissance Enhanced Chemiluminescence (ECL): (Amersham) 
4) developing solution: (Calumet Photographic LTD 757314) 
5) fixing solution: (Calumet Photographic LTD 2000RT) 
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2.15.2. Protocol 
The gel and nitrocellulose (Hybond-C, Amersham) were soaked in Western 
transfer buffer prior to contact. Protein on the gel was transferred to the 
membrane by blotting overnight at room temperature (Fisherbrand 
Electrophoresis Unit) at 40mA. To confirm successful transfer, the blot was 
stained with Ponceau S solution for 1 min (until bands were visible), then 
destained with distilled water. Information about antibodies (manufacturer and 
dilutions), incubation times, wash buffer and blocking buffer can be found in 
Appendix II. Ponceau S stain was removed by washing in wash buffer. 
Membranes were incubated in blocking solution prior to incubating in either 
primary antibody, or horseradish peroxidase (HRP)-conjugated antibody. 
Membranes were washed 3 x 5 min with wash buffer to remove excess and 
unbound antibodies. Blots incubated in primary antibody were then incubated 
with secondary antibody, and subsequently washed 3 x 5 min in wash buffer. 
Washed membranes (both those incubated in secondary and HRP-conjugated 
antibodies) were then immersed for 1 min in Renaissance ECL solutions. 
Hyperfilm ECL (Amersham Biosciences) was exposed to the blot for between 1-
20 min prior to developing (with developing solution). Film was then washed in 
distilled water, fixed (in fixing solution), washed again in water and finally air-
dried.  
 
2.16. Thrombin cleavage 
2.16.1. Solutions 
1) Tris-buffered saline (TBS)-Triton: 10mM Tris, 150mM sodium chloride, 
pH 7.5 (HCl) 0.1% (v/v)  Triton x100 
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2) glutathione-Sepharose beads (stored in ethanol) 
3) thrombin cleavage buffer: 20mM Tris, 150mM sodium chloride, 2.5mM 
calcium chloride dihydrate, pH 8.4 (HCl) 
4) thrombin 0.5units/ l 
 
2.16.2. Protocol 
Cell pellets resulting from protein overexpression were sonicated on ice 7 x 15s 
at 6-7 microns (30s cooling.) The sample was centrifuged at 35000 rcf at 4oC for 
30 min in an Avanti JA-25-50 rotor. 1ml glutathione-Sepharose beads (per 
sample) were equilibrated with 5ml TBS-Triton, in a polyprep column (BioRad). 
Once centrifuged, the pellet formed was discarded and the supernatant incubated 
with beads for a minimum of 1 hr, at 4oC while rotating. Beads were washed with 
3 x 10ml TBS Triton and 1 x 10ml thrombin cleavage buffer (to equilibrate). For 
thrombin cleavage of the GST tag, 10 units of thrombin were added per column in 
1ml thrombin cleavage buffer and incubated overnight at 4oC whilst rotating. The 
following day, recombinant protein was collected from the beads in solution. The 
purified protein was resolved by SDS PAGE and stained with Coomassie Blue for 
1 hr, and destained with Coomassie destain (see Section 2.13).  
 
2.17. Coupling protein to Sepharose beads 
2.17.1. Solutions 
1) cyanogen bromide-activated-Sepharose-4B (CNBr Seph 4B) (GE 
Healthcare) 
2) 1mM HCl 
3) coupling buffer: 100mM NaHCO3, 500mM NaCl, pH8.3 (HCl) 
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4) 1M ethanolamine, pH8.0 (HCl) 
5) acetate buffer: 100mM NaOAc, 500mM NaCl, pH4 (acetic acid) 
6) Tris buffer: 100mM Tris (hydroxymethyl) methylamine pH8 (HCl) 
7) column storage buffer: 25mM Tris (hydroxymethyl) methylamine, 1mM 
sodium azide, pH7.4(HCl) 
 
2.17.2. Protocol 
Cyanogen bromide Sepharose 4B (CNBr Seph 4B) was hydrated for 15 min in HCl 
solution, and transferred to a polyprep column (BioRad.) Beads were washed 
with 5 bed volumes of coupling buffer. Protein that was coupled with Sepharose 
beads was either ubiquitin or thrombin cleaved protein (either FL ZNF216 WT, 
FL ZNF216 C30/33A, Znf_A20 or Znf_UBP). Thrombin cleaved proteins/ubiquitin 
were diluted to the appropriate concentration with coupling buffer and 
incubated with the beads for 3 hours at 4oC (see Results for final concentrations 
of mg protein/ml Sepharose). Protein solution was passed through the beads, 
which were then washed with 5 bed volumes of ethanolamine and incubated in 
ethanolamine overnight at 4oC. The following day, this solution was removed, and 
beads were washed with 5 bed volumes of coupling buffer 3 x. Beads were 
washed alternately with 5 bed volumes of acetate or Tris buffer 4 x. Beads were 
finally washed with column storage buffer, and stored in a 50% slurry in column 
storage buffer. Control Sepharose (protein omitted, replaced by coupling buffer) 
was prepared in parallel to protein coupled beads. 
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2.18. Deubiquitination assay 
2.18.1. Solutions 
1) USP2, catalytic core (rat, recombinant); (0.5 g/ l; Enzo Life Sciences) 
2) TBSA: 50mM Tris, 0.1% (w/v) bovine serum albumin (BSA) pH7.5 
3) Polyubiquitin chains: Lys48 (K48) or Lys63 (K63) linked polyubiquitin 
chains, (Enzo Life Sciences) in TBSA, 0.125 g/30 l 
4) gel application buffer (GAB): 0.15M Tris, 8M urea, 2.5% (w/v) SDS, 20% 
(v/v) glycerol, 10% (w/v) 2-mercaptoethanol, 3% (w/v) DTT, 0.1% w/v 
bromophenol blue, pH6.8 (HCl) 
 
2.18.2. Protocol 
FL ZNF216 WT-Sepharose (17.75mg/ml), FL ZNF216-C30/33A-Sepharose 
(17.75mg/ml) and control-Sepharose were produced by covalently immobilising 
proteins on CNBr Seph 4B (see Section 2.17.) 0.125 g K48-linked polyubiquitin 
chains (in TBSA buffer) were incubated overnight at 37oC with 30 l Sepharose 
(as noted above), in the absence of Sepharose or with 0.5 g USP2. 50 l GAB was 
added to beads/solutions, and the remaining protein was resolved by SDS PAGE 
(Section 2.13) and proteins were immunoblotted with anti-ubiquitin antibodies 
(Section 2.15). 
 
2.19. UbiquitinȂSepharose binding assay 
2.19.1. Solutions 
1) Tris-buffered saline (TBS)- Triton: 10mM Tris, 150mM sodium chloride, 
pH7.5 (HCl) 0.1% (v/v) Triton X-100 
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2) gel application buffer (GAB): 0.15M Tris, 8M urea, 2.5% (w/v) SDS, 20% 
(v/v) glycerol, 10% (w/v) 2-mercaptoethanol, 3% (w/v) DTT, 0.1% 
(w/v) bromophenol blue, pH6.8 (HCl) 
 
2.19.2. Protocol 
Previous to this protocol, pellets were spun down from 10ml overnight E. coli 
cultures. These cultures were previously induced to overexpress the following 
recombinant proteins: GST, GST-WT-ZNF216 and GST- ZNF216-C30/33A. Pellets 
were thawed and resuspended in 1ml TBS-Triton, sonicated 4 x 15s (with 30s 
cooling intervals) and centrifuged at 16000 rcf for 10 min. The pellet that 
resulted was discarded and the supernatant collected. 50 l glutathione, control 
and ubiquitin-Sepharose (10mg/ml) beads (see Section 2.17) were equilibrated 
in 1ml TBS-Triton. For all supernatants, except for GST, 50 l supernatant was 
added to each type of Sepharose bead. Only 25 l of the GST supernatant was 
added as it is more efficiently expressed in E. coli relative to the other proteins. 
The beads were incubated with supernatant for 30 min at 4oC while rotating. 
After incubation, beads were washed 2 x 1ml TBS-Triton, and bead-bound 
protein was eluted with 50 l gel application buffer. Samples were boiled for 5 
min and resolved by SDS PAGE (Section 2.13). 20 l sample was loaded per lane. 
One gel was stained for protein using Coomassie (Section 2.13) and one was 
transferred overnight by Western blotting (Section 2.15) and subsequently 
probed with anti-GST antibodies. 
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2.20. Polyubiquitin chain-binding assay 
2.20.1. GST-tagged proteins 
2.20.1.1. Solutions 
1) Tris-buffered saline (TBS)- Triton: 10mM Tris, 150mM sodium chloride, 
pH7.5 (HCl) 0.1% (v/v) Triton X-100 
2) TBSA: 50mM Tris, 0.1% (w/v) Bovine serum albumin (BSA) pH7.5 (HCl) 
3) polyubiquitin chains: Lys48 (K48)- or Lys63 (K63)-linked polyubiquitin 
chains, (Enzo Life Sciences) in TBSA, 0.5 g/50 l 
4) gel application buffer (GAB): 0.15M Tris, 8M urea, 2.5% (w/v) SDS, 20% 
(v/v) glycerol, 10% (w/v) 2-mercaptoethanol, 3% (w/v) DTT, 0.1% w/v 
bromophenol blue, pH6.8 (HCl) 
  
2.20.1.2. Protocol 
Previous to this protocol, pellets were spun down from 10ml overnight E. coli 
cultures. These cultures were previously induced to overexpress the following 
recombinant proteins: GST, GST-WT-ZNF216 and GST-C30/33A-ZNF216. Pellets 
were thawed and then resuspended in 1ml TBS-Triton, sonicated 4 x 15s (with 
30s cooling intervals) and centrifuged at 16000 rcf for 10 min. The resultant 
pellet was discarded and supernatant collected. 50 l glutathione Sepharose 
beads were equilibrated in 1ml TBS-Triton. For all supernatants, except GST, 
50  supernatant was added to each type of Sepharose bead. Only 25  of the 
GST supernatant was added as it is more efficiently expressed in E. coli relative to 
the other proteins. The beads were incubated with supernatant for 30 min at 4oC 
while rotating. After incubation, beads were washed 2 x 1ml TBS-Triton and 
equilibrated with TBSA. K48/K63 polyubiquitin chains (0.5 g) were added to 
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each set of beads in 50 l Tris BSA buffer. Beads were incubated for 30 min at 4oC 
with gentle agitation every 5 min. Solution was discarded and beads were 
washed 2 x 1ml Tris BSA. Bound protein was eluted with 50 l GAB. Proteins were 
resolved by SDS PAGE (Section 2.13), transferred to nitrocellulose overnight by 
Western blotting and probed with anti-ubiquitin (Section 2.15). 
 
2.20.2. Thrombin cleaved proteins 
2.20.2.1. Solutions 
1) binding buffer: 50mM Tris, 150mM NaCl, 0.5% (v/v)  NP-40, 0.1% (w/v) 
bovine serum albumin (BSA; Sigma-Aldrich), 1mM DTT, pH 7.5 (HCl) 
2) polyubiquitin chains: Lys48 or Lys63 linked polyubiquitin chains, (Enzo 
Life Sciences) in binding buffer, 0.25 g/50 l 
3) ubiquitin 5 +1: Ub5+1 (Enzo Life Sciences), in binding buffer, 0.125 g/50 l 
4) gel application buffer (GAB): 0.15M Tris, 8M urea, 2.5% (w/v) SDS, 20% 
(v/v) glycerol, 10% (w/v) 2-mercaptoethanol, 3% (w/v) DTT, 0.1% w/v 
bromophenol blue, pH6.8 (HCl) 
 
2.20.2.2. Protocol 
Znf_A20- (5mg/ml), Znf_UBP- (10mg/ml) or control-Sepharose (50 l each) were 
equilibrated in binding buffer. Beads were incubated with 0.25 g of K48-/K63-
linked polyubiquitin chains or 0.125 g Ub5+1  (in binding buffer) for 30 min at 
4oC, with gentle agitation every 5 min (see Results for further detail). Beads were 
washed twice in 1ml binding buffer and bound proteins were eluted with 50 l 
GAB, resolved by SDS PAGE (Section 2.13) and immunoblotted with anti-
ubiquitin (Section 2.15). 
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2.21. MG132 treatment of U20S cells 
2.21.1. Solutions 
1) dimethyl sulphoxide (DMSO): (Sigma-Aldrich D2650) 
2) MG132: 10mM MG132 (Enzo Life Sciences), in DMSO  
3) Penicillin/Streptomycin: (Sigma-Aldrich). Penicillin/Streptomycin 
solution contained 10,000 units of Penicillin and 10mg/ml Streptomycin 
in 0.9% (w/v) NaCl 
4) ǯǯ(DMEM): 4500mg/L glucose, 2mM 
L-glutamine and 100mg/L sodium pyruvate (Sigma-Aldrich) 
5) Fetal Bovine Serum (FBS): (Sigma-Aldrich).  
6) media: DMEM, 10% (v/v) foetal calf serum (FCS), 1% (v/v) 
penicillin/streptomycin 
7) Phosphate Buffer Saline (Sigma-Aldrich) 
 
2.22.2. Protocol 
U20S cells (derived from a human osteosarcoma cell line) were grown to ~80% 
confluence in 2 x 75cm2 cell culture flasks (Corning®, cell culture flask, 75cm2). 
One flask was then treated with MG132 (to a final concentration of 1 M) and the 
other with the same volume of DMSO, in fresh media, for 16 hours and incubated 
at 37oC. Cells were then targeted for affinity capture, as detailed in Section 2.22.3. 
 
2.22. Pulldown Assays 
2.22.1. Rat muscle 
2.22.1.1. Affinity chromatography 
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2.22.1.1.1. Solutions 
1) dimethyl sulphoxide (DMSO): (Sigma-Aldrich D2650) 
2) MG132: 10mM MG132 (Enzo Life Sciences), in DMSO  
3) mammalian protease inhibitor cocktail (Sigma-Aldrich) 
4) Tris DTT: 50mM Tris, 1mM DTT, 20 M MG132, 0.1% (v/v) mammalian 
protease inhibitor cocktail, pH 7.5 (HCl) 
5) gel application buffer (GAB): 0.15M Tris, 8M urea, 2.5% (w/v) SDS, 20% 
(v/v) glycerol, 10% (w/v) 2-mercaptoethanol, 3% (w/v) DTT, 0.1% w/v 
bromophenol blue, pH6.8 (HCl) 
 
2.22.1.1.2. Protocol 
Affinity chromatography was typically utilised to capture polyubiquitinated 
proteins/unanchored polyubiquitin, using CNBr Seph 4B immobilised FL ZNF216 
WT, FL ZNF216 C30/33A, Znf_A20 and Znf_UBP (Section 2.17). In the first 
instance, approximately 7g of control, mixed rat muscle was homogenised in 
50ml Tris DTT buffer. Rat muscle was kindly donated by L. Lyons; muscle was 
taken from rat hind legs and includes EDL, soleus, biceps femoris, tibialis 
anterior, gastrocnemius and gluteus superficialis muscles. Rat muscle 
homogenate was centrifuged at 35000 rcf at 4oC for 30 min in an Avanti JA-25-50 
rotor. The insoluble pellet was discarded, and the supernatant passed through 
glass wool to remove any debris. Supernatant was split three ways between 
either 150 l FL ZNF216 WT-Sepharose, 150 l ZNF216 C30/33A-Sepharose or 
150 l control-Sepharose (in polyprep column; BioRad) at 4oC. Muscle lysate was 
passed through Sepharose twice and then washed three times with 10ml Tris 
DTT. Bound proteins were eluted with GAB and resolved by SDS PAGE and 
visualised either by Coomassie staining (Section 2.13), stained using Silver 
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Staining Kit (GE Healthcare; ǯȌǡ 
gel was transferred via Western blotting and immunoblotted with anti-ubiquitin 
antibodies (see Section 2.15). Subsequent rat muscle pulldowns were a variation 
of this protocol, and details can be found in the appropriate Results and Figure 
legends. Some affinity captured proteins were resolved instead by 2DE and 
colloidal Coomassie stained (Section 2.14) or captured on Znf_A20- or Znf_UBP-
Sepharose. Rat muscle was subsequently homogenised in optimised buffers, and 
Sepharose was washed in varying buffers and details of analysis are detailed in 
Figure legends; i.e. SDS PAGE or 2DE, antibodies used, use of deubiquitination 
and PMF/liquid chromatography tandem mass spectrometry (LC-MS/MS), rat 
muscle (total mass, muscle type), Sepharose (type, volume, concentration) and 
buffer (volume, composition). Some affinity captured ubiquitinated proteins 
were subjected to deubiquitination, as detailed below in Section 2.22.1.2. 
 
2.22.1.2. Deubiquitination 
 2.22.1.2.1. Solutions 
1) USP2, catalytic core  (rat, recombinant); (0.5 g/ l; Enzo Life Sciences) 
2) Deubiquitination (DUB) buffer: 50mM Tris, 1mM DTT, pH 7.5 (HCl) 
3) gel application buffer (GAB): 0.15M Tris, 8M urea, 2.5% (w/v) SDS, 20% 
(v/v) glycerol, 10% (w/v) 2-mercaptoethanol, 3% (w/v) DTT, 0.1% w/v 
bromophenol blue, pH6.8 (HCl) 
 
2.22.1.2.2. Protocol 
Rat muscle proteins were captured on Znf_A20- /Znf_UBP-Sepharose, as 
described in Section 2.22.1.1. To elute ubiquitinated proteins specifically, rather 
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than eluting all bound proteins using GAB, Sepharose was deubiquitinated using 
USP2. Typically, 800 l of Sepharose that has been washed three times in the 
appropriate wash buffer was then washed 1 x 10ml DUB buffer. An equal volume 
of DUB buffer (800 l) to beads was added, +/- 10 g USP2 core for 2hrs at 37oC. 
Limited deubiquitination was also performed, in which beads were incubated for 
only 1hr. Solutions were collected from beads, and two further equal volume DUB 
buffer washes were performed, and the washes pooled. Proteins bound to beads 
were eluted with GAB, resolved by SDS PAGE, Coomassie stained (Section 2.13) 
and some proteins were excised for tryptic digestion and PMF (Section 2.23). 
Alternatively, SDS PAGE gels were transferred overnight and immunoblotted 
with a number of antibodies (Section 2.15; see Results for information on 
antibodies used.) Solutions were treated the same as beads, or were tryptically 
digested and analysed by LC-MS/MS. 
 
2.22.2. Mouse cortex  
2.22.2.1. Affinity chromatography 
2.22.2.1.1. Solutions 
1) dimethyl sulphoxide (DMSO): (Sigma-Aldrich D2650) 
2) MG132: 10mM MG132 (Enzo Life Sciences), in DMSO  
3) mammalian protease inhibitor cocktail (Sigma-Aldrich) 
4) homogenising buffer:  50mM Tris, 150mM NaCl, 0.5% (v/v) NP-40, 5mM 
N-ethylmaleimide, 20 M MG132, 0.1% (v/v) mammalian protease 
inhibitor cocktail (Sigma), pH 7.5 
5) wash buffer: 50mM Tris, 150mM NaCl, 0.5% NP-40, 1mM DTT, pH 7.5 
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6) gel application buffer (GAB): 0.15M Tris, 8M urea, 2.5% (w/v) SDS, 20% 
(v/v) glycerol, 10% (w/v) 2-mercaptoethanol, 3% (w/v) DTT, 0.1% w/v 
bromophenol blue, pH6.8 (HCl) 
 
2.22.2.1.2. Protocol  
Mouse cortexes from wild type and Psmc1 knockout mouse brain (~15mg each) 
were donated by L. Bedford. Cortexes were homogenised in 5ml homogenising 
buffer. Homogenate was centrifuged, supernatant passed through glass wool. 
DTT was added to the supernatant to a final concentration of 10mM, and mixed 
at 4oC for 15 minutes. Supernatant was passed twice through 50 l Znf_A20-
/control-Sepharose for 1 hour at 4oC. Beads were washed three times in wash 
buffer and bound proteins eluted with GAB, resolved by SDS PAGE (Section 2.13) 
and immunoblotted with anti-ubiquitin (Section 2.15).  
 
2.22.3. U20S cells 
2.22.2.1. Affinity chromatography 
2.22.2.1.1. Solutions 
1) dimethyl sulphoxide (DMSO): (Sigma-Aldrich D2650) 
2) MG132: 10mM MG132 (Enzo Life Sciences), in DMSO  
3) mammalian protease inhibitor cocktail (Sigma-Aldrich) 
4) homogenising buffer:  50mM Tris, 150mM NaCl, 0.5% (v/v) NP-40, 5mM 
N-ethylmaleimide, 20 M MG132, 0.1% (v/v) mammalian protease 
inhibitor cocktail (Sigma), pH 7.5 
5) wash buffer: 50mM Tris, 150mM NaCl, 0.5% NP-40, 1mM DTT, pH 7.5 
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6) gel application buffer (GAB): 0.15M Tris, 8M urea, 2.5% (w/v) SDS, 20% 
(v/v) glycerol, 10% (w/v) 2-mercaptoethanol, 3% (w/v) DTT, 0.1% w/v 
bromophenol blue, pH6.8 (HCl) 
 
2.22.2.1.2. Protocol 
U20S cells were grown to >80% confluence in 3 x 75cm2 cell culture flasks 
(Corning®, cell culture flask, 75cm2). Cells were scraped into 8ml homogenising 
buffer, while the MG132-treated/DMSO-only cells (Section 2.21), each from 1 x 
75cm2 cell culture flask, was scraped into 4ml homogenising buffer. All samples 
were then sonicated 3 x 30s (with 30s cooling), centrifuged at 12000 rcf and the 
supernatant was passed through glass wool. Insoluble material that pelleted was 
discarded and DTT was added to the supernatant to a final concentration of 
10mM, and mixed at 4oC for 15 min. Protein concentration was approximately 
4mg protein per flask. Lysate was either passed through Sepharose twice (+/- 
MG132 cells), or incubated overnight (untreated U20S cells only) at 4oC. 
Untreated cell lysate was incubated with either FL ZNF216 WT- or FL ZNF216 
C30/33A-Sepharose, while +/- MG132 treated cells were passed through either 
Znf_A20-, Znf_UBP- or control-Sepharose (Section 2.17) (further details in 
Results). Beads were then washed 3 x 10ml wash buffer, proteins were eluted 
with GAB, resolved by SDS PAGE (Section 2.13) and immunoblotted (Section 
2.15), as detailed in the Results chapters. 
 
2.22.3. Human muscle 
2.22.2.1. Affinity chromatography 
2.22.2.1.1. Solutions 
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1) dimethyl sulphoxide (DMSO): (Sigma-Aldrich D2650) 
2) MG132: 10mM MG132 (Enzo Life Sciences), in DMSO  
3) mammalian protease inhibitor cocktail (Sigma-Aldrich) 
4) homogenising buffer:  50mM Tris, 150mM NaCl, 0.5% NP-40, 5mM N-
ethylmaleimide, 20 M MG132, 0.1% (v/v) mammalian protease inhibitor 
cocktail (Sigma), pH 7.5 
5) wash buffer: 50mM Tris, 150mM NaCl, 0.5% NP-40, 1mM DTT, pH 7.5 
6) gel application buffer (GAB): 0.15M Tris, 8M urea, 2.5% (w/v) SDS, 20% 
(v/v) glycerol, 10% (w/v) 2-mercaptoethanol, 3% (w/v) DTT, 0.1% w/v 
bromophenol blue, pH6.8 (HCl) 
  
2.22.2.1.2. Protocol  
Human muscle biopsy samples (~10mg each), taken from 5 healthy volunteers 
(donated by P. Atherton), were homogenised in 1ml homogenising buffer. 
Homogenate was centrifuged, supernatant passed through glass wool and DTT 
added to the supernatant to a final concentration of 10mM, and mixed at 4oC for 
15 minutes. Supernatant was incubated with 50 l Znf_A20-Sepharose for 1 hour 
at 4oC. Beads were washed three times in wash buffer and bound proteins eluted 
with GAB, resolved by SDS PAGE (Section 2.13) and immunoblotted with anti-
ubiquitin (Section 2.15).  
 
2.23. Trypsinolysis and mass spectrometry analysis 
2.23.1. Solutions 
1) Trypsin: 5 g.mL-1 sequencing grade porcine trypsin (Promega) 
2) acetonitrile 
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3) ammonium bicarbonate: 0.1M ammonium bicarbonate, 50% (v/v) 
acetonitrile, pH 8.0 
4) DTT: 1mM DTT, in ammonium bicarbonate 
5) iodoacetamide: 2mM iodoacetamide, in ammonium bicarbonate 
6) 0.1% formic acid(aq) 
7) 0.1% formic acid in 70% acetonitrile(aq) 
 
2.23.2. Protocol 
All detected components were manually excised and then trypsinolysed using 
standard automated robotic procedures. Briefly; bands/spots were incubated 
with 1mM DTT followed by 2mM iodoacetamide with interim washing. Gel pieces 
were then washed with acetonitrile, dried and then rehydrated with sufficient 
trypsin in aqueous 0.1M ammonium bicarbonate. Proteolytic peptides were 
extracted by recovering sequential washes with 0.1% formic acid(aq) and 0.1% 
formic acid in 70% acetonitrile(aq) and then dried. 
 
For PMF analysis, extracted tryptic peptides were analysed by MALDI-TOF-MS 
and the resulting peak-list was used to interrogate genome databases using the 
Peptide-Mass-Fingerprint application in MASCOT software (Matrix Science). 
Alternatively, to analyse mixtures proteins eluted by deubiquitination (Section 
2.22.1.2.), mixtures of tryptic peptides were analysed by LC-MS/MS. 
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CHAPTER 3 
Expression profiling of ZNF216 in different models of 
skeletal muscle atrophy 
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3.1. Introduction  
Skeletal muscle atrophy may be activated by a number of different stimuli, for 
example in acidosis conditions as occurs during diabetes or chronic renal failure 
[201, 202], during sepsis in which macrophages release cytokines that then 
trigger specific signalling cascades [4-6, 48, 51], and upon treatment with the 
cholesterol-lowering drugs, statins [203]. Burn injury may also induce muscle 
wasting [204], as can the onset of cancer[47, 205] and infection with human 
immunodeficiency virus (HIV) [206]. Fasting, disuse and denervation may also 
trigger skeletal muscle atrophy [207], but unlike other atrophy modes, is 
triggered by a lack of nutrients and inactivity. Different atrophy triggers may 
induce muscle wasting via different molecular pathways that regulate protein 
synthesis and breakdown. When considering protein degradation, the E3 
ubiquitin ligase enzymes, muscle atrophy F-box protein (MAFbx) and muscle 
RING-finger 1 (MuRF1) ȋǮǯȌ, have been shown to play a 
critical role in a number of different atrophy models, suggesting that there are 
likely to be common downstream molecular pathways. The zinc finger protein 
216 (ZNF216) proteiǮ ?implicated in skeletal muscle 
atrophy, thought to act at a later stage of the atrophy programme by shuttling 
ubiquitinated substrates (presumably modified by the actions of MAFbx and/or 
MuRF1) to the 26S proteasome for their degradation [56]. This proposal is based 
on evidence that ZNF216 localises (via its Znf_AN1 domain) with the 26S 
proteasome and simultaneously can bind to polyubiquitin (via its Znf_A20 
domain) [56]. ZNF216 has previously been shown to be up-regulated in 
denervation and starvation-induced mouse models of skeletal muscle atrophy, 
and indeed is required for muscle atrophy to occur (based on gene knock-out 
studies in mice) [56]. However, changes in ZNF216 expression have yet to be 
determined in other models of muscle atrophy or in pathophysiological 
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conditions in which skeletal muscle atrophy is a feature. In this Chapter, ZNF216 
mRNA expression levels were determined in a rat model of lipopolysaccharide 
(LPS)-induced endotoxaemia, in which indices of muscle atrophy are apparent 
[32]. We also measured ZNF216 mRNA expression in rat muscle in which LPS-
induced muscle mass loss was blunted by low dose dexamethasone (Dex) co-
administration without altering MAFbx and MuRF1 mRNA expression [208], and 
in an in vivo rat model of statin-induced myopathy [209]. Given that ZNF216 is 
thought to function in the same pathway as MAFbx and MuRF1, we hypothesise 
that ZNF216 expression changes may mirror those of MAFbx and MuRF1. 
 
3.2. Primer and probe sets specifically target ZNF216, MAFbx, MuRF1, 
Fbxo25, AWP1 and HMBS mRNA sequences 
Primer and probe sets designed to specifically amplify rat ZNF216, MAFbx, 
MuRF1, F-box protein 25 (Fbxo25) and hydroxymethylbilane synthase (HMBS) 
mRNAs were selected from the Applied Biosystems TaqMan® inventoried 
database. No inventoried primer/probe set existed within the database that 
guaranteed specific targeting of rat sequence protein associated with PRK1 
(AWP1) mRNA sequences as of the start of the study, but primers/probes were 
manually designed by Dr. Tim Constantin-Teodosiu (School of Biomedical 
Sciences) to prevent genomic DNA amplification. Rat AWP1 shares 55.8% protein 
sequence homology with rat ZNF216 (Fig 3.1a), but the former has not been 
reported for its involvement in muscle atrophy. The atrogene MAFbx shares 
59.1% amino acid sequence identity with Fbxo25 (rat sequences) (Fig 3.1b), but 
while MAFbx expression has been observed to increase in multiple atrophy 
models, similarly to AWP1, is not induced during atrophy [103]. The 
housekeeping gene HMBS was selected as the internal control, as expression is 
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Figure 3.1  
a) 
55.8% identity in 226 residues overlap 
rZNF216,       1 MAQETNQTPGPMLCSTGCGFYGNPRTNGMCSVCYKEHLQRQQNS-GRMSPMGTASGSNSP 
rAWP1,         1 MAQETNHSQAPMLCSTGCGFYGNPRTNGMCSVCYKEHLQRQNSSNGRISP---PAASVSS 
                 ******    *******************************  * ** **      * *  
 
rZNF216,      60 TSDSASVQRADATLNNCEGAAGSTSEKSRNVPV----------AALPVTQQMTEMSISRE 
rAWP1,        58 LSESLPVQCADGSVPDAQSALDSTSSSMQPGPVSNQSLLSESVAPSQVDSTSVDKAVSET 
                  * *  ** **        *  ***      **          *   *         *   
 
rZNF216,     110 DKITSPKTEVSEPVVTQPSPSVSQPSSSQSEE--KAPELPKPKKNRCFMCRKKVGLTGFD 
rAWP1,       118 EDLQGPRAEGLVPLECDPPSSVSDTTQQPSEEQSKSLEKPKQKKNRCFMCRKKVGLTGFE 
                      *  *   *    *  ***      ***  *  * ** *****************  
 
rZNF216,     168 CRCGNLFCGLHRYSDKHNCPYDYKAEAAAKIRKENPVVVAEKIQRI 
rAWP1,       178 CRCGNVYCGVHRYSDVHNCSYNYKADAAEKIRKENPVVVGEKIQKI 
                 *****  ** ***** *** * *** ** ********** **** * 
 
b) 
59.1% identity in 357 residues overlap 
rMAFbx,        1 MPFLGQDWRSPGQSWVKTADGWKRFLDEKSGTFVSDLSSYCNKENLFNSLNYDV------ 
rFbxo25,       1 MPFLGQDWRSPGWSWIKTEDGWKRCDPCSHEIRSEDNQYPVNHSIILNSGEEEIFNNDCE 
                 ************ ** ** *****           *     *     **            
 
rMAFbx,       55 -AAKKRKKDIQNSKTKTQYFHQEKWIYVHKGSTKERHGYCTLGEAFNRLDFSTAILDSRR 
rFbxo25,      61 YAAKKRKKQHFGNDTAAHSFYREKWIYVHKESTKERHGYCTLGEAFNRLDFSSAIQDIRR 
                  *******      *    *  ******** ********************* ** * ** 
 
rMAFbx,      114 FNYVVRLLELIAKSQLTSLSGIAQKNFMNILEKVVLKVLEDQQNIRLIRELLQTLYTSLC 
rFbxo25,     121 FTYVVKLLQLIAKSQLTSLSGVAQKNYFNILDKIVQKVLDDHQNPRLIKDLLQDLSSTLC 
                 * *** ** ************ ****  *** * * *** * ** ***  *** *   ** 
 
rMAFbx,      174 TLVQRVGKSVLVGNINMWVYRMETTLHWQQQLNSIQISRPAFKGLTITDLPVCLQLNIMQ 
rFbxo25,     181 ILVRGVGKSVLVGNINIWICRLETVLNWQEKLQNLQMTKQVNTGLTLSDLPLHMLNNILY 
                  **  *********** *  * ** * **  *   *       ***  ***     **   
 
rMAFbx,      234 RLSDGRDLVSLGQAAPDLHVLSEDRLLWKRLCQYHFSERQIRKRLILSDKGQLDWKKMYF 
rFbxo25,     241 RFSDGWDIVTLGQVTPTLYMLSEDRRLWKRLCQYHFAEKQFCRHLILSEKGHIEWKLMYF 
                 * *** * * ***  * *  ***** ********** * *    **** **   ** *** 
 
rMAFbx,      294 KLVRCYPRREQYGVTLQLCKHCHILSWKGTDHPCTANNPESCSVSLSPQDFINLFKF 
rFbxo25,     301 TLQKYYPTKEQYGDTLHFCRHCSILFWKDSGHPCTAADPDSCFTPVSPEHFIDLFKF 
                  *   **  **** **  * ** ** **   *****  * **    **  ** **** 
 
 
 
Figure 3.1 Rat sequences of a) ZNF216 vs. AWP1 and b) MAFbx vs. Fbxo25 were aligned 
using http://expasy.org/tools/sim-prot.html. Matching residues are denoted by an 
asterisk (*). ZNF216 and AWP1 shared 55.8% sequence identity and MAFbx and Fbxo25 
sequences were 59.1% identical. 
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unaffected by the LPS insult [31]. The database contains primers and probes 
designed to cross exon-exon boundaries which selectively amplify mRNA 
sequences and not genomic DNA; mammalian genomic DNA contains non-coding 
sequence (introns) between exons that is removed upon mRNA processing. 
Primers cannot bind to both halves of the genomic sequence simultaneously, 
greatly reducing binding of primers to genomic DNA relative to binding to mRNA. 
A TRIzol based method, which separates RNA, DNA and protein based on 
solubility after the addition of chloroform, was utilised to extract mRNA from 
extensor digitorum longus (EDL) muscle of control and LPS-infused animals. 
Male Sprague-Dawley rats were split into two groups and intravenously infused 
continuously  ? ?ȋ ? Ɋ-1 h-1; n=6) 
or an equal volume of saline (0.4 ml h-1; n=8) via inserted catheters. The EDL 
muscles were then removed from the hindlimbs and freeze-clamped while the 
animals were under terminal anaesthesia after administration of thiobutabarbital 
sodium (Section 2.1). Muscles were stored in liquid nitrogen. Procedures were 
carried out by Julie March and Philip Kemp and were approved by the University 
of Nottingham Ethical Review Committee and were performed under Home 
Office Project and Personal license authority. We measured mRNA expression 
specifically in fast-twitch EDL muscle, because it has previously been noted for its 
sensitivity to sepsis relative to slow-twitch soleus muscle, via observed 
upregulated energy-dependent protein degradation and ubiquitin mRNA 
expression [31, 32, 210]. To control for genomic DNA contamination, when 
mRNA samples were reverse transcribed to cDNA a control sample lacking 
reverse transcriptase was included, which was tested against all primer/probe 
sets and no significant contamination was observed. Efficiency of primer and 
probe sets were tested by producing standard curves of amplification in the 
presence of pooled cDNA of varying concentrations (the pooled cDNA generated 
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from equal amounts of all of the LPS cDNA samples), such as ZNF216 primer and 
probe set in Figure 3.2a, and subsequently cDNA samples were diluted to a 
concentration at which efficiency of amplification was between 90-110%. 
Housekeeping and target gene amplification efficiencies are approximately equal, 
allowing the use of the cycle-threshold (Ct) method for relative quantification of 
gene expression [31]. Finally, end point PCR products from each primer/probe 
set were resolved by agarose gel electrophoresis, and amplicons were found to 
migrate at the correct predicted molecular weights (Fig 3.2b). The raw data, in 
the form of amplification curves, produced for all experimental samples and ȂRT 
control samples for each primer and probe set are shown in Figure 3.3. 
 
3.3. Continuous infusion of LPS for 24h decreases the protein-to-DNA 
ratio of rat EDL muscle 
Expression of the atrogenes MAFbx and MuRF1 has previously been noted to 
increase at the mRNA level in EDL muscle in LPS-induced endotoxaemia; 
Crossland et al. 2008 & 2010 similarly used an LPS-infusion rat model (also at 15 Ɋ-1 h-1) and assessed expression levels at 24 hours [32, 208]. Decreased 
muscle size, resulting from reduced muscle protein synthesis and increased 
degradation, is also a recognised feature of muscle atrophy. Crossland et al. 
observed a decrease in the protein-to-DNA ratio in EDL using this model, in 
which protein concentration reduces relative to DNA concentration, as would be 
expected from shrinking cells. This ratio may be considered as an index of muscle 
atrophy measuring net protein catabolism [30-32]. Consistent with these 
previous observations, we also observe a decrease in the protein-to-DNA ratio by 
43% (p = 0.028) in EDL muscle from animals after 24 hours of LPS infusion, 
relative to control saline- infused animals (Fig 3.4). The magnitude of this change  
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Figure 3.2  
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Figure 3.2 Validating the use of the Ct method and confirming amplification of amplicons 
of the correct molecular weight. a) The ZNF216 TaqMan primer and probe set was 
validated by performing RT-PCR with a series of 2-fold dilutions of pooled cDNA, 
obtained from equal volumes of each LPS cDNA sample, to obtain a standard curve of Ct 
number vs. Log relative concentration. Ct relates to the cycle in the reaction at which the 
products fluorescence is detected above the background during the exponential phase of 
amplification. Efficiency is determined via a calculation involving the gradient of the 
slope: Efficiency = 100* (10^(-1/slope)-1), thus in this case the slope = 3.21 and 
efficiency = 104.9%. Standard curves for all primer and probe sets were found to amplify 
with approximate equal efficiencies, allowing use of the Ct method. b) RT-PCR amplicons 
produced using specific primer and probe sets to amplify targeted sequences in pooled 
cDNA (generated by combination of equal volumes of each LPS cDNA sample) were 
resolved by agarose gel electrophoresis (4% w/v agarose) to confirm amplicons migrated 
at the correct predicted molecular weights. Electrophoresis was at 70V for approximately 
1 hour and the gel was stained with ethidium bromide. DNA was detected under UV. Lane 
1: HMBS (99bp), Lane 2: ZNF216 (76bp), Lane 3: MAFbx (61bp), Lane 4: MuRF1 (56bp), 
Lane 5: AWP1 (107bp), Lane 6: Fbxo25 (86bp) 
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Figure 3.3 
 
a) 
 
  
b) 
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d) 
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e) 
 
  
f) 
 
Figure 3.3 Amplification curves produced by RT-PCR for a) HMBS, b) ZNF216, c) MAFbx, 
d) MuRF1, e) AWP1 and f) Fbxo25. Delta Rn represents the magnitude of the signal 
produced via fluoresence, corrected for background signal. * Denotes the ȂRT control 
amplification curves, which amplify at a considerably later cycle number, relative to 
sample amplification curves. 
97 
  
 Figure 3.4 
 
 
 
 
Figure 3.4 Total alkaline soluble protein and DNA was extracted from approximately 
3mg of freeze-dried and powdered Saline- or LPS-infused EDL muscle using perchloric 
acid (PCA). Protein was isolated using KOH and total content measured via a Lowry assay. 
DNA quantification was performed using a diphenylamine reaction, as detailed in 
Forsberg et al. 1991 [200]. Values represent ± SEM. * Significantly different from control  ? ?Ǥ ? ?ȋȗȗȋ ? ?Ǥ ? ?ȌǤ ? ?ǡ ? ? 
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was very similar to the observations of Crossland et al., who also noted a 40% 
reduction in this ratio [208]. Notably however, Crossland et al. reported no 
significant change in the DNA concentration but only a decrease in protein 
concentration. In contrast we found that that DNA concentration significantly 
increased by 22% (p < 0.01) and whilst there was a trend for reduced protein 
levels in EDL muscle from the LPS animals relative to controls of 31%, the change 
did not reach statistical significance (p = 0.09). Although we observed a similar 
reduction in protein-to-DNA ratio, we see an increase in DNA as opposed to a 
decrease in protein, although the reasons for the differences between our 
observations and those of Crossland et al. are unclear. 
 
3.4. Continuous infusion of LPS for 24h increases ZNF216 mRNA 
levels in rat EDL muscle 
We compared relative mRNA expression levels of selected genes in saline-infused 
and LPS-infused EDL muscle after 24 hours relative to the housekeeper HMBS, 
which was selected for its fixed levels regardless of the LPS insult [31]. Crossland 
et al. 2008 observed significant increases in MAFbx (5.5-fold, P < 0.001) and 
MuRF1 mRNA expression (21-fold, P < 0.001), relative to saline controls, after 24 
hours [32]. Using Real Time PCR (RT-PCR) we similarly observed MAFbx and 
MuRF1 mRNA levels to significantly increase in response to LPS in the EDL, in 
this study by 3.8-fold (p<0.001) and 10.4-fold (p<0.001), respectively, relative to 
saline-infused control muscle (Fig 3.5). Fbxo25 has not previously been found to 
play a role in skeletal muscle atrophy, and showed no increase in expression 
levels in EDL after 24 hours of LPS-infusion. Interestingly, a small but significant 
decrease of Fbxo25 expression by 0.8-fold (p<0.05) was noted in LPS-infused 
EDL relative to control, contrasting that of its structural homologue MAFbx. We 
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Figure 3.5  
 
 
 
 
 
 
 
 
Figure 3.5 Relative mRNA expression levels of LPS or saline (Con) infusion in rats. 
Significant fold increase changes are observed in ZNF216, MAFbx and MuRF1 mRNA 
levels in response to LPS infusion over control, saline-infused animals in EDL muscle after 
24 hours. Fold changes are normalised relative to HMBS mRNA expression levels. Values  ?Ǥȗ ? ?Ǥ ? ?ȋȗȗȋ ? ?Ǥ ? ?ȌǢȗȗȗȋ ? ?Ǥ ? ? ?ȌȌǤ ? ?ǡ ? ? 
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observed, for the first time in this model, an increase of ZNF216 mRNA levels in 
EDL in response to LPS-infusion by 2.3-fold (p<0.001) relative to control muscle. 
The structural homologue of ZNF216, AWP1, contains Znf_A20 and Znf_AN1 
domains at its N- and C-termini respectively, but unlike ZNF216 it has not been 
implicated in muscle atrophy. Supporting this, we saw no significant change in 
AWP1 mRNA expression levels after 24 hours of LPS-infusion. 
 
3.5. Low dose Dex treatment fails to blunt increases in ZNF216 mRNA 
levels induced by LPS in rat EDL muscle 
Intravenous LPS-infusion induces skeletal muscle atrophy in rats, but 
simultaneous treatment with a low dose of the corticosteroid Dex ȋ ? ?Ǥ ?Ɋ-1 h-
1) during ȋ ? ?Ɋ-1 h-1) (LPS+Dex) has previously been observed to prevent 
the atrophy response in EDL muscle observed using LPS alone, indicated by a 
lack of change in protein-to-DNA ratio in LPS+Dex [32]. Crossland et al. 2010 
investigated whether coadministration of the anti-inflammatory agent Dex with 
LPS prevented muscle atrophy via the Akt/Forkhead box, class O (FOXO) 
pathways [208]. However, despite the diminished atrophy response (i.e. sparing 
of muscle loss) via prevention of reduced protein-to-DNA ratio, decreased Akt 
phosphorylation and partial prevention of reduction in FOXO1 phosphorylation, 
Crossland et al. observed that Dex+LPS failed to affect the increased MAFbx and 
MuRF1 mRNA levels that result from LPS infusion relative to saline-treated 
animals. Infusion of Dex alone was shown to have no effect on MAFbx and MuRF1 
relative to saline-infused control muscle. Similarly, we found that Dex alone did 
not induce increases in ZNF216 expression and measurements of ZNF216 mRNA 
levels in Dex+LPS animals relative to LPS alone revealed no blunting in 
expression levels (Fig 3.6). Thus Dex fails to blunt the increase in MAFbx,  
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Figure 3.6 
 
 
 
 
 
Figure 3.6 Relative ZNF216 mRNA expression levels in saline (Con), Dex, LPS and 
Dex+LPS infusion in rats. Significant fold increase changes are observed in ZNF216 in 
response to LPS infusion over control, saline-infused animals in EDL muscle after 24 
hours. Low doses of Dex alone does not induce atrophy and no significant change in 
ZNF216 expression is observed. A low dose of Dex administered to LPS treated rats 
(Dex+LPS) blunts the atrophy response, however, no significant change in ZNF216 
expression is observed relative to levels in LPS treated rats, thus the pathway by which 
Dex acts appears to be independent of ZNF216. Fold changes are normalised relative to 
HMBS mRNA expression levels. Values represent ± SEM. * Significantly different from 
c ? ?Ǥ ? ?ȋȗȗȋ ? ?Ǥ ? ?ȌǢȗȗȗȋ ? ?Ǥ ? ? ȌȌǤ ? ?ǡ ? ?ǡ ? ? ?ǡ
n=7 
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MuRF1[208] and ZNF216 mRNA levels associated with LPS infusion. This implies 
that Dex exerts a muscle sparing effect via a mechanism excluding affecting 
mRNA expression of the measured atrogenes (see Crossland et al. 2010 for 
mechanism suggested [208]). 
 
3.6. Daily simvastatin treatment for 12 days increases ZNF216 mRNA 
levels in rat EDL muscle 
Statins are commonly prescribed to reduce cholesterol but patients may suffer 
unwanted side effects from these drugs including muscle myopathy [211]. 
Reasons for this response are unclear and so Mallinson et al. 2009 previously 
performed a study to identify the elusive molecular mechanisms responsible for 
the adverse effects of statins [209]. Their focus was on the transcription factor 	 ?ǯs, due to their interest in PI3-Kinase (PI3K)/Akt 
signalling, which includes FOXO regulation. After 12 days of 88mg kg-1 day-1 
simvastatin treatment by gavage they noted increased levels and activation (as 
observed by decreased phosphorylation) of FOXO1 protein in the nuclear fraction 
of biceps femoris muscle, and increased atrogene MAFbx and MuRF1 mRNA 
levels. Additionally, they noted a 29% decrease in protein-to-DNA ratio 
compared with control (p < 0.05) and plasma creatine kinase levels increased 
315-fold relative to control (p < 0.01). Cellular injury liberates cytoplasmic 
creatine kinase into surrounding serum, and thus acts as an indicator of muscle 
damage. Thus 12 days of statin treatment using the dosing regime of Mallinson et 
al. produced a severe myopathic response in rats. Consistent with previous 
observations, we noted MAFbx and MuRF1 showed elevated levels greater than 
those in the LPS-infusion model, presenting increases of 16.1-fold (p<0.05) and 
30.0-fold (p<0.05), respectively (Fig 3.7) in the same cDNA. Similarly to increases  
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Figure 3.7 
 
 
 
 
 
 
Figure 3.7 Relative mRNA expression levels of Statin or saline (Con) infusion in rats. 
Significant fold increase changes are observed in all mRNA  expression levels in response 
to 88mg Statin over control, saline-infused animals in EDL muscle after 12 days. Creatine 
Kinase levels are vastly increased at this time point indicative of muscle damage. 
Atrogenes ZNF216, MAFbx and MuRF1 levels are particularly elevated by Statin infusion 
between 5 and 30 fold, whereas non-atrophy related AWP1 and Fbxo25 show a lesser, yet 
statistically significant, increase in expression. Fold changes are normalised relative to 
HMBS mRNA expression levels. Values represent ± SEM. * Significantly different from  ? ?Ǥ ? ?ȋȗȗȋ ? ?Ǥ ? ?ȌǢȗȗȗȋ ? ?Ǥ ? ? ?ȌȌǤ ? ?ǡ ? ?
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seen in MAFbx and MuRF1 which exceed those observed in the LPS model, 
ZNF216 showed an increase of 5.0-fold (p<0.05) in simvastatin treated muscle 
relative to control after 12 days. It should be noted that AWP1 and Fbxo25 also 
showed significant, but lower, increases in expression both by 1.6-fold (p<0.05). 
The severity of this model is likely to explain reasons behind the significant, 
although slight, increase in AWP1 and Fbxo25. While a number of pathways are 
likely to be activated under such severe conditions, increases in MAFbx, MuRF1 
and ZNF216 implicates that protein degradation pathways are amongst those 
triggered in this model. Indeed atrogene mRNA are expressed at a significantly 
higher level than AWP1 and Fbxo25, and strongly mirror the pattern of 
expression levels measured in our LPS-infusion model. 
 
3.7. Discussion 
 
3.7.1. ZNF216 mRNA expression is upregulated in EDL muscle in an LPS-
infusion model of sepsis 
For the first time in this model we have noted upregulated ZNF216 mRNA levels 
in response to LPS-infusion by 2.3-fold (p<0.001) relative to saline control. This 
is, to our knowledge, the first quantitative measurement of ZNF216 mRNA levels, 
via real-time PCR. Our observations support previous findings by Northern 
blotting that ZNF216 expression was noticeably upregulated in a Dex-induced 
atrophy model in differentiated C2C12 myotubes from the earliest time point of 
24 hours up until the latest at 96 hours [56]. Dex treatment was at a high 
concentration of 100 M to induce atrophy, unlike lower levels of Dex which 
spares muscle from wasting, as discussed in Section 3.5. Our data additionally 
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supports increased ZNF216 mRNA levels noted in fasting and denervation 
models of atrophy in mice, after 2 days and 7 days respectively [56]. Supporting 
the hypothesis that ZNF216 is upregulated during a specific atrophy programme, 
rather than via non-specific transcription, the structural homologue AWP1 
showed no significant change of expression in this model. We also noted 
increases in MAFbx and MuRF1 that are consistent with previous findings in the 
same model [32], authenticating the accuracy of our methodology, in which we 
noted an increase in ZNF216 mRNA expression. 
 
3.7.2. ZNF216 mRNA expression is induced to a lesser level than other 
atrogenes under LPS-induced atrophy and statin-induced myopathy 
conditions 
We have observed an increase in ZNF216 mRNA expression to a lesser degree 
than that of MAFbx and MuRF1, but this does not mean that the role of ZNF216 is 
less important than the other atrogenes during the atrophy response. The 
importance of ZNF216 during denervation-induced atrophy has previously been 
demonstrated, as Northern blotting revealed an increase in ZNF216 mRNA levels 
in wild type animals during denervation induced atrophy, but while upregulation 
was apparent it appears to increase to a lesser extent than MuRF1 expression, 
and yet animals lacking ZNF216 demonstrated resistance to denervation-induced 
wasting [56]. Hishiya et al. measured ZNF216 mRNA and protein expression in 
RAW264.7 cells treated with LPS and number of cytokines and observed a rapid 
increase in ZNF216 mRNA expression within an hour of LPS treatment, which 
had declined by the 24 hour time point [198]. Should our rat model mirror 
expression patterns observed in LPS treated cells, then ZNF216 mRNA 
expression may have peaked at an earlier time point. Lacking an efficient ZNF216 
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antibody against rat ZNF216 protein has limited us to measuring mRNA 
expression, but interestingly Hishiya et al. measured both protein levels and 
mRNA levels in cells after RANKL treatment and observed that mRNA expression 
declined after 48 hours but protein expression persisted even at 96 hours [198]. 
At 24 hours in our rat LPS-induced sepsis model we may be measuring mRNA 
levels after they have already peaked but ZNF216 protein may still be expressed Ǥǡ	 ? ? ?ǯ a shuttling protein implies it is 
downstream of the MAFbx and MuRF1, and so upregulated expression may occur 
at a later time point than 24 hours. However, ethical considerations limit us to 
the 24 hour time point when using the LPS-infusion model, so future additional 
observations could only be made at earlier time points. However, expression 
levels alone are not the only consideration for the importance of a gene in a 
specific process. Frost et al. measured MAFbx and MuRF1 expression in 
gastrocnemius muscle from rats exposed to polymicrobial sepsis by cecal ligation 
and puncture (CLP) (n=7/8 per group) [212]. Samples were taken over a time 
course up to 72 hours, during which MAFbx expression reached its peak around 
12 hours after CLP and remained elevated throughout the 72 hour time course. 
The authors suggest MAFbx to be more important than MuRF1 in contributing to 
muscle proteolysis in this model due to the maintenance of expression, thus 
future measurements of ZNF216 over a time course would elucidate how 
expression changes over time. Should ZNF216 expression be maintained at 
around a 2.3 fold in LPS-infused rats, this may indicate its importance throughout 
sepsis. Further measurements of temporal expression levels would also confirm 
whether ZN	 ? ? ?ǯǡ
show a continuing increase in expression throughout the time course.  
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3.7.3. Fbxo25 may compete with MAFbx for binding to components of SCF-
type E3s in rats 
Fbxo25 is a highly similar structural homologue of MAFbx, but has not been 
shown to be involved in skeletal muscle atrophy and accordingly we observed no 
significant increase in mRNA expression in this sepsis model. Indeed, Fbxo25 
showed a slight but significant decrease of expression 0.8-fold (p<0.05) in LPS-
infused muscle relative to control, contrasting that of structural homologue 
atrogene MAFbx. Maragno et al. noted that Fbxo25 could bind to Skp1, Cul1 and 
Roc1 and assemble an SCFFBXO25 complex with E3 ligase activity [103]. MAFbx 
also requires the formation of this complex for ligase activity, so Fbxo25 and 
MAFbx may compete for binding to these components, or Maragno et al. suggest 
they may bind the same substrate considering their homology, and could explain 
the reduction in Fbxo25 mRNA expression in response to the LPS insult and 
upregulated MAFbx expression. However, observations in mice show that tissue 
specific expression of Fbxo25 and MAFbx differ, as Fbxo25 mRNA and protein is 
more strongly expressed in tissues such as brain, kidney and intestine and while 
Fbxo25 mRNA has been found at a lower level in muscle and brain compared to 
other tissues, protein is undetectable in muscle tissue in mice [103, 213]. 
Conversely, MAFbx mRNA expression has been observed mostly in muscle and to 
a lesser extent the heart in mice [97]. Thus evidence from mice tissues suggests 
MAFbx and Fbxo25 may not compete should they be expressed differentially, 
although there is no information specifically on Fbxo25 expression in rats which 
may express Fbxo25 and MAFbx simultaneously in muscle, as we have detected 	 ? ?Ǥ	 ? ?ǯ
function has yet to be confirmed, and considering that mice exhibit differential 
tissue expression for Fbxo25 and MAFbx, there may be other reasons for its 
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downregulation during sepsis-induced atrophy in rats than reducing competition 
for SCF complex components or substrates. 
 
3.7.4. ZNF216 may be activated by the same pathways as atrogenes MAFbx 
and MuRF1 
A recent study measured the effects on downstream targets of FOXO (including 
MAFbx and MuRF1) when the LPS-induced atrophy response in rats was 
impaired by co-administration of low-dose Dex with LPS [208]. In the present 
study, ZNF216 mirrors MAFbx and MuRF1 expression changes, inasmuch as Dex 
did not blunt increased ZNF216 expression induced by LPS-infusion, and nor did 
it blunt expression of other atrogenes. Interestingly, Crossland et al. noted lower 
levels of dephosphorylated (and thus active) FOXO1, which lead them to conclude 
that an alternative Akt-FOXO mechanism may be responsible for observed 
MAFbx and MuRF1 levels, and they suggested MAFbx upregulation may be in 
response to FOXO4, concordant with other findings [214]. Constitutively active 
FOXO4 has also been shown to upregulate ZNF216 mRNA expression [56] and 
together this suggests that ZNF216 may be upregulated by a similar pathway to 
MAFbx. 
 
3.7.5. Statin-induced myopathy induces ZNF216 expression 
A recent study used a rat model of statin-induced myopathy to better 
characterise the elusive molecular mechanisms behind myopathic changes 
observed in some patients taking statins [209]. Observations included 
measurements of mRNA expression of genes associated with proteasomal-
mediated proteolysis, to better understand the effect of statins on PI3k/Akt 
109 
  
signalling, a pathway involved in FOXO regulation. As the authors hypothesised, 
after 12 days of 88mg kg-1 day-1 simvastatin they noted increased FOXO1 in the 
nuclear fraction of biceps femoris muscle and decreased phosphorylation (and 
thus increased activation) and increased MAFbx and MuRF1. We confirmed 
MAFbx and MuRF1 mRNA having elevated expression levels greater than those in 
the LPS-infusion model (and concordant with levels recorded previously), and 
similarly ZNF216 showed a greater degree of upregulation compared to the 
sepsis model. It should be noted that AWP1 and Fbxo25 also showed significant, 
but lower, increases in expression. Considering the muscle damage, as indicated 
by elevated creatine kinase measurements and exhibition of minimal-mild 
necrosis, increased expression of AWP1 and Fbxo25 may result from some loss of 
transcriptional control. Increased expression of ZNF216 is consistent with it 
playing a role coupled with that of E3 ubiquitin ligases in situations where 
muscle undergoes proteolysis. Interestingly, we noted a positive correlation 
between creatine kinase levels and atrogene expression; where creatine kinase 
levels were high and muscle damage was thus more severe, we observed 
increased ZNF216, MAFbx and MuRF1 expression in individual animals within 
the simvastatin-treated group (not shown). In addition to high levels of muscle 
damage, 12 days of 88mg kg-1 day-1 simvastatin treatment increased the risk of 
mortality, as only four of six rats survived. Less samples were available for 
analysis as a direct result of the models severity, thereby reducing statistical 
power and revealing the limitations of this model. 
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3.7.6. Protein-to-DNA ratio may not be a sensitive indicator of skeletal 
muscle atrophy 
Reduced muscle size is an indicator of muscle atrophy, but reduced protein-to-
DNA ratio has since been shown to be an additional index of wasting and has 
been measured in all of the models discussed in this Section. We noted an 
increase in DNA levels, that differs from observations by Crossland et al. 2008, 
and may be a result of increased muscle satellite cell activation in this LPS-
infusion model. While reduced protein-to-DNA ratio has been observed in the 
LPS model, this has been recorded as a reduction between 29%-40% in the same 
model [32, 208] and only a 29% reduction in protein-to-DNA ratio was noted in 
the statin-induced myopathy model, despite evidence of muscle damage, via 
increased creatine kinase levels [209]. However, atrogene levels are notably 
elevated in the more severe statin-induced myopathy model relative to the 
sepsis-infused model, each more than doubling in the statin model relative to the 
sepsis model. It seems that atrogene expression may act as a more sensitive index 
of skeletal muscle atrophy, as loss of protein-to-DNA ratio appears to have an 
upper limit. Preliminary data mentioned above in 3.7.5. corresponds with this 
notion, as muscle damage, measured by creatine kinase levels, and atrogene 
expression appear to positively correlate. However, it should be noted that in 
some situations atrogenes are expressed without any muscle damage, as noted 
earlier during co-administration of LPS+Dex [208]. Further to this, MAFbx and 
MuRF1 expression was upregulated during both PPARdelta agonist 
administration [215] and acute alcohol intoxication in rats [216], but did not 
induce UPS-mediated proteolysis.  
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Atrogene expression studies are important for elucidating the proteins that are 
involved in various modes of skeletal muscle atrophy. However, information on 
atrogene function is also critical for understanding the pathways involved in 
skeletal muscle atrophy. 
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CHAPTER 4 
Functional characterisation of the ZNF216 protein 
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4.1. Introduction 
In Chapter 3 we observed that zinc finger protein 216 (ZNF216) mRNA 
expression levels increased in rat extensor digitorum longus (EDL) tissue in the 
lipopolysaccharide (LPS)-infused model of skeletal muscle atrophy as well as in 
the statin-induced myopathy model. This mirrored increases in muscle atrophy 
F-box protein (MAFbx) and muscle RING-finger 1 (MuRF1) mRNA expression, 
suggesting that ZNF216 may be involved in the atrophy programme. However, 	 ? ? ?ǯȋȌ
molecular level. In order to understand the biological significance of increases in 
ZNF216 expression, we sought to identify proteins that interact with ZNF216 to 
reveal its possible substrates. Previous work has demonstrated that ZNF216 is 
able to bind to polyubiquitin, presumably mediating delivery of 
polyubiquitinated substrates to the 26S proteasome [56]. However, the specific 
polyubiquitinated substrates of ZNF216 have yet to be determined. 
 
In order to attempt the direct identification of ubiquitinated proteins that bind to 
ZNF216, we expressed recombinant GST-tagged rat ZNF216 (rZNF216) protein Ǯǯvia affinity 
chromatography. The cDNA sequence encoding the 213 amino residue rZNF216 
was previously cloned in the lab into the bacterial expression plasmid pGEX-4T-
1, and was provided at the outset of this study; this plasmid was transformed into 
XL10 gold E. coli. The rZNF216 sequence was verified by DNA sequencing and 
confirmed to encode the full length (FL) rZNF216 protein as shown in Figure 4.1. 
Residues 11-35 of rZNF216 encode the zinc finger A20 domain (Znf_A20) which 
has been previously shown to bind to polyubiquitin [56]; in contrast, 	 ? ? ?ǯ
AN1 zinc finger domain (Znf_AN1), between residues 154-194, binds to TNF- 
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Figure 4.1 
 
 
 
 
 
 
Figure 4.1 Schematic representation and peptide sequence of 213 residue wild-type rat 
ZNF216. The N-terminal Znf_A20 domain is encoded by amino acids 11-35 while residues 
154-194 contain the C-terminal Znf_AN1 domain, highlighted in blue and red, 
respectively. 
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receptor associated factor 6 (TRAF6) but its precise function remains unknown 
[196]. Characteristic of many zinc fingers, both the Znf_A20 and the Znf_AN1 
domains contain 4 cysteine residues that chelate a single zinc atom to form the 
distinctive zinc finger structure. Previous studies showed that mutation of two 
cysteines to alanine in the Znf_A20 domain is sufficient to disrupt zinc binding 
and abolish formation of the zinc finger structure, impairing polyubiquitin 
binding [56]. Therefore, as a negative control for ubiquitin-binding, the rZNF216 
plasmid was mutated using site-directed mutagenesis to convert cysteines 30 
and 33 to alanines (C30/33A mutant). 
 
4.2. Recombinant GST-rZNF216 protein binds to ubiquitin-Sepharose 
In order to test the functionality of recombinant GST-rZNF216 protein with 
respect to ubiquitin-binding, commercially available purified bovine ubiquitin 
was covalently immobilised (at 10mg/ml) on cyanogen bromide activated 
Sepharose-4B (CNBr Seph 4B) beads (ubiquitin-Sepharose); control Sepharose 
was produced in parallel using the same coupling process but omitting ubiquitin. 
GST, GST-rZNF216 (wild type) or GST-rZNF216 (C30/33A) proteins were 
expressed in 10ml overnight E. coli cultures from plasmids encoding GST/GST-
tagged proteins. Bacterial pellets were lysed by sonication in TBS-Triton prior to 
centrifugation (10 min, 16000 rcf, 4oC), after which the pelleted insoluble 
material was discarded and GST/GST-tagged proteins in the supernatant were 
incubated with an excess (50 l) of ubiquitin-Sepharose (10mg/ml), glutathione-
Sepharose (commercially available) or control-Sepharose beads at 40C for 30 
minutes. Unbound proteins were removed by extensive washing and bound 
proteins were eluted with gel application buffer. Proteins were either visualised 
via SDS PAGE and Coomassie staining, or Western blotting using an anti-GST 
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antibody; approximately 10 g and 1 g bound protein were loaded per lane for 
Coomassie staining (Fig 4.2ai) or Western blotting (Fig 4.2aii), respectively. All of 
the GST-tagged proteins tested bound glutathione-Sepharose consistent with the 
presence of the GST tag (schematic diagram in Fig 4.2b), however whilst wild 
type GST-rZNF216 bound to ubiquitin-Sepharose as predicted, the C30/33A 
mutant was unable to bind ubiquitin. Protein binding to the control-Sepharose 
was not seen; thus our recombinant GST-tagged wild type rZNF216 retains its 
specific monoubiquitin-binding function.  
 
4.3. Recombinant GST-rZNF216 protein binds to K48- and K63-linked 
polyubiquitin chains 
Our analyses in Section 4.2 confirm that recombinant wild type GST-rZNF216 can 
bind to immobilised monoubiquitin. As 	 ? ? ?ǯfunctions is to 
shuttle polyubiquitinated substrates to the 26S proteasome [56], we next 
assessed r	 ? ? ?ǯubiquitin polymers, which more closely 
resembles its proposed physiological substrates. GST, GST-rZNF216 or GST-
rZNF216(C30/33A) proteins were purified from 10ml cultures of E. coli by 
immobilising on glutathione-Sepharose and incubated with 1 g commercial 
Lysine 48 (K48)-linked or K63-linked unanchored polyubiquitin chain mixtures. 
Bound polyubiquitin chains were eluted with gel application buffer, resolved by 
SDS PAGE, transferred overnight to nitrocellulose membrane and probed with 
anti-ubiquitin (Fig 4.3). Ponceau S staining confirmed approximately equal 
expression of the GST fusions. Wild type GST-rZNF216 alone bound both K48- 
and K63-linked polyubiquitin chains whereas the C30/33A mutant did not, 
further demonstrating 	 ? ? ?ǯbind ubiquitin via its Znf_A20 domain 
and confirming that the recombinant protein was functional. Figure 4.3 clearly  
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Figure 4.2  
a i) 
 
 
 
 
 
 
 
 
 
ii)
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Figure 4.2  
b)      c) 
 
 
 
Figure 4.2 Recombinant GST-tagged rZNF216, but not C30/C33A mutant, binds to 
ubiquitin-Sepharose. a) IPTG-induced 10ml overnight E. coli cultures produced 
recombinant proteins GST, GST-rZNF216 (WT rZNF216) or GST-rZNF216 (C30/33A) 
(Mut rZNF216), were extracted in TBS-Triton (TBS-T) and incubated with 50 l of 
glutathione- (G), control- (C) or ubiquitin- (U) Sepharose beads at 4oC for 30 min (in TBS-
T). Subsequently, Sepharose was washed twice with TBS-T and bound proteins eluted in 
gel application buffer. 50 % of proteins that bound to glutathione-, control- or ubiquitin-
Sepharose beads were detected by i) Coomassie staining and 50% by ii) immunoblotting 
using anti-GST. b) & c) Models of glutathione-Sepharose and ubiquitin-Sepharose-bound 
proteins, respectively (no protein bound to control-Sepharose). Note that GST forms a 
strong dimer. 
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Figure 4.3  
a)       
 
b) 
 
 
Figure 4.3 Immobilised GST-rZNF216 binds to K48- and K63-linked polyubiquitin chains. 
GST, GST-rZNF216 (WT rZNF216) or GST-rZNF216 (C30/33A) (Mut rZNF216) proteins 
were extracted from 10ml E. coli cultures that were grown overnight and induced with 
IPTG to overexpress GST-tagged proteins. GST-tagged proteins were captured on 50 l of 
glutathione-Sepharose (in TBS-T) for 30 min at 4oC and washed twice in TBS-T. 
Subsequently, 0.25 g of a) K48- or b) K63-linked polyubiquitin chains were then 
incubated with glutathione-captured GST-tagged proteins in 50mM Tris, 0.1% BSA (pH 
7.5) (TBSA) for a further 30 minutes at 4oC. Beads were washed twice in TBSA and bound 
proteins eluted with gel application buffer. Load (L) represents 100% of the 
polyubiquitin load. Western blots were Ponceau stained to ensure equal loading (left 
panel) and subsequently immunoblotted with anti-ubiquitin (right panel). 
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demonstrates that whilst diubiquitin and longer polyubiquitin chains readily 
bind wild type rZNF216, monoubiquitin does not in this assay.  
 
These observations, and those in Section 4.2, are consistent with the findings of 
Hishiya et al. [56] who showed that FLAG-tagged ZNF216 and HA-tagged 
ubiquitin interacted via co-immunoprecipitation experiments in HEK293 cells, 
confirming their initial observations that ZNF216 and polyubiquitin C clones 
interacted via yeast two-hybrid experiments. Additionally, the authors identified 
that polyubiquitin binding was dependent on the Znf_A20 domain, as the N-
terminal mutant which lacked the Znf_A20 domain and the Znf_A20 C30/33A 
mutant (noted earlier in Section 4.1) lacked polyubiquitin binding ability. Whilst 
rZNF216 can bind to single ubiquitin moieties, the interaction is weak (Kd = 8 M 
at 298K [217]) relative to avidity effects afforded by multiple ubiquitin-binding 
domain (UBD)-ubiquitin interactions. Indeed, our own work (Fig 4.2a) 
demonstrates that wild type rZNF216 can indeed bind to immobilised 
monoubiquitin, but this probably occurs via avidity effects. GST is known to form 
strong dimers [218] and it is likely that GST-tagged rZNF216 will dimerise via the 
GST-tag in solution, allowing two rZNF216 proteins to bind simultaneously to 
two single ubiquitins brought into close proximity when immobilised at high 
protein concentration (Fig 4.2c). In experiments when GST-rZNF216 is 
immobilised on beads (as in Figure 4.3), the high concentration of rZNF216 
protein presumably places multiple UBDs in close proximity, allowing 
simultaneous interactions with multiple ubiquitins within the same polyubiquitin 
chain. Notably Huang et al. 2004 suggested that ZNF216 forms homodimers 
[196] pointing to a possible mechanism by which it may attain higher affinity 
polyubiquitin-binding in vivo. 
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4.4. Recombinant GST-rZNF216 protein does not exhibit 
deubiquitinating activity 
As noted earlier Hishiya et al. proposed that ZNF216 may act as a shuttle protein 
transporting ubiquitinated proteins to the 26S proteasome for their degradation. 
This suggestion was based on its ability to bind polyubiquitin chains, and its co-
precipitation with the 26S proteasome [56]. However, the complete physiological 
significance of the ZNF216 protein has not yet been fully determined. 	 ? ? ?ǯ
N-terminal zinc finger Znf_A20 domain was accordingly named because of 
similarity to the A20 protein, which contains seven zinc fingers at its C-terminus. 
A20 has both deubiquitinating activity and E3 ligase activity, but despite 	 ? ? ?ǯ ? ?ǡHishiya et al. 2006 [56] detect no 
deubiquitinating or E3 ligase activity. Our interest in ZNF216, as further detailed 
in Section 4.5, developed into exploiting its ubiquitin-binding ability for purifying 
ubiquitinated proteins. To confirm that ZNF216 does not have deubiquitinating 
activity, which would impede purification of ubiquitinated proteins, we 
performed a deubiquitinating assay with our recombinant rZNF216 proteins. In 
this case GST-rZNF216 and GST-rZNF216 (C30/33A) were first purified using 
glutathione-Sepharose affinity chromatography and thrombin cleaved (within a 
thrombin site at the C-terminus of the GST-tag), eluting FL wild type or C30/33A 
mutant rZNF216 with 2 additional N-terminal residues (GS; see Fig 4.4). This is 
because subsequent affinity purifications (in this Chapter) involve thrombin-
cleaved GST-ZNF216. The double cysteine mutation only substitutes two amino 
acids, and does not change the overall length of the protein, thus only fractionally 
changing the size by the mass difference between two cysteines/alanines. 
Resolving the wild type and mutant GST-tagged recombinant rZNF216 proteins 
by SDS PAGE revealed no difference in denatured molecular weight, however 
notably upon thrombin cleavage and removal of the GST-tag,  
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Figure 4.4  
 
 
Figure 4.4 Thrombin cleavage of GST-rZNF216. Recombinant rZNF216 protein was 
expressed to have a GST-tag at its N-ǡ	 ? ? ?ǯ
codon. GST-rZNF216 was captured on glutathione-Sepharose via its GST-tag, the C-
terminus of which contains a sequence of 6 amino acids (Leu-Val-Pro-Arg-Gly-Ser) that is 
absent within the wild-type rZNF216 sequence. The sequence is recognised by thrombin, 
which cleaves this site within GST to liberate the recombinant rZNF216 protein that 
consequently gains an additional 2 residues from the GST-tag after cleavage. The residual 
GST-tag remains bound to glutathione-Sepharose. 
123 
  
wild type and mutant rZNF216 proteins migrated differently with the mutant 
appearing smaller by approximately 4-5kDa (Fig 4.5). This apparent difference in 
size after cleavage was confirmed not to be truncation of the mutant protein by 
thrombin, as no thrombin cleavage site was introduced by the double mutation, 
and antibodies recognising epitopes at the N- and C-terminus (not efficient for 
recognising endogenous rat ZNF216 in Chapter 3, but proficient for recognising 
recombinant ZNF216) still recognised mutant rZNF216 (not shown). In addition, 
peptide mass fingerprinting (PMF) could not discern any differences in primary 
sequence (with the exception of the engineered C/A mutations; not shown) Ǥǡ	 ? ? ?ǯ
denatured molecular weight is approximately 25kDa, but wild type recombinant 
rZNF216 migrates at greater than 30kDa when resolved by SDS PAGE. Hence the 
double cysteine mutant is in fact closer to the predicted molecular weight of the 
protein. We speculate that, when liberated from GST fusion, the wild type 
Znf_A20 domain may fail to fully denature during SDS PAGE despite the presence 
of denaturing agents in the gel application buffer, and the additional positive 
charge resulting from zinc ion binding may impede protein migration on the gel. 
This effect may be negligible within the larger GST-tagged protein, potentially 
explaining why no differences in migration are observed for tagged versions.  
 
K63-linked polyubiquitin is generally associated with non-degradative signalling 
events including DNA repair [170], nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF- B) signalling [160] and innate immunity [181], whilst K48-
linked polyubiquitin can be recognised by the 26S proteasome and targets 
proteins for degradation [219]Ǥ	 ? ? ?ǯ 
26S proteasome, we selected K48-linked polyubiquitin as a substrate for the 
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Figure 4.5  
 
 
Figure 4.5 Thrombin cleavage of GST-rZNF216 and GST-rZNF216 (C30/33A). GST-tagged 
proteins expressed from 5l of IPTG-induced E. coli were purified in TBS-T on glutathione-
Sepharose beads, after incubation for 1 hr at 4oC and subsequent washing. A small sample 
of glutathione-beads were retained to ensure GST-tagged protein binding (Beads -). The 
remaining GST-rZNF216 (GST-rZNF216 WT)/GST-rZNF216 (C30/33A) (GST-rZNF216 
Mut) bound to glutathione-Sepharose was then incubated with 10 units thrombin in 
thrombin cleavage buffer (20mM Tris, 150mM Sodium Chloride, 2.5mM Calcium Chloride 
Dihydrate, pH 8.4) overnight at 4oC. The GST-tag remained on beads after thrombin 
cleavage (Beads +), and recombinant rZNF216 WT/rZNF216 Mut was eluted into solution 
(Elution), and proteins were detected by Coomassie staining. 
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deubiquitinating assay. Cleaved rZNF216 proteins were covalently immobilised 
using CNBr Seph 4B beads. K48-linked polyubiquitin chain mixtures were 
incubated with control-Sepharose, rZNF216-Sepharose or rZNF216 (C30/33A)-
Sepharose or in the absence of any Sepharose beads overnight at 37oC (Fig 4.6). 
Wild type or mutant rZNF216 was covalently coupled to CNBr Seph 4B at a high 
concentration in case deubiquitinating activity was weak (17.75mg/ml), and a 
bead volume of 15 l was incubated with 0.125 g of polyubiquitin chains in a 
reaction volume of 25 l for 30 minutes at 4oC, prior to overnight incubation at 
37oC. Ubiquitin specific peptidase 2 (USP2) catalytic core, which has broad 
spectrum deubiquitinating activity was used here as a positive control and 
readily disassembled K48-linked polyubiquitin chains to monoubiquitin under 
these conditions. Wild type rZNF216 (or mutant) beads had no effect on 
polyubiquitin chain composition, confirming that immobilised rZNF216 has no 
deubiquitinating activity. To verify that rZNF216 immobilisation does not 
abrogate deubiquitinating activity, an assay was performed using wild type and 
mutant rZNF216 in solution, rather than covalently immobilised on beads, and 
again no activity was observed (data not shown).  
 
4.5. Using immobilised rZNF216 protein to purify in vivo 
ubiquitinated skeletal muscle proteins 
Should ZNF216 assist translocation of ubiquitinated proteins to the 26S 
proteasome for their degradation and be a bona fide atrogene, we reasoned that 
endogenously ubiquitinated proteins that bind recombinant rZNF216 may 
represent its substrates which are degraded during muscle atrophy. The identity 
of the ubiquitinated substrates of ZNF216 has not yet been determined, thus we 
sought to identify them by directly purifying them with recombinant rZNF216. 
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Figure 4.6  
 
 
 
Figure 4.6 Recombinant immobilised rZNF216 exhibits no deubiquitinating activity. 
0.125 g K48-linked polyubiquitin chains were incubated overnight at 37oC with 30 l 
rZNF216 WT-Sepharose (ZNF WT; 17.75mg/ml), rZNF216 (C30/33A)-Sepharose (ZNF 
Mut; 17.75mg/ml), control-Sepharose (Con), in the absence of Sepharose (-) or with 
0.5 g USP2. Remaining protein was immunoblotted with anti-ubiquitin. Load (L) 
represents 100% of the polyubiquitin load. 
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For these experiments the rZNF216 (C30/33A) mutant acts as a control, as 
proteins binding the Znf_A20 domain mutant must bind in a ubiquitin-
independent manner. Thus this provided a method of disregarding proteins that 
bind in the absence of an intact Znf_A20 domain. To allow the preparative 
purification of rZNF216-binding proteins in sufficient quantities to allow protein 
identification we required substantial amounts of muscle tissue. Rat EDL muscle 
was used for expression profiling of ZNF216 (Chapter 3), however, the limited 
size of this muscle type led us to use ǲmixedǳ muscle which was more readily 
accessible in large amounts. Increased expression of atrogenes has been 
observed in muscle types other than EDL. Hindlimb suspension increased MuRF1 
levels in soleus muscle [220], tibialis anterior muscle and gastrocnemius muscle 
have exhibited upregulation of MAFbx and MuRF1 under denervation conditions 
[53] and MAFbx increases as a result of fasting in gastrocnemius [97]. Mixed 
muscle was taken from rat hind legs, and includes all of the aforementioned 
muscles as well as a number of other muscles including biceps femoris and 
gluteus superficialis. Rates of protein breakdown increase in atrophy conditions, ǡǲǳ
[221], and therefore we reasoned that polyubiquitinated proteins which ZNF216 
binds during atrophy conditions would still be present in basal muscle but at 
lower concentrations. We thus aimed to optimise purification methods using ǲǳǡ
applied to identifying changes in ubiquitinated proteins in atrophying muscle.  
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4.5.1. Profile of rat skeletal muscle proteins binding to wild type or 
C30/33A mutant rZNF216 are indistinguishable by SDS PAGE 
To affinity capture rZNF216-binding proteins from rat muscle, tissue was 
homogenised in the presence of protease inhibitors and the proteasome-specific 
inhibitor MG132 to reduce levels of protein degradation by inhibiting in vivo 
proteases and proteasomes that might eliminate the ubiquitinated proteins we 
were aiming to purify. The clarified supernatant was incubated with either 
immobilised wild type recombinant rZNF216 or C30/33A mutant rZNF216 
covalently coupled to CNBr Seph 4B, as described earlier (Section 4.4).  
 
After extensive washing to remove unbound material, proteins retained on the 
beads were resolved by SDS PAGE and stained with both Coomassie Blue and by 
silver staining. Despite the difference in ubiquitin-binding ability between the 
wild type and C30/33A mutant rZNF216 proteins, a subjective visual analysis of 
the resulting gels revealed no distinguishable differences between the profile of 
purified proteins (Fig 4.7a and b). However, immunoblotting with anti-ubiquitin 
clearly demonstrated the ability of the wild type rZNF216 alone to enrich 
ubiquitinated proteins from rat muscle (Fig 4.7c). Ubiquitin-independent binding 
proteins thus appear to mask wild-type rZNF216 specific ubiquitin-dependent 
binding proteins when visualised by Coomassie staining, or even using more 
sensitive staining methods such as silver staining. 
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Figure 4.7  
a)   
b) 
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c) 
 
 
Figure 4.7 Rat muscle proteins that bound to recombinant rZNF216 (WT) and rZNF216 
(C30/33A) mutant (Mut). Mixed, control rat muscle (~7g) was homogenised in 50ml Tris 
DTT (50mM Tris, 1mM DTT, 20 M MG132, 0.1% mammalian protease inhibitor cocktail 
(Sigma), pH 7.5) at 4oC. Homogenate was centrifuged and the supernatant was split three 
ways and passed twice through either 150 l rZNF216-Sepharose (WT), 150 l rZNF216-
Sepharose (C30/33A) or 150 l control-Sepharose (Con) at 4oC. Beads were washed three 
times in Tris DTT, bound proteins were eluted with gel application buffer and 1/15th 
visualised by a) Coomassie staining, b) silver staining and c) immunoblotting with anti-
ubiquitin. Load (L) represents approximately 1/200th of the proteins loaded. 
  
131 
  
4.5.2. Two-dimensional gel electrophoresis (2DE) preferentially resolves 
lower molecular weight rZNF216-binding proteins 
As noted in Section 4.5.1, ubiquitin-independent binding partners of rZNF216 
were predominantly visualised when purified protein samples were analysed by 
SDS PAGE and Coomassie staining. We next used 2DE to resolve rZNF216-binding 
proteins by both denatured molecular weight and protein iso-electric point (pI), 
in an attempt to identify subtle differences in proteins interacting with wild type 
compared to mutant rZNF216. Coomassie Blue and silver staining of resulting 
2DE gels revealed broadly similar spot patterns (Fig 4.8a for Coomassie staining, 
silver staining not shown). Ubiquitin-positive spots were also visualised by anti-
ubiquitin immunoblotting, with discrete spots that bound wild type rZNF216 
only clearly visible (Fig 4.8a). However in contrast to the immunoblots of 
samples resolved by SDS PAGE, in which a smear of ubiquitin-positive proteins 
were evident up to 250kDa (Fig 4.7c), there was an absence of ubiquitinated 
proteins over 75kDa on anti-ubiquitin blots of the 2DE gels. This suggests that 
the higher molecular weight ubiquitinated proteins probably do not efficiently 
enter the first dimension immobilised pH gradient (IPG) strip and that lower 
molecular weight ubiquitin-positive proteins are preferentially included, limiting 
the applicability of this approach. However, lower molecular weight discrete 
ubiquitin-reactive spots (binding to rZNF216) are readily discernible via 
immunoblotting of 2D gels. 
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Figure 4.8  
a)
b) 
 
Figure 4.8 Coomassie staining and anti-ubiquitin immunoblotting of two-dimensional gel 
electrophoresis of rat muscle proteins bound to recombinant wild type rZNF216 and anti-
ubiquitin immunoblotting of commercial K48 and K63-linked polyubiquitin chains. a) 
Mixed rat muscle (~1.5g) was homogenised in 10ml Tris DTT (50mM Tris, 1mM DTT, 
20 M MG132, 0.1% mammalian protease inhibitor cocktail (Sigma), pH 7.5) at 4oC. 
Homogenate was centrifuged and the supernatant was passed twice through 100 l wild 
type rZNF216-Sepharose at 4oC. Beads were washed three times in Tris DTT and bound 
proteins were eluted with isoelectric focussing (IEF) sample buffer. b) IEF buffer was also 
added to 0.5 g of commercial K48- or K63-linked polyubiquitin chains. 100% of all 
samples were incubated with immobilised IPG pH gradient strips (pH 3-11NL) and 
actively rehydrated at 50V at 20oC overnight and isoelectrically focused. Strips were 
washed 3 x 5 min with equilibration buffer I (6M urea, 2% SDS, 0.375M Tris-Cl, 2% DTT, 
pH 8.8, 20% glycerol) and then 3 x 5 min with equilibration buffer II (6M urea, 2.5% 
iodoacetamide, 0.375M Tris-Cl, 2% DTT, pH 8.8, 20% glycerol) prior to resolving 
isoelectrically focused proteins by SDS PAGE, and either Coomassie staining or 
immunoblotting with anti-ubiquitin. 
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4.5.3. Spot pattern of ubiquitin-positive rZNF216-binding proteins resolved 
by 2DE is similar to that of unanchored polyubiquitin chains 
Anti-ubiquitin immunoblotting of wild type rZNF216 binding proteins purified 
from rat skeletal muscle and separated by 2DE revealed several series of protein 
spots resolved at the same pI but migrating at different molecular weights (Fig 
4.8a). When commercial K48- or K63-linked polyubiquitin chain mixtures were 
resolved using 2DE and blotted with anti-ubiquitin antibodies, a strikingly similar 
pattern was seen (Fig 4.8b). The lower molecular weight spots within the ladder 
derived from the rZNF216-binding proteins, at the corresponding positions of the 
mono (spot 1) and diubiquitin (spot 2) standards, were excised from a Coomassie 
Blue-stained gel (Fig 4.9) and submitted for matrix-assisted laser 
desorption/ionisation time-of-flight (MALDI-TOF) PMF analysis. Briefly, in this 
analysis, protein sample is first digested in gel into peptide fragments using 
trypsin, and the resulting peptides are ionised. A TOF analyser measures how 
long ions take to reach a detector (through a flight tube) when accelerated 
through a fixed potential. The resulting trace, contains information about m/z 
values of resulting ions formed and the relative abundance of the ions, producing 
a mass fingerprint. This fingerprint can be compared to theoretical fingerprints of 
proteins, determined based on known sequences. The statistically most similar 
matching fingerprint provides the most likely identity of the test protein.  
 
Analysis of PMF data derived from the two rZNF216-binding protein spots 
revealed them to contain the ubiquitin sequence, each containing four matching 
peptides (not shown). The higher molecular weight protein (spot 2) additionally 
contains an unmatched peptide. This may represent sequence from a ubiquitin-
modified target, although further identification of a ubiquitinated target is not  
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Figure 4.9 
 
 
Figure 4.9 Two-dimensional gel electrophoresis of rat muscle proteins bound to 
recombinant wild type rZNF216. Mixed rat muscle (~1.5g) was homogenised in 10ml Tris 
DTT (50mM Tris, 1mM DTT, pH 7.5) at 4oC. Homogenate was centrifuged and the 
supernatant was passed twice through 100 l wild type rZNF216-Sepharose at 4oC. Beads 
were washed three times in Tris DTT, bound proteins were eluted with isoelectric 
focussing (IEF) sample buffer (100% of sample loaded onto immobilised IPG pH gradient 
strips (pH 3-11NL)) and treated identically to samples in Figure 4.8 up to the stage that 
proteins were resolved by SDS PAGE, and colloidal Coomassie-stained. Spots 1 and 2 
were excised and analysed by PMF.  
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feasible as there is only one unmatched peptide, and multiple peptides are 
required to confirm protein identity. Protein spots above this molecular weight 
were not discernable via Coomassie Blue staining of 2D gels, but presumably can 
be visualised using anti-ubiquitin antibodies on Western blot because longer 
polyubiquitin chains have more epitopes available for antibody binding, 
increasing the signal. 
 
Binding assays of wild type ZNF216 against control muscle, analysed by anti-
ubiquitin Western blotting of SDS PAGE (Fig 4.7c) and anti-ubiquitin Western 
blotting and PMF analysis of 2DE (Fig 4.8a and Fig 4.9 respectively), revealed the 
insubstantial but definite presence of monoubiquitin. However, as noted earlier, 
binding assays of rZNF216 against commercial ubiquitin chain mixtures 
confirmed ubiquitin binding, but only when 2 or more ubiquitins were 
conjugated in a chain, which we previously reasoned was a result of avidity 
effects. We would expect this avidity effect when rZNF216 is immobilised on 
CNBr Seph 4B (Fig 4.10) as well as when using glutathione Sepharose (Fig 4.2c). 
We reasoned that monoubiquitin was unlikely to bind from control muscle, based 
on our observations using commercial ubiquitin chains. Thus we rationalised that 
in this case, in the absence of N-ethylmaleimide (NEM) (see Section 4.5.5), co-
purification of deubiquitinating enzymes from control muscle may generate 
monoubiquitin by deubiquitination of longer chains in the purified samples.  
 
4.5.4. Optimising affinity capture by ZNF216 of ubiquitinated proteins using 
different buffers 
We noted previously, in Section 4.5.1, that while the C30/33A mutation ablates 
136 
  
Figure 4.10 
 
 
 
 
 
 
 
 
Figure 4.10 A model of polyubiquitin binding to immobilised rZNF216. Avidity effects 
may enhance binding to polyubiquitin, as multiple ubiquitin proteins within a chain may  ? ? ?Ǥǲǳǡ
the Znf_A20 domain via its polyubiquitin tag. 
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 the ubiquitin binding ability of ZNF216, there were no discernable differences in 
the profile of proteins binding to wild type or C30/33A mutant by Coomassie 
staining, thus we aimed to optimise binding conditions to reduce non-specific 
binding. Rat skeletal muscle proteins that bound to wild type rZNF216 or to the 
C30/33A mutant rZNF216 using four different homogenising/binding buffers 
were compared using Coomassie staining and anti-ubiquitin immunoblotting (Fig 
4.11). No ubiquitinated proteins were detected binding to the C30/33A mutant 
under any conditions, by immunoblotting with anti-ubiquitin (Fig 4.11b). 
Notably, the most stringent of the four buffers was considered the most 
favourable (containing salt and detergent Ȃ 50mM Tris, 1mM DTT, 150mM NaCl, 
0.5% NP40, pH 7.5) as it reduced the intensity and number of ǲ-ǳ 
proteins binding to both wild type and mutant rZNF216 bound proteins, as 
evidenced by Coomassie Blue staining, (Fig 4.11a) and simultaneously enhanced 
ubiquitin-positive binding partners to wild type rZNF216, evidenced via 
immunoblotting, relative to the other three buffers (Fig 4.11b). 
 
4.5.5. Using on bead deubiquitination to identify ubiquitinated muscle 
proteins bound to FL rZNF216 and the Znf_A20 domain under optimised 
affinity capture conditions  
Despite improvements in our affinity capture method, subjective visual analysis 
of Coomassie Blue-stained SDS PAGE gels still proved not to be sensitive enough 
to distinguish ubiquitinated proteins that selectively bound to wild type rZNF216 
compared to the C30/33A mutant. Thus an alternative strategy was devised. It 
has previously been established that the Znf_AN1 domain of ZNF216 is not 
required for polyubiquitin-binding [56]. Hence we reasoned that removing this C-
terminal domain from our recombinant rZNF216 protein used for our  
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Figure 4.11  
a) 
b) 
 
Figure 4.11 Optimising binding of ubiquitinated rat muscle proteins to recombinant 
rZNF216 wild type (WT). Mixed rat muscle (~1g each) was homogenised in 4 different 
buffers (10ml) at 4oC of different compositions; buffers were 1) 50mM Tris, 1mM DTT, 
20 M MG132, 0.1% mammalian protease inhibitor cocktail (Sigma), pH 7.5; 2) Buffer 1 
+150mM NaCl, pH 7.5; 3) Buffer 1 + 0.5% NP-40, pH 7.5 and; 4) Buffer 1 + 150mM NaCl, 
0.5% NP-40, pH 7.5. (Buffer 1) is the composition of the previously used buffer, in Figures 
4.7-4.9). Homogenate was centrifuged and the supernatant was passed twice through 
50 l of wild type rZNF216-Sepharose (WT) or rZNF216 (C30/33A) at 4oC. Beads were 
washed three times in the same buffer that muscle was homogenised in, and bound 
proteins were eluted with gel application buffer. Proteins were resolved by SDS PAGE and 
a) 50% Coomassie-stained or b) 50% immunoblotted with anti-ubiquitin. Load (L) 
represents approximately 1/200th of the proteins loaded. 
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polyubiquitin-ǲ-ǳ
proteins (that bound independently of ubiquitin; Fig 4.12) and mask the specific 
interactors. The Znf_A20 domain is contained within the first 60 amino acids 
(residues 11-35) of the rZNF216 wild type sequence. Site directed mutagenesis 
was used to introduce an early stop codon after residue 60. The Znf_A20 domain 
was expressed as a GST-fusion, purified using glutathione-Sepharose and 
thrombin cleaved (Fig 4.13a). The resulting Znf_A20 peptide was immobilised 
(with CNBr Seph 4B; at 5 mg/ml) and found to retain binding to commercial K48-
linked polyubiquitin chains; control-Sepharose produced in tandem did not (Fig 
4.13b). We reasoned that proteins binding in a ubiquitin-dependent manner 
would no longer interact with rZNF216 or the Znf_A20 domain after 
deubiquitination; a similar approach was used by Ventadour et al. [194] in which 
ubiquitinated proteins from C2C12 cells were bound to immobilised ubiquitin 
binding domains of proteasomal S5a subunit, before subsequent deubiquitination 
with the catalytic domain of USP2. Our new approach was to combine previously 
optimised conditions (using a more stringent homogenising buffer) in 
combination with on bead deubiquitination to selectively elute ubiquitin-
dependent binding proteins, and to include the use of the Znf_A20 domain alone 
as well as FL ZNF216. 
 
For these experiments during homogenisation of the muscle sample, we 
permanently inactivated any co-purifying deubiquitinating enzymes through the 
addition of NEM to our previously determined optimal binding buffer. NEM is a 
thiol-reactive compound that irreversibly modifies cysteine residues in proteins, 
and can be used as an inhibitor of many deubiquitinating enzymes (DUBs) which 
use this residue catalytically. Muscle homogenate was subsequently treated with 
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Figure 4.12  
 
a)     b) 
 
 
 
 
Figure 4.12 Model of a) FL rZNF216 and b) the Znf_A20 domain binding to rat muscle 
proteins. Increased ubiquitin-dependent binding may result from using the Znf_A20 
domain for pulldown assays, as proteins that bind FL rZNF216 via its Znf_AN1 domain 
might sterically block ubiquitinated proteins binding the Znf_A20 domain. ǲǳǲǳ ? ? ?ǡǲǳǲǳǲ-ǳvia the Znf_AN1 domain of 
ZNF216. 
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Figure 4.13  
a)       b) 
 
 
Figure 4.13 Thrombin cleavage of the GST-tagged Znf_A20 domain (GST-Znf_A20) and 
binding to K48-linked polyubiquitin. a) GST-Znf_A20 expressed from 5l of IPTG-induced 
E. coli was purified in TBS-T on glutathione-Sepharose beads, after incubation for 1 hr at 
4oC and subsequent washing. A small sample of glutathione-beads were retained to 
ensure GST-tagged protein binding (Beads -). The remaining GST-Znf_A20 domain bound 
to glutathione-Sepharose was then incubated with 10 units thrombin in thrombin 
cleavage buffer (5mM Tris, 150mM Sodium Chloride, 2.5Mm Calcium Chloride Dihydrate, 
pH 8.4) overnight at 4oC. The GST-tag remained on beads after thrombin cleavage (Beads 
+), and recombinant Znf_A20 WT was eluted into solution (Elution), and SDS PAGE 
resolved proteins were stained with Coomassie Blue. b) Znf_A20-Sepharose (A) or 
control-Sepharose (C) was incubated with 0.25 g of K48-linked polyubiquitin chains in 
binding buffer (50mM Tris, 150mM NaCl, 0.5% NP-40, 0.1% bovine serum albumin (BSA), 
1mM DTT, pH 7.5) for 30 minutes at4oC. Beads were washed twice in binding buffer, 
bound proteins were eluted with gel application buffer, resolved by SDS PAGE and 
immunoblotted with anti-ubiquitin. Load (L) represents 100% of the polyubiquitin load.  
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an excess of DTT to quench the NEM, as cysteine linking is vital for the Znf_A20 
zinc finger domain structure and would affect the affinity capture. Using this 
protocol we captured ubiquitinated proteins from skeletal muscle with FL 
rZNF216-Sepharose or Znf_A20-Sepharose, and treated the proteins on beads 
with the catalytic core of USP2 deubiquitinating enzyme. The anti-ubiquitin 
immunoblotting profile of Znf_A20 bound ubiquitinated proteins (Fig 4.14a) 
mirrored previous observations of rZNF216 captured material (Fig 4.7c). Anti-
ubiquitin immunoblotting revealed that deubiquitination of Znf_A20 bound 
proteins (Fig 4. 14a) and FL rZNF216 bound proteins (not shown), diminished 
the smear of bound ubiquitinated proteins following 2 hours of USP2 treatment 
and monoubiquitin was produced as a result of deubiquitination in the eluted 
fraction. Ubiquitinated proteins that bound FL rZNF216 or Znf_A20 via their 
polyubiquitin tag may thus also be released into solution and no longer retained 
on the beads (fraction iv in Figure 4.14), rendering them amenable to further 
analysis. 
 
4.5.6. LC-MS/MS analyses of deubiquitinated FL rZNF216/Znf_A20 domain-
binding proteins 
While PMF is a useful technique, and was used previously when identifying 
ubiquitin-positive protein spots which bound to rZNF216 (Fig 4.9), it is not 
applicable to a complex mixture of proteins, such as those liberated from FL 
rZNF216 or the Znf_A20 domain binding via deubiquitination with USP2. In order 
to identify proteins within this mixture, we used liquid chromatography tandem 
mass spectrometry (LC-MS/MS). This technique is often employed to identify 
individual proteins within a complex mixture of proteins. Initially, the mixture of 
proteins is digested using trypsin, generating a complex mixture of resultant 
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Figure 4.14  
a)      b) 
Figure 4.14 Elution of Znf_A20-Sepharose-bound ubiquitinated rat muscle proteins via 
deubiquitination. Mixed, control rat muscle (~15g) was homogenised in 100ml 
homogenising buffer (50mM Tris, 150mM NaCl, 0.5% NP-40, 5mM N-ethylmaleimide, 
20 M MG132, 0.1% mammalian protease inhibitor cocktail (Sigma), pH 7.5). Homogenate 
was centrifuged and DTT added to the supernatant to a final concentration of 10mM, and 
mixed at 4oC for 15 minutes. Supernatant was passed twice through 800 l Znf_A20-
Sepharose at 4oC. Beads were washed three times in wash buffer (50mM Tris, 150mM 
NaCl, 0.5% NP-40, 1mM DTT, pH 7.5) and incubated in DUB buffer (50mM Tris, 1mM 
DTT, pH 7.5) (an equal volume solution to beads), incubated +/- 10 g USP2 core for 2hrs 
at 37oC . Solution was collected, and gel application buffer was added separately to 1/40th 
beads/solutions (the remaining was frozen). a) Proteins eluted from beads in the absence 
(i) and presence (iii) of USP2 core, and their respective solutions were resolved by SDS 
PAGE and immunoblotted with anti-ubiquitin. Part b) represents proteins present in 
lanes i Ȃ iv and proteins highlighted by Ș(smear of ubiquitinated proteins) and * 
(monoubiquitin). (K48)=0.25 g K48-linked polyubiquitin, (L)=Load 1/250th lysate 
applied to beads, (B)=beads, (S)=solution. 
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peptides. These are then separated using LC, separating peptides based on 
differences in hydrophobicity, upstream of a tandem mass spectrometer. During 
tandem MS, peptides are ionised and detected in the first mass spectrometer, and 
selected fragments can be further fragmented and analysed in a second mass 
spectrometer which generates peptide sequence information. This information 
can be interrogated against sequence databases affording protein identification. 
Although sequence coverage is typically low using this approach, it can be 
extensive and broadly representative of the protein components within a 
complex mixture.  
 
Protein mixtures released by USP2 treatment of rat skeletal muscle proteins 
captured on rZNF216 or Znf_A20-Sepharose were analysed using LC-MS/MS. 
Analysis exclusively focused on peptide sequences that are unique to a single 
protein hit within the database, in this case within the mammalia taxonomy of 
the NCBI nr protein sequence database (containing all non-redundant GenBank 
CDS translations). Proteins identified within samples were analysed based on 
number of unique peptides and function, the latter including possible binding to 
atrogenes and/or involvement in skeletal muscle atrophy. We additionally 
inputted sequences into Ubipred [222] to detect predicted ubiquitination sites 
and substantiate evidence that these proteins were indeed ubiquitinated targets. 
Proteins identified from control experiments (eluted from beads treated in 
parallel but -USP2) were presumed to be non-ubiquitinated and resulting from 
leaching from beads into solution, and were discounted from +USP2 analysis. ǡǲǳȋ	 ? ? ?Ȍǡǡ
trypsin and USP2 sequences were omitted. Tables 4.1 and 4.2 lists proteins 
identified that were eluted into solution only in the presence of USP2 from 
  
Table 4.1 
Subsection GI number Protein name GenBankTM  Total Function 
      accession no peptides   
i 149036532 actin, gamma 2, isoform CRA_b EDL91150.1 2 Z disc component 
  49868 put. beta-actin (aa 27-375) CAA27396.1 2 Dystrophin binding 
  20521786 KIAA1180 protein BAA86494.2 1 Erk activation in brain 
  149494200 PREDICTED: similar to KIAA1582 protein  XP_001517138.1 1 MicroRNA regulation 
  56188 glyceraldehyde 3-phosphate-dehydrogenase  CAA26150.1 1 Apoptosis/Autophagy/Glycolysis 
ii 73992595 PREDICTED: similar to serologically defined colon XP_543057.2 1 Transcription factor during development 
     cancer antigen 33 like        
  73948200 PREDICTED: similar to carcinoembryonic antigen-related  XP_541572.2 1 Mutated in autosomal dominant hearing loss 
    cell adhesion molecule 5       
  22129749 protein CASC3 NP_671485.1 1 Nonsense-mediated mRNA decay (NMD) 
iii 7106864 HSPC237 AAF36157.1 1 Unknown 
  109094596 PREDICTED: cysteine-rich with EGF-like domain  XP_001116152.2 1 Unknown 
    protein 2-like       
  71043870 tudor domain-containing protein PHF20L1 NP_001020873.1 1 Unknown 
  194041852 PREDICTED: CWF19-like protein 1 XP_001929566.1 1 Unknown 
  220829516 novel protein similar to mouse B230396O12Rik CAQ10653.2 1 Unknown 
  26342434 unnamed protein product  BAC34879.1 1 Unknown 
  149634714 PREDICTED: similar to C10orf63 protein  XP_001506317.1 1 Unknown 
  5929884 nucleolin-related protein NRP  AAD56625.1 1 Unknown 
  58331230 DALR anticodon-binding domain-containing  NP_001009996.1 1 Unknown 
    protein 3 isoform 1       
  10438978 unnamed protein product  BAB15392.1 1 Unknown 
 
Table 4.1 Proteins eluted into solution after USP2-mediated deubiquitination of Znf_A20-Sepharose-bound rat muscle proteins, identified by LC-MS/MS. All Ǥǲǳȋ ? ? ?Ȍǡǡpsin and USP2 were omitted from 
analysis, and none of the above proteins were detected in ȂUSP2 control samples. Subsection i); proteins of known function of particular interest; ii) other proteins 
of known function; iii) proteins with unknown function.  
  
Table 4.2 
Subsection GI number Protein name GenBankTM  Total Function 
      accession no peptides   
i 10945605 perforin AAG24611.1 1 Apoptosis 
  194664014 PREDICTED: hypothetical protein isoform 5  XP_879713.4 1 Microtubule stabilisation 
  119921446 PREDICTED: TSPY-like 2 isoform 2 XP_874476.2 1 Chromatin remodelling 
  74001392 PREDICTED: similar to Nucleolar preribosomal-associated  XP_544859.2 1 Ribosome biogenesis 
    protein 1       
  8918488 adenylate kinase isozyme 1 BAA97655.1 1 Possible MuRF1 binder, AMP signalling 
ii 149728930 PREDICTED: ATR interacting protein  XP_001494950.1 1 Involved in DNA damage checkpoint pathway 
  1098543 interleukin-2 receptor alpha  AAC48487.1 1 Signal transduction 
  194220872 PREDICTED: zinc finger protein 513  XP_001500950.2 1 Transcription factor 
  29825889 small conductance calcium-activated potassium  AAN46636.1 1 Potassium channel 
    channel subfamily N member 3 variant 1B       
  126273765 PREDICTED: similar to Blooms syndrome protein XP_001368666.1 1 Helicase 
iii 149487896 PREDICTED: hypothetical protein, partial  XP_001519894.1 1 Unknown 
  149642231 PREDICTED: similar to phosphoglucomutase 2 XP_001511051.1 1 Unknown 
  6330472 KIAA1205 protein BAA86519.1 1 Unknown 
  149633328 PREDICTED: hypothetical protein XP_001505775.1 1 Unknown 
  149618229 PREDICTED: similar to dual specificity phosphatase 19,  XP_001508319.1 1 Unknown 
    partial       
  90076816 unnamed protein product BAE88088.1 1 Unknown 
  159570900 novel protein  CAP19250.1 1 Unknown 
  126283044 PREDICTED: hypothetical protein  XP_001378841.1 1 Unknown 
 
Table 4.2 Proteins eluted into solution after USP2-mediated deubiquitination of FL rZNF216-Sepharose-bound rat muscle proteins, identified by LC-MS/MS. All Ǥǲǳȋ	 ? ? ?Ȍǡǡsin and USP2 were omitted from analysis, and 
none of the above proteins were detected in ȂUSP2 control samples. Subsection i); proteins of known function of particular interest; ii) other proteins of known 
function; iii) proteins with unknown function.
147 
  
Znf_A20 and FL rZNF216, respectively. Where possible, the rat sequence was 
selected over other mammalian species. All proteins identified were predicted to 
have ubiquitination sites, ranging from a single possible site to forty-five (not 
shown). Each table is split into 3 subsections; i) proteins of known function of 
particular interest ii) other proteins of known function iii) proteins with 
unknown function. Proteins within subsections ii) and iii) have either yet to be 
established for their roles within the cell, or have no obvious connections with 
muscle atrophy, and thus our analysis concentrates on subsection i). Five 
proteins of particular interest were identified in subsections i) of both Znf_A20 
and FL rZNF216 eluted proteins, although interestingly we observed no overlap 
of proteins binding to the Znf_A20 domain alone and to FL ZNF216. Two 
apoptosis related proteins were identified, one each binding Znf_A20 and FL 
rZNF216 (GI 56188 and GI 10945605, respectively). Two proteins binding 
Znf_A20 were identified that are key components of muscle cells, including a Z 
disc component (GI 149036532) and a dystrophin binding protein (GI 49868), 
and whilst all other bound proteins were identified by only by a single unique 
peptide, 2 unique peptides identified these two proteins. Proteins binding the 
Znf_A20 domain include one involved in Erk signalling (GI 20521786) and 
microRNA regulation (GI 149494200). FL rZNF216 binders further included a 
microtubule stabilising protein(GI 194664014), one involved in chromatin 
remodelling (GI 119921446) and ribosome biogenesis (GI 74001392). 
Interestingly, adenylate kinase 1 protein (AK1) (GI 8918488), identified in 
fractions of deubiquitinated FL rZNF216 binding proteins, has previously been 
identified as a MuRF1 binder (and presumed substrate) by yeast two-hybrid 
interaction studies [109]. We attempted to validate our LC-MS/MS approach by 
probing rat muscle proteins bound to rZNF216 wild type, rZNF216 (C30/33A) 
and Znf_A20 +/- DUB with an antibody specific for AK1 (Fig 4.15). AK1 was only 
148 
  
identified in the FL rZNF216 elution and not the Znf_A20 elution by LC-MS/MS, 
and accordingly we see AK1 binding specifically to FL and not the Znf_A20 
domain alone by immunoblotting, although the failure to detect AK1 in solution 
indicates a lack of sensitivity of Western blotting. AK1 appears to be unmodified 
as evidenced by the presence of only a single band and binds both the FL wild 
type ZNF216 and the C30/33A mutant. Together these results suggest that 
binding is, in fact, via a ubiquitin independent mechanism, and reduces the 
confidence in the LC-MS/MS approach. 
 
4.6. Discussion 
 
4.6.1. ZNF216 polyubiquitin binding and linkage specificity 
Lysine-48 (K48)-linked chains have, until recently, been widely recognised as the 
signal for proteasomal degradation [219], whereas K63-linked chains tend to 
have non-proteolytic functions (see Chapter 1.9.1.5.). Our results indicate that 
recombinant GST-rZNF216 has no K48-linkage specificity preferentially to K63-
chains, as might be expected from a proteasomal shuttle protein. The UBA 
domain of shuttle protein Rad23 shows considerable preference for K48-linked 
ubiquitin chains by surface plasmon resonance analysis over K63- and K29-
linked polyubiquitin [223]. While our binding assay and immunoblotting method 
allows us to detect presence or absence of ubiquitin binding, this method is less 
sensitive or quantitative than surface plasmon resonance that can quantify 
association and dissociation between two proteins. This more sensitive method 
may detect a preference of ZNF216 for a specific ubiquitin linkage that is not 
detectable under our conditions. However, Li & Yi 2008 [224] notes that the  
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Figure 4.15  
 
 
       
 
 
 
Figure 4.15 Anti-adenylate kinase 1 (AK1) immunoblotting of rat muscle proteins bound 
to rZNF216 wild type, rZNF216 C30/33A and Znf_A20 beads and elutions +/- 
deubiquitination (-/+DUB) with USP2. As previously for LC-MS/MS samples, mixed rat 
muscle (~7g) was homogenised in 50ml homogenising buffer (50mM Tris, 150mM NaCl, 
0.5% NP-40, 5mM N-ethylmaleimide, 20 M MG132, 0.1% mammalian protease inhibitor 
cocktail (Sigma), pH 7.5) prior to centrifugation. DTT was added to the resulting 
supernatant to a final concentration of 10mM and mixed at 4oC for 15 minutes. 
Supernatant was passed twice through 150 l rZNF216 WT/ rZNF216 C30/33A or 
Znf_A20-Sepharose at 4oC. Beads were washed three times in wash buffer (50mM Tris, 
150mM NaCl, 0.5% NP-40, 1mM DTT, pH 7.5) and incubated in DUB buffer (50mM Tris, 
1mM DTT, pH 7.5) (an equal volume solution to beads), +/- USP2 core for 2hr at 37oC . 
Solution was collected, and gel application buffer was added separately to 
beads/solutions. (L)=Load 1/200th lysate loaded onto beads, (B)=1/15th beads, 
(S)=1/15th solution. 
150 
  
ubiquitin receptor p62 shows no polyubiquitin linkage specificity in vitro, as 
observed by our lab where p62 binds K48- and K63-linked chains in vitro [184], 
but in vivo evidence implicates a preference of p62 for K63-linked polyubiquitin 
[225]. Similarly, ZNF216 may exhibit polyubiquitin linkage specificity in vivo, 
possibly via association with other ubiquitin binding proteins and factors that 
confer selectivity. 
 
4.6.2. ZNF216 as a shuttle protein for polyubiquitinated proteins 
ZNF216 has been established as a polyubiquitin binding protein, but lacks 
deubiquitinating (Figure 4.6 and Hishiya et al. 2006 [56]) or E3 ubiquitin ligase 
activity [56]. Whilst these activities can be straightforward to assay in vitro, 	 ? ? ?ǯǤ
Further evidence from Hishiya et al. [56] supporting the shuttle protein 
hypothe	 ? ? ?ǯ
accumulation of polyubiquitinated proteins in atrophying ZNF216 knockout 
mice. As discussed in Chapter 1.9, ubiquitin ligases MAFbx and MuRF1 
polyubiquitinate substrates during muscle atrophy to target proteins for Ǥ	 ? ? ?ǯ
atrophy, as observed by increased expression under various atrophy conditions 
and resistance of ZNF216 knockout animals to atrophy, led us to reason that 
ZNF216 may function to shuttle MAFbx and MuRF1 ubiquitinated substrates to 
the proteasome. Should this be the case, then any evidence of MAFbx or MuRF1 	 ? ? ?	 ? ? ?ǯ
a shuttle protein. UBDs can be utilised as tools for capturing ubiquitinated 
proteins [193, 194] and similarly we have successfully captured 
polyubiquitinated proteins using FL rZNF216, or ZNF216ǯs ubiquitin-binding 
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Znf_A20 domain alone. Interestingly, we observed that AK1 was apparently 
eluted in solution from FL rZNF216 via deubiquitination with USP2, a protein 
which has previously been reported as a MuRF1 binding protein in yeast two-
hybrid studies [109], further substantiating the shuttle protein hypothesis. As 
observed from our LC-MS/MS data, AK1 was only eluted from FL rZNF216, and 
not to the Znf_A20 domain alone, which suggests that the FL protein may provide 
increased specificity of binding relative to the UBD alone. However, while AK1 
has been identified as a MuRF1 binder in yeast two-hybrid experiments, there is 
currently no evidence of MuRF1 specifically polyubiquitinating AK1. In addition, 
as discussed later, Western blotting evidence indicates that AK1 captured on FL 
rZNF216 may not be polyubiquitinated.  
 
There are limitations to our polyubiquitinated proteins purification methods. 
ZNF216 may require additional association with other ubiquitin binding proteins 
for higher specificity, as discussed in the previous Section. Consequently, the 
observed binding of polyubiquitinated substrates to rZNF216/Znf_A20, may lack 
the in vivo specificity. To eliminate the effect of co-purifying DUBs, we treated 
homogenate with NEM to irreversibly inactivate in vivo DUBs, as confirmed by 
the lack of monoubiquitin in the ȂUSP2 sample. Prior to incubation with the 
Znf_A20 domain, homogenate had to be treated with DTT to quench NEM and 
prevent it modifying the zinc finger of the Znf_A20 domain itself. Similarly, 
structures of zinc finger proteins within the homogenate are irreversibly 
disrupted by NEM treatment. It is possible that some zinc finger proteins that 
would bind polyubiquitin in vivo might aid ZNF216 binding, and NEM-induced 
disruption of these zinc fingers might then change the complement of proteins 
that binds ZNF216 under these conditions. These limitations could reduce the 
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number of identified genuine in vivo ZNF216 binding proteins, which may 
account for only identifying two proteins as a known atrogene E3 ligase binding 
protein out of the thirty-six proteins identified. 
 
4.6.3. Znf_A20 and ZNF216-binding polyubiquitinated protein candidates 
revealed by LC-MS/MS 
As revealed by the LC-MS/MS data, a number of proteins of known function 
bound FL rZNF216 and the Znf_A20 domain, such as glyceraldehyde 3-
phosphate-dehydrogenase (GAPDH) that bound Znf_A20. GAPDH has been used 
as a real time-PCR and protein internal standard in some muscle wasting studies 
[226-228], on the assumption that its mRNA and protein expression levels 
remain constant under basal and atrophying conditions. However, GAPDH has 
been observed to stabilise an E3 ubiquitin ligase Siah1 after apoptotic 
stimulation, which mediates nuclear protein degradation during apoptosis [229]. 
Mounting evidence links apoptosis to a number of atrophy models, including 
denervation induced muscle atrophy [230] and to hindlimb unloading-induced 
muscle atrophy in rats [231]. Should GAPDH be involved in apoptosis, a pathway 
that may promote muscle atrophy, then its elution by deubiquitination may seem 
counter-intuitive as it would implicate GAPDH as an atrophy substrate. However, 
studies that have linked apoptosis and atrophy have, to date, not included sepsis-
induced muscle atrophy models, which may induce different pathways to other 
stimuli. Alternatively, the presence of polyubiquitinated forms may be 
rationalised by GAPDH being an abundant protein in vivo, that like other proteins 
needs to be turned over.  
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GAPDH was not the only apoptosis related protein identified by LC-MS/MS, as 
perforin was also eluted from FL rZNF216, a protein that forms transmembrane 
pores in cells during apoptosis to allow granzymes to enter and induce apoptosis. 
Negative feedback may be an alternative explanation for targeted 
polyubiquitination and possible downstream proteasomal degradation of 
apoptosis related proteins. A protein eluted from the Znf_A20 domain (GI 
149494200) has been implicated in microRNA regulation. Whilst this specific 
protein has not been linked with muscle atrophy, Güller et al. 2010 [232] review 
the involvement of microRNAs in skeletal muscle, in which they consider that ǲǳ
atrophy. More intuitively, two proteins that are known constituents of all cell 
types as part of the cytoskeleton, gamma-actin and beta-actin, were eluted from 
the Znf_A20 domain. These were the only two candidates identified by more than 
a single unique peptide. Interestingly, in support of our findings, a very recent 
study published after completion of our experiments, has not only provided 
evidence of actin polyubiquitination via methods highly similar to our own, but 
also presents data that indicates both MuRF1 interaction with actin, and MuRF1-
dependent ubiquitin polymerisation [114]. MuRF1 knockout in C2C12 myotubes, 
via transfection with MuRF1 targeting siRNA, stabilised flag-actin under Dex 
induced atrophy conditions relative to atrophying myotubes transfected with 
scrambled siRNA control, implicating a role for MuRF1 in destabilising actin. 
However, this study refers to the alpha form of actin, rather than beta and gamma 
forms that we have detected. In relation to beta actin, Prins et al. 2011 observed 
that specific ablation of beta actin in skeletal muscle results in quadriceps 
myopathy, highlighting its involvement with another form of muscle wasting 
[233]. Interestingly, a further MuRF1 binder was eluted from FL rZNF216 and not 
from the Znf_A20 domain alone; AK1. However, AK1 immunoblotting indicated 
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that AK1 was not polyubiquitinated, as only a single band was observed as 
opposed to a smear of polyubiquitinated AK1, which bound both the FL rZNF216 
and the C30/33A mutant. AK1 failed to bind Znf_A20, which suggests that AK1 
binding was via the Znf_AN1 domain and thus may have been eluted into solution 
by leaching. It is possible that a small fraction of AK1 is indeed ubiquitinated, but 
below the detectable limit, although its ability to bind independently of ubiquitin 
and the lack of detectable AK1 eluted into solution after deubiquitination makes 
this unlikely. This highlights the importance of immunoblotting candidates to 
validate that they bound via polyubiquitination.  
 
4.6.4. Limitations of the LC-MS/MS approach 
Ion scores are calculated for lists of peptides during LC-MS/MS analysis, and 
those above a threshold of 20 are considered significant and certain when above 
30. The greater the chance of random protein hits, the lower the score. Scores for 
peptides identified in Tables 4.1 and 4.2 are all below 20, the threshold of 
significance, with the exception of the two Znf_A20 bound proteins that have 2 
unique peptides, identified as gamma-actin (GI 149036532) and beta-actin (GI 
49868) which have scores of 90 and 61, respectively. Using this approach the 
majority of proteins identified were from only a single peptide; for a more 
assured confirmation, two or more peptide sequences from the same protein are 
ideally required (which increases the total ion score). This approach is limited in 
success as many of the single peptides used for the identifications had low ǲǳǡrified proteins, for example by 
immunoblotting, is clearly desirable. Our attempted validation of the LC-MS/MS 
method by immunoblotting for the candidate AK1 was unsuccessful, as various 
analysis indicated that AK1 was not polyubiquitinated. It is likely that AK1 
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leached from rZNF216 WT beads during overnight incubation and indicates that 
other candidates could also be ubiquitin-independent binding proteins. The lack 
of binding to the Znf_A20 domain suggests that AK1 may bind via the Znf_AN1 
domain of ZNF216, but the functional significance of this is unclear. 
 
4.6.5. Utilising the Znf_A20 domain of ZNF216 to bind polyubiquitinated 
proteins 
The caveat to the LC-MS/MS approach is that other regions of ZNF216, other than 
the Znf_A20 polyubiquitin binding domain, may impart substrate specificity. This 
is supported by the observed binding of AK1 to FL rZNF216 in a ubiquitin-ǡ	 ? ? ?ǯ ?
AN1 domain. What is apparent from this analysis is that the two confident 
protein matches were eluted from Znf_A20 beads, substantiating the notion that 
FL rZNF216 may bind fewer ubiquitinated proteins due to non-ubiquitinated 
proteins binding in other regions, including the C-terminal ZnF_AN1 domain. 
Identifying ubiquitinated substrates may be limited using this approach because 
of the broad range of ubiquitinated proteins that can bind (evidenced by anti-
ubiquitin Western blot), which reduces the concentration of individual 
ubiquitinated proteins and reduces the chances that peptide sequences are 
identified using LC-MS/MS, which has limited sensitivity. However, use of the 
Znf_A20 domain alone may provide a method of comparing global ubiquitination 
profiles by binding polyubiquitinated proteins indiscriminately (see Chapter 5). 
While there is little evidence via LC-MS/MS of highly concentrated specific 
ubiquitinated FL rZNF216 binding proteins, this does not rule out the possibility 
that FL rZNF216 may have more specificity than Znf_A20 domain alone. This, 
combined with our elution of actin specifically from the Znf_A20 Sepharose, 
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supports that using the UBD alone may be more useful when capturing 
ubiquitinated species to observe global ubiquitination profiles. 
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CHAPTER 5 
Polyubiquitinated protein profiling and the purification of 
unanchored polyubiquitin chains 
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5.1. Introduction  
Our affinity purification strategy, using covalently immobilised full length rat 
sequence ZNF216 (FL rZNF216) protein or the Znf_A20 domain alone, allowed 
enrichment of polyubiquitinated proteins from rat skeletal muscle (Chapter 4). 
Liberation of proteins that bound these immobilised proteins via a polyubiquitin 
tag was achieved through USP2-mediated deubiquitination and eluted proteins 
were analysed via liquid chromatography tandem mass spectrometry (LC-
MS/MS). This approach had a number of limitations. Only a single unique peptide 
was detected for all except 2 purified candidates, indicating that this method 
provided limited coverage of eluted proteins present. Despite removing ǲǳȋ
of USP2) LC-MS/MS still identified proteins that leached from beads, as 
evidenced by the absence of a smear of polyubiquitinated adenylate kinase 1 
protein (AK1) in the purified fractions by Western blotting, and AK1 binding to 
the double cysteine C30/33A rZNF216 mutant, which lacks ubiquitin-binding 
ability. Failure to detect multiple peptides for the majority of candidates suggests 
this approach may not be sensitive enough to identify proteins for proteomic 
analysis. 
 
5.2 The Znf_A20 domain can be used to profile global ubiquitination 
changes in proteasome-knockout mouse brains 
Although identification of ubiquitinated binding partners of rZNF216 (or more 
specifically the Znf_A20 domain) has been restricted by experimental limitations, 
given the high affinity with which the Znf_A20 domain binds to polyubiquitinated 
proteins (Kd = 8 M at 298K [217]) we also investigated whether it may be used 
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more generally as a tool to globally profile changes in ubiquitinated targets. In 
this case, the quantitative capture of ubiquitinated proteins from different 
biological samples is required. Although the intention was to apply this method 
to uncover global changes in ubiquitination of skeletal muscle proteins from 
tissue undergoing atrophy, in the first instance the approach was used to analyse 
biological samples where changes in the pool of ubiquitinated proteins were 
known or expected to show significant alterations. 
 
To determine whether our affinity capture and blotting method is sensitive 
enough to detect changes in global ubiquitination, we first applied the Znf_A20 
domain purification method to brains from 26S proteasome-depleted mice, in 
which ubiquitin neuropathology is observed two weeks after proteasomal 
depletion in the forebrain relative to wild type controls [174]. This model was 
developed by Bedford et al. 2008, who depleted 26S proteasomal activity in vivo 
without using pharmacological inhibitors. Conditional knockout using a Cre/loxP 
system was employed to inactivate the Psmc1 gene in selected neurons of the 
forebrain, leading to polyubiquitin accumulation (assessed by Western blotting) 
and atrophy of the forebrain. We found that polyubiquitin accumulation in 
proteasomal knockout mice relative to wild type controls is evident in crude 
protein extracts from the brains (denoted by the loads in Fig 5.1a and by Bedford 
et al. 2008), but that the Znf_A20 domain affinity purification allows differences 
in smaller ubiquitin-positive species that were previously undetectable to be 
observed, via enrichment of the same samples (Fig 5.1a). Clearly the 26S 
proteasome fails to efficiently degrade ubiquitinated proteins in the knockout 
mouse, and the accumulation of ubiquitinated proteins captured by the Znf_A20  
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Figure 5.1  
a)         b) 
 
  
Figure 5.1 Anti-ubiquitin immunoblotting of a) wild type and Psmc1 knockout mouse 
brain (~15mg each) and b) +/- MG132 treated U20S cell proteins (~4mg each) (cells 
treated with 1 M MG132 for 16 hours) bound to Znf_A20 beads. Samples were 
homogenised in a) 5ml or b) 4ml homogenising buffer (50mM Tris, 150mM NaCl, 0.5% 
NP-40, 5mM N-ethylmaleimide, 20 M MG132, 0.1% mammalian protease inhibitor 
cocktail (Sigma), pH 7.5), centrifuged, and the supernatant collected. DTT was added to 
the lysate to a final concentration of 10mM and mixed at 4oC for 15 minutes. Lysate was 
passed twice through a) 50 l Znf_A20-Sepharose or b) split between 80 l of control or 
Znf_A20 Sepharose at 4oC. Beads were washed three times in wash buffer (50mM Tris, 
150mM NaCl, 0.5% NP-40, 1mM DTT, pH 7.5). Bound proteins were eluted in gel 
application buffer. a) (K48)=0.25 g K48-linked polyubiquitin, (L)=Load 1/100th lysate 
loaded onto beads, (A)=100% of Znf_A20 bound proteins, WT=wild type mouse cortex, 
KO=Psmc1 knockout mouse cortex. b) (K48)=0.25 g K48-linked polyubiquitin, 
(K63)=0.25 g K63-linked polyubiquitin, (L)=Load 1/80th lysate loaded onto beads, 
(C)=50% of Control Sepharose bound proteins (A)=50% of Znf_A20 bound proteins. 
Arrows denote ubiquitin positive species that increase upon Psmc1 knockout or MG132 
treatment. 
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domain confirms that this protocol is sensitive to changes in global ubiquitination 
in the samples. 
 
 5.3. The Znf_A20 domain can be used to profile global ubiquitination 
changes in cells following pharmacological proteasome inhibition 
As a further demonstration that our Znf_A20 domain affinity-capture method can 
be used to detect changes in overall ubiquitination, we treated U20S cells (a 
human osteosarcoma-derived cell line) with a pharmacological inhibitor of the 
proteasome, MG132. This provides a pharmacological equivalent of the genetic 
ablation of the proteasome, although MG132 treatment is performed in cells as 
opposed to tissue specific genetic knockout in vivo. An increase of ubiquitinated 
proteins similar to that seen upon genetic proteasomal inhibition in mice may be 
expected, due to reduced proteasomal activity and thus less degradation of 
ubiquitinated substrates. As predicted, overnight treatment of U20S cells with a 
relatively low (1 M) concentration of MG132, followed by capture of 
ubiquitinated proteins with the Znf_A20 domain, resulted in purification of 
increased levels of ubiquitinated proteins relative to untreated cells; (Figure 5. 
1b). Therefore, it appears that this approach is able to detect and amplify gross 
changes in protein ubiquitination. Changes in global ubiquitination have in the 
past been analysed by simply resolving crude (unpurified) samples by SDS PAGE 
and probing with anti-ubiquitin antibodies [174]. Our protocol provides a 
method of pre-fractionating and enriching ubiquitinated material, potentially 
increasing the sensitivity with which changes in protein ubiquitination can be 
detected. 
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5.4. The Znf_A20 domain reveals subtle changes in the profile of 
ubiquitinated proteins in rat EDL muscle after 24 hours of LPS 
infusion  
In sections 5.2 and 5.3, affinity capture of ubiquitinated proteins using 
immobilised Znf_A20 domain confirmed global differences in protein 
ubiquitination between proteasomal knockout mouse brains compared to wild 
type, and in MG132-treated U20S cells relative to untreated cells. Previously, in 
Chapter 3, we used rat extensor digitorum longus (EDL) muscle for mRNA 
expression profiling from lipopolysaccharide (LPS)- or saline-infused animals at a 
24 hour time point. Subsequent to these analyses, we additionally gained access 
(from other investigators in the group) to EDL muscle from rats infused with the 
same concentration LPS or saline for 2 and 6 hours. Procedures were again 
carried out by Julie March and Philip Kemp (the same investigators as 
previously) and were approved by the University of Nottingham Ethical Review 
Committee and were performed under Home Office Project and Personal license 
authority. EDL muscle protein extracts from animals treated for 2, 6 and 24 hours 
with saline or LPS infusion were incubated with Znf_A20-coupled Sepharose, and 
purified ubiquitinated proteins were identified using anti-ubiquitin 
immunoblotting (Fig 5.2). Similarly to earlier observations, we saw an 
enrichment of ubiquitinated proteins bound to Znf_A20 when compared to 
blotting crude muscle lysate alone (Fig 5.3). Notably, we saw a clear increase in a 
species (band 1 in Fig 5.3) migrating at the same level as K48- and K63-linked 
diubiquitin standards (commercial unanchored polyubiquitin chains) after 24 
hours of LPS infusion relative to saline infusion, a change not seen at the earlier 
LPS-infusion time points i.e. 2 and 6 hours only in the Znf_A20 purified samples. 
(Fig 5.2). A further ubiquitin-positive species above the presumed diubiquitin 
(band 2 in Fig 5.3) also appears to show increased levels after 24 hours of LPS 
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Figure 5.2 
       
 
Figure 5.2 Anti-ubiquitin Western blot of Znf_A20 captured proteins from EDL muscle, 
from control rats (C) (infused with saline) or LPS-infused rats (L), after either 2, 6 or 24 
hours of infusion. Samples (approximately 20mg each) were homogenised in 1.5ml 
homogenising buffer, NEM quenched with DTT and bound to 40 l beads, that were then 
washed with wash buffer (as detailed in Fig 5.1). 50% of Znf_A20 captured proteins were 
probed with anti-ubiquitin. (K48)=0.25 g K48-linked polyubiquitin, (K63) =0.25 g K63-
linked polyubiquitin. Arrows labelled 1 and 2 denote ubiquitin positive species that 
increase after 24 hours of LPS infusion. 
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Figure 5.3 
       
 
 
 
Figure 5.3 Anti-ubiquitin Western immunoblotting of EDL muscle homogenate, from 
control rats (C) (infused with saline) or LPS-infused rats (L), after either 2, 6 or 24 hours 
of infusion, that was incubated with Znf_A20 Sepharose in Fig 5.2. (K48)=0.25 g K48-
linked polyubiquitin, (K63) =0.25 g K63-linked polyubiquitin. Represents 1/300th of 
protein loaded on beads in Fig 5.2. 
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infusion. In contrast to these increases in lower molecular weight ubiquitin-
positive species after 24 hours of LPS infusion in EDL, levels of higher molecular 
weight species appear to remain unchanged, indicating that gross changes in 
global ubiquitination do not change in this model. This is in contrast to 
observations of the increased higher molecular weight ubiquitin species that 
accumulated during proteasomal inhibition in U20S cells by MG132. Further to 
this, we probed the Znf_A20-purified fractions with an antibody that specifically 
recognises only K48- linked polyubiquitin (Fig 5.4) [234]. Anti-K48 specific 
antibody specifically recognises commercial K48-linked and not K63-linked 
polyubiquitin chains. This antibody appears to preferentially bind longer 
polyubiquitin chains, as diubiquitin in the commercial chain mixture is not as 
strongly detected by anti-K48-ubiquitin antibodies relative to our pan anti-
ubiquitin antibody which detects all linkages. No clear change in global K48-
linked ubiquitination between the purified samples from LPS-infused compared 
to saline-infused tissue was observed, although K48-linked polyubiquitinated 
proteins were readily detected in our samples. 
 
5.5. Reassessment of the presumed diubiquitin band purified by the 
Znf_A20 domain 
The obvious change in the ubiquitin-reactive band co-migrating with the 
diubiquitin standard, that was elevated in the ubiquitinated fraction purified 
from LPS-infused EDL tissue, drew our attention to its existence. Retrospective 
analysis of previous Figures (Figs 4.7c, 4.8a & 4.15a) demonstrates that it was 
consistently captured by rZNF216/Znf_A20 domain from a diverse range of 
biological samples, including human U20S cells, rat muscle and mouse brain. In 
addition, peptide mass fingerprinting (PMF) analysis of a protein spot resolved  
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Figure 5.4 
       
 
Figure 5.4 Immunoblotting of Znf_A20 captured proteins using anti-K48 (that detects 
only K48-linked polyubiquitin) from EDL muscle, from control rats (C) (infused with 
saline) or LPS-infused rats (L), after either 2, 6 or 24 hours of infusion, as in Fig 5.2. 50% 
of Znf_A20 captured proteins were probed with anti-K48. (K48)=0.25 g K48-linked 
polyubiquitin, (K63) =0.25 g K63-linked polyubiquitin. 
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by two-dimensional gel electrophoresis (2DE), previously purified from rat 
muscle using rZNF216 (Fig 4.9) and presumed to be equivalent to the ubiquitin 
dimer indicated the ubiquitin protein sequence to be present (Section 4.5.3). This 
poses the question of whether this ubiquitin-reactive species does indeed 
represent diubiquitin, or alternatively a small protein that is monoubiquitinated 
and consistently purified on rZNF216/Znf_A20 Sepharose. Having previously 
established that monoubiquitin from commercial ubiquitin chain mixtures and 
monoubiquitin from rat muscle (under our optimised affinity capture conditions) 
does not bind to immobilised rZNF216 or Znf_A20 domain (Fig 4.3 & Fig 4.14a), it 
seemed more likely that the protein represented a ubiquitin dimer. Our 
observations that only Ub2 species and above are efficiently captured by the 
Znf_A20 domain suggests a preference of the domain for polyubiquitin over 
monoubiquitin, which we investigate later using gas phase MS analyses (Chapter 
5.8.3) and structural modelling (Chapter 5.10). Remarkably, we noted that this 
presumed ubiquitin dimer is spared from deubiquitination when Znf_A20-
immobilised rat muscle proteins are treated with USP2, as demonstrated by anti-
ubiquitin immunoblotting in Figure 4.14a (repeated in Figure 5.5a, with a 
corresponding Coomassie stained sample of USP2 treated beads in Figure 5.5b), 
suggesting a non-covalent interaction with the UBD may in fact protect this 
species from deubiquitination. We investigate the rationale behind sparing of the 
ubiquitin dimer during deubiquitination in Section 5.6.6.  
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Figure 5.5 
a)        b) 
       
 
Figure 5.5 a) Anti-ubiquitin Western blot from Figure 4.14 (details of purification in Fig 
4.14) and corresponding b) Coomassie stained gel of lane iii, of deubiquitinated Znf_A20 
captured rat muscle proteins, from 100 l Znf_A20 beads (10-fold more protein loaded 
than equivalent lane iii in part a)). Proteins hiȘ
proteins. (K48)=0.25 g K48-linked polyubiquitin, (L)=Load 1/80th lysate loaded onto 
beads, (B)=beads, (S)=solution. 
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5.6. Unanchored polyubiquitin chains 
 
5.6.1. Physiological significance of unanchored polyubiquitin chains 
Studies into the molecular binding and structure of polyubiquitin are often based 
on the simplest possible model, Ub2 [235-239], as opposed to considering it as a 
valid in vivo species. Polyubiquitin structure varies depending on ubiquitin 
linkage. This is evident in anti-ubiquitin blots of commercially produced K48- and 
K63-linked polyubiquitin. In vitro produced K48 or K63 chains contain practically 
identical molecular weight polyubiquitin chains that vary by only 28Da per 
monomer, as commercial K63-linked polyubiquitin chains are synthesised from 
wild type ubiquitin, but K48-linked chains are synthesised using a ubiquitin K29R 
mutant to prevent polymerisation at this residue. However, despite the negligible 
mass difference, chains longer than Ub2 in K48- or K63-linked chains migrate 
differently, as linkage affects structure and thus migration through the 
polyacrylamide gel. Whilst structures of linear, K48-, K63-, K6- and K11-linked 
Ub2 have been revealed by crystallography/nuclear magnetic resonance (NMR) 
analysis using in vitro synthesised polyubiquitin chains [187, 236, 239, 240], ǲǳ 
ubiquitin dimers or polyubiquitin chains from an in vivo source to date.  
 
Unanchored polyubiquitin chains have become of increasing interest as potential 
regulators of ubiquitin-mediated processes. Free chains synthesised in vitro were 
found to compete with polyubiquitinated substrates for binding to the 
proteasome [68] and accumulation of free chains in cells as a result of 
isopeptidase T (isoT) knockdown inhibited degradation of polyubiquitinated p53 
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by the 26S proteasome [177]. Free chains were additionally proposed to act as a 
source of monoubiquitin, which is depleted by increased polyubiquitination 
under heat stress conditions in S. cerevisiae, regulated by deubiquitinating 
enzyme Doa4 and its inhibitor regulator of free ubiquitin chains 1 (Rfu1) [178]. 
Further to this, recent studies have highlighted a potential role of unanchored 
K63-linked chains in both activating kinases [179] and in signalling during innate 
immunity [180, 181]. Studies have mostly focused on longer unanchored 
polyubiquitin chains, but interestingly a possible role has been identified for Ub2; 
in vitro studies into the deubiquitinating enzyme ubiquitin carboxyl-terminal 
hydrolase isozyme L3 (UCH-L3) revealed its hydrolase activity was reduced in 
the presence of K48-linked Ub2 [241]. Further detail on the physiological 
significance of unanchored chains is provided in Section 5.7.2. Similarly to 
conjugated ubiquitin chains, in which different linkages are associated with 
different biological processes, the roles of unanchored chains also seem to exhibit 
linkage specificity. This highlights the importance of identifying ubiquitin linkage, 
should analysis confirm the spared ubiquitin species to be a ubiquitin dimer. 
 
5.6.2. PMF analysis confirms ubiquitin sequence in the presumed ubiquitin 
dimer purified using Znf_A20 domain  
Previous PMF data confirmed the presence of both monoubiquitin and 
diubiquitin from rat muscle captured on FL rZNF216 Sepharose (Chapter 4). 
However, subsequently revised affinity capture conditions included inhibition of 
endogenous deubiquitinating enzyme (DUB) activity using N-ethylmaleimide 
(NEM), and consequently monoubiquitin was not captured. This suggests that 
monoubiquitin may have previously been liberated post-affinity capture from 
longer polyubiquitin chains by co-purifying catalytically active DUBs. In the 
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absence of polyubiquitin processing by in vivo DUBs, a species co-migrating with 
the ubiquitin dimer of commercial unanchored polyubiquitin chains is still 
captured, as observed by anti-ubiquitin immunoblotting. Interestingly, this 
species resists the deubiquitinating activity of USP2 (Fig 5.5a). Affinity capture 
was performed using the Znf_A20 domain alone, as opposed to FL rZNF216, from 
rat muscle. To confirm the capture of Ub2 on the Znf_A20 domain and identify the 
protein spared from deubiquitination, we excised the corresponding band from a 
Coomassie stained gel of Znf_A20 captured rat muscle proteins treated with USP2 
core (Fig 5.5b). Bound proteins were eluted from beads by the addition of gel 
application buffer and approximately 10 times more sample was loaded for 
Coomassie staining relative to anti-ubiquitin immunoblotting, to account for 
lower sensitivity. The Coomassie-stained gel from which bands were excised and 
analysed by matrix-assisted laser desorption/ionisation (MALDI) PMF (from 
USP2 treated Znf_A20 Sepharose beads) and the corresponding anti-ubiquitin 
Western blot (from Figure 4.14) are shown in Figure 5.5 (b and a, respectively). 
PMF analysis of the band corresponding to the presumed ubiquitin dimer 
confirmed the presence of five peptides corresponding to ubiquitin (referred to 
later, in Figure 5.8c), covering 55% of the ubiquitin sequence. This provides 
strong evidence that the purified protein indeed represents diubiquitin. To 
substantiate PMF results, we analysed the sample using electrospray ionisation 
(ESI)-MS (Fig 5.6) in the absence of tryptic digest to perform intact mass analysis 
with high accuracy. The ubiquitin species was eluted directly from beads using 
formic acid. Purification of a free ubiquitin dimer was confirmed as the intact 
mass was identical to that of an unanchored and unmodified ubiquitin dimer, 
with a monoisotopic mass of 17120Da. 
 
  
Figure 5.6 
 
Figure 5.6 ESI-MS of Ub2 purified from rat skeletal muscle. The observed mass is identical to that of unanchored, unmodified Ub2, with a monoisotopic mass of 
17120Da. 
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5.6.3.  The Znf_A20-purified ubiquitin dimer from skeletal muscle is K48-
linked  
 
 5.6.3.1 Evidence from K48-polyubiquitin specific 
immunoblotting of the ubiquitin dimer 
Evidence of an isopeptide linkage between two ubiquitin proteins would further 
substantiate the purification of an endogenous ubiquitin dimer, as well as 
possibly providing information related to ubiquitin linkage selectivity of the  ? ? ?ȋ	 ? ? ?ǯȌǤWe used an antibody 
that only binds to K48-linked polyubiquitin [234] and anti-ubiquitin (that 
recognises all linkages) to probe rat skeletal muscle proteins bound both to 
untreated Znf_A20 Sepharose and partially deubiquitinated Znf_A20 Sepharose 
(incubated +/- USP2 core for 1 hour rather than the previous 2 hour 
deubiquitination in Figures 4.15 and 5.5) (Fig 5.7). The anti-K48 antibody does 
not detect commercial K63 polyubiquitin chains or monoubiquitin, but does 
detect commercial K48 chains, as expected. Interestingly, the ubiquitin dimer was 
detected weakly by the K48 antibody. The corresponding band was detected in 
both +/- USP2 treated samples, by both antibodies. This provides evidence that 
the ubiquitin dimer that is spared from deubiquitination may be K48-linked. This 
then raises the question of whether other linkage dimers are also spared from 
deubiquitination. The smear of longer polyubiquitinated proteins bound to 
Znf_A20 Sepharose that was not deubiquitinated is both anti-ubiquitin and anti-
K48 positive, as is a ladder that appears in the partially deubiquitinated sample. 
Should this ladder in the partially deubiquitinated sample represent unanchored 
polyubiquitin, then it appears chains of up to 13 ubiquitin moieties in length can 
be detected. The significance of this ladder will be discussed later (Section  
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Figure 5.7 
a)         b) 
 
 
      
Figure 5.7 Limited deubiquitination of Znf_A20 Sepharose-captured ubiquitinated 
proteins reveals a ladder consistent with free polyubiquitin chains. a) Rat muscle 
proteins were captured on Znf_A20 Sepharose, as in Fig 4.14, but instead incubated +/- 
USP2 core for only 1hr at 37oC, and 2-fold more protein loaded . Limited deubiquitination 
revealed a number of ubiquitin bands as opposed to a smear of polyubiquitinated 
proteins, observed using both anti-ubiquitin and anti-K48 linkage specific antibodies. 
(K48)=0.25 g K48-linked polyubiquitin, (K63)=0.25 g K63-linked polyubiquitin. b) 
Diagrammatic representation of free ubiquitin chains from Ub2 to Ub7. 
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5.6.10). It is also notable that the bands that may correspond to free 
polyubiquitin up to Ub5 in length are also detectable in non-deubiquitinated 
beads by both anti-ubiquitin and anti-K48 antibodies. Interestingly, we noted a 
doublet of both anti-ubiquitin and anti-K48 positive bands, one band within the 
doublet comigrating with K48- linked tetraubiquitin, suggesting we may have 
also purified unanchored tetraubiquitin. The other band within the doublet may 
be a ubiquitinated substrate or may possibly be an unanchored polyubiquitin 
chain of mixed linkage (i.e. including, but not exclusively, the K48 linkage). 
Having established that ubiquitin linkage effects chain migration, this variance in 
migration may be due to the presence of different linkages altering the structure 
enough to retard its migration through the polyacrylamide gel. 
 
5.6.3.2. Mass spectrometry analysis confirms the K48 linkage within 
the ubiquitin dimer 
To confirm immunoblotting results that indicate the presence of the K48-linkage 
in the Znf_A20-purified ubiquitin dimer, we reanalysed earlier PMF data. Other 
ubiquitin linkage specific antibodies were not available to us at this time to test 
for other linkages, and so MS analysis provided an unbiased method to identify 
the presence of other linkages and validate immunoblotting data. As discussed 
previously, MALDI PMF analysis involves initial trypsin cleavage of proteins to 
distinctive peptides, as this enzyme cuts proteins specifically at the carboxyl side 
of lysine or arginine residues, with the exception of those followed by a proline 
residue. Polyubiquitin chains typically form via linkage of the C-terminus of one 
ubiquitin to a lysine residue within another ubiquitin. Alternatively ubiquitin can 
link in a linear manner, by condensation of the C-terminal glycine (Gly76) of one 
ubiquitin to the N-terminal methionine (Met1) of another. Ubiquitin isopeptide 
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Figure 5.8 
a)
  
 
 
 
b) 
 
 
 
 
c) 
 
 
    
Figure 5.8 PMF analysis of USP2 spared Ub2 species captured from rat skeletal muscle on 
Znf_A20-Sepharose (Ub2 in Figure 5.5b). a) A diagrammatic representation of the unique 
branched peptide resulting from trypsin cleavage of K48-linked polyubiquitin. b) 
Expected monoisotopic ǲǳmasses from branched peptides liberated by trypsin 
cleavage for different polyubiquitin linkages. c) Results of PMF analysis of the USP2 
spared ubiquitin band. Five ubiquitin peptides were identified, and one of the ǲǳisotopic mass of the branched peptides 
generated by tryptic cleavage of the K48-linkage (as highlighted). 
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linkage can occur at any of 7 lysine residues within ubiquitin. Upon trypsin 
cleavage, isopeptide bonds between ubiquitins are not broken and the lysine 
involved in the linkage is not proteolysed, and so for each type of linkage a ǡǲǳǡ remains (a di-glycine ǲǳǡ different polyubiquitin linkages) (Fig 5.8a). Although the 
MASCOT database contains information linking peptide mass to predicted amino 
acid sequences liberated by trypsin cleavage, it does not contain predicted 
masses for the branched polyubiquitin signature peptides that result from tryptic 
digestion. A table in Figure 5.8b contains calculated monoisotopic masses of 
theoretical branched peptides resulting from cleavage of polyubiquitin of specific 
linkages. The original PMF results of the ubiquitin dimer are in Figure 5.8c, in 
which we saw five peptides that matched ubiquitin and covered 55% of the 
ubiquitin sequence (see Section 5.6.2), but additionally some peptides were ǲǳ. Manual 
analysis of peptide masses that previously identified diubiquitin in the Znf_A20-
purified fraction revealed an unmatched peptide of mass 1460.77 Da. This closely 
matches the calculated size of the branched peptide liberated from trypsin 
cleaved K48-linked polyubiquitin (Fig 5.8b). Molecular masses generated by this 
type of MS are accurate within 0.01%, thus an expected peptide of mass 1460.88 
may be detected +/- 0.14 Da (between 1460.74-1461.02 Da), which places the 
unmatched peptide within range. Interestingly, manual analysis of earlier PMF 
data from 2DE analysis of FL rZNF216 captured proteins reveals the presence of 
an unmatched peptide of 1460.81 Da (not shown) (also within range) in the 
presumed diubiquitin spot that is absent from the monoubiquitin spot (Fig 4.9), 
again supporting that notion that this unmatched peptide represents the K48-
linked signature peptide. The presence of ubiquitin peptides, combined with a 
peptide mass matching that derived from the K48-linkage that was additionally 
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absent from a monoubiquitin sample provides strong evidence that the Znf_A20 
domain binds to a K48-linked dimer. Peptides with masses equivalent to other 
ubiquitin signature peptides were not detected, perhaps indicating that the 
Znf_A20 domain specifically binds K48-linked diubiquitin. However, previously 
rZNF216 was shown to bind equally well to commercial K48 and K63-linked 
polyubiquitin chain mixtures (Fig 4.3) including dimers from the mix. 
Alternatively, it may be that other linkages could bind to Znf_A20 but are not 
present in high enough concentrations in vivo to be detected or may not exist at 
all. Finally, the sensitivity of detection of other ubiquitin linkage signature 
peptides by MALDI MS is not known. To definitively confirm that the unmatched 
peptide identified by PMF was indeed the signature peptide predicted from K48-
ubiquitin linkage tryptic digestion, peptides were fragmented using collision 
induced dissociation (CID) (Fig 5.9) and electron-capture dissociation (ECD) (not 
shown). Peptides were positively ionised and sequenced using MS/MS, 
performed by Lucy Roach. MS/MS confirmed the sequence of the K48-linkage 
signature peptide, and validated accumulating data that we have purified an in 
vivo unmodified (see Section 5.7) K48-linked diubiquitin species from rat muscle. 
 
5.6.3.4. The Znf_A20 domain shows no apparent ubiquitin linkage 
specificity in the gas phase 
Our observations that immobilised Znf_A20 readily precipitates in vitro 
generated K48- and K63-linked polyubiquitin chains including dimers suggests 
the domain has no clear intrinsic binding specificity for (these) polyubiquitin 
linkages (binding to K48 linkages shown in Figure 4.13b, K63 binding not 
shown). Consistent with this proposal, ESI-MS, used to monitor the interaction 
between the Znf_A20 domain and monoubiquitin or diubiquitin (K48- and K63-
  
Figure 5.9 
a)  
 
 
 
b) 
 
 
 
  
Figure 5.9 Evidence for K48-linkage within Ub2 purified from rat skeletal muscle by CID analysis. CID tryptic peptide LIFAGKQLEDGR containing the K48 (gly-gly) 
tag a) MS/MS of [M+3H]3+ at m/z 487.7 b) MS/MS of [M+2H]2+ at m/z 731.0.
180 
  
linked) in the gas phase, indicated almost identical Kdǯ ?ǣ ?ǡ
with no apparent linkage selectivity (performed in collaboration with Neil 
Oldham, not shown).  
  
To further investigate the structural basis of ubiquitin recognition by ZNF216 
and its Znf_A20 domain, we performed a collaborative analysis (Mark Searle, 
School of Chemistry) to investigate how the Znf_A20 domain binds to ubiquitin. 
 
5.6.4. The Znf_A20 domain binds via the acidic D58 interaction surface on 
ubiquitin 
While many proteins are covalently monoubiquitinated or polyubiquitinated, 
there are also proteins (such as ZNF216) that non-covalently bind to ubiquitin via 
one of 3 binding surfaces, which are described according to the key residues 
required for interaction; D58 [139], I44 [140] and GG (at the C-terminus) [141]. 
Point mutations at these key residues interfere with ubiquitin-binding, and 
provide a simple route to determine which ubiquitin binding surfaces receptor 
proteins interact with. Ubiquitin mutants with mutations in these sites (I44A, 
D58A, des-G75-G76) were dot-blotted onto a membrane and incubated with GST-
rZNF216 protein (work by previous lab member James Cavey [217]). Unbound 
protein was removed by washing, and anti-GST used to identify which ubiquitin 
mutants GST-rZNF216 would bind to (Fig 5.10). The double cysteine mutant GST-
rZNF216 did not bind to any ubiquitin proteins, whilst wild type GST-rZNF216 
bound all mutant ubiquitin with the exception of D58A, indicating that rZNF216 
binds ubiquitin at the D58 face of ubiquitin. Interestingly, this corresponds with  
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Figure 5.10 
 
 
Figure 5.10 ZNF216 binds via the D58 binding surface. Wild type ubiquitin and ubiquitin 
mutants I44A, D58A and -G75-G76 were dot-blotted onto a membrane, as observed by 
anti-ubiquitin, and incubated with GST-rZNF216 (wt) or GST-ZNF216 (C30/33A), from 
the equivalent of ~1ml of overexpressed bacterial cultures. Unbound protein was 
removed by washing and bound protein was probed with anti-GST. The double cysteine 
mutant GST-rZNF216 did not bind to any ubiquitin proteins, but wild type GST-rZNF216 
bound all mutant ubiquitin except for D58A. (Work by James Cavey [217]) 
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other reports of Znf_A20 domains binding at the D58 surface, such as zinc finger 
4 (ZnF4) of the A20 protein [139] and the Znf_A20 domain of Rabex-5 [185, 242]. 
 
5.6.5. Structural models of monoubiquitin and diubiquitin binding Znf_A20 
Evidence of rZNF216 binding ubiquitin via its D58 surface and the notion that 
Znf_A20 does not bind with linkage specificity (as shown by ESI-MS, Section 
5.8.3) is supported by structural models of the Znf_A20 domain in complex with 
ubiquitin and diubiquitin; the structure of the Znf_A20-Ub complex was 
experimentally determined in a parallel collaborative project (Fig 5.11). Further 
analysis of this complex showed that Znf_A20 binding does not occlude any of the 
seven lysine residues of ubiquitin involved in isopeptide linkages within 
polyubiquitin chains and binds at the D58 binding surface. Further, close 
inspection of models of Znf_A20 domains in complex with different ubiquitin 
dimers (K48 open and closed conformations, K63, K11, K6 and linear; PDB 
structures 2PE9, 2PEA, 2JF5, 2XEW, 2XK5, 2W9N respectively) generated by 
replacing monoubiquitin units from the published structures of the dimers with 
ubiquitin-Znf_A20 structures, did not indicate additional contacts of a single 
Znf_A20 with the second ubiquitin in the dimers (Fig 5.12) (work done by Tom 
Garner). In each case the D58 surfaces of ubiquitin moieties within the dimers, 
required for recognition by the Znf_A20 domain, were surface exposed. Thus, 
given that our purification strategy using the Znf_A20 domain resulted in the 
isolation of exclusively K48-linked diubiquitin from skeletal muscle, when all ǯ
formation, this suggests that the K48-linked form may be the predominant dimer 
in vivo since other dimers should have been purified were they present.  
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Figure 5.11 
 
 
Figure 5.11 Structural model of the Znf_A20 domain in complex with ubiquitin, which 
binds at the D58 binding surface. (Work by Tom Garner [217]) 
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Figure 5.12 
 
 
 
 
 
 
Figure 5.12 Model of the Znf_A20 in complex with K48-linked diubiquitin in its open (A) 
and closed (B) conformation and with diubiquitin linked through K6 (C) and K11 (D) and 
K63 (E) and to linear diubiquitin (F). Models are based on the complex presented in 
Figure 5.11 and PDB structures 2PE9, 2PEA, 2XK5, 2XEW, 2JF5 and 2W9N. (Work by Tom 
Garner). 
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Inspection of the structures of Znf_A20 domains in complex with the open 
conformation of K48-Ub2 did, however, reveal the possibility of steric clashes 
between the distal ubiquitin of the dimer and the Znf_A20 in complex with the 
proximal ubiquitin, suggesting preferential binding of two Znf_A20 domains to 
the closed conformation. Interestingly, within this closed conformation the I44 
surface of ubiquitin, which is commonly recognised by many other ubiquitin-
binding domains (UBDs)/ubiquitin-binding receptors, is occluded. Indeed pull-
down analyses from skeletal muscle sampǲǳ
(tandem-repeated ubiquitin-binding entities) based on head to tail repeats of 
UBA domains which recognise I44 of ubiquitin Ȃ at an equimolar concentration to 
the Znf_A20 domain - did not result in the purification ubiquitin dimers (Fig 
5.13), as assessed by Western blotting. The lack of diubiquitin binding to TUBEs, 
which did not bind K48-linked diubiquitin, supports that notion that other 
linkages within ubiquitin dimers may not exist (or predominate) in vivo.   
 
5.6.6. Sparing of K48-Ub2 from USP2-mediated deubiquitination 
We next sought to rationalise why the Znf_A20-bound K48-Ub2 was spared from 
processing by the USP2 core enzyme, which has previously been shown to be a 
versatile tool for the in vitro removal of ubiquitin from ubiquitin conjugates 
[243]. As noted earlier, examination of the structural models of K48-Ub2 in 
complex with two Znf_A20 domains (Fig 5.12) showed no evidence of steric 
hindrance of the isopeptide bond within the ubiquitin dimer by either of the 
Znf_A20 domains. Consequently, we predicted that other co-precipitating 
ubiquitin receptors from the muscle sample, which are able to form ternary 
complexes with a single Znf_A20:Ub moiety through other interaction surfaces on 
ubiquitin, may provide the steric block which protects the ubiquitin dimer from  
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Figure 5.13 
 
 
Figure 5.13 Commercial TUBEs fail to purify diubiquitin from skeletal rat muscle (~1.5g) 
that was homogenised in 4ml homogenising buffer and treated identically to that 
described in Figure 4.14, up to and including wash steps. Supernatant was split 4 ways 
and incubated with 20 l TUBEs-, GST-, ZNF216 WT- or Znf_A20-Sepharose overnight at 
4oC. TUBEs (GST-RAD23; 35mg/ml) and GST were bound to glutathione Sepharose while 
ZNF216 WT and Znf_A20 were covalently coupled to CNBr Seph 4B. All were 
bound/coupled to Sepharose at approximately equimolar concentrations. 100% of bound 
protein was loaded. Anti-ubiquitin immunoblotting revealed that no ubiquitinated 
proteins bound GST alone, but did bind to all other Sepharose. (K48)=0.25 g K48-linked 
polyubiquitin, (K63)=0.25 g K63-linked polyubiquitin, (L)=Load 1/400th lysate loaded 
onto beads. 
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deubiquitination. This seems likely as evidenced from the co-precipitation of in 
vivo deubiquitinating enzymes (activities) in the absence of NEM. Consistent with 
this proposal we noted that K48-Ub2 from a commercial polyubiquitin chain 
mixture was not spared from processing by USP2 when bound to the Znf_A20 
domain on beads (Fig 4.6). Additionally, we found it is possible to co-precipitate 
the p62 ubiquitin-receptor with ubiquitinated proteins from cultured cells using 
immobilised wild type rZNF216 protein, but not with the C30/33A mutant (Fig 
5.14) i.e. simultaneous binding of multiple ubiquitin receptors to the same 
ubiquitin or polyubiquitin chain(s) is possible [217]. Equally, it is possible that 
binding of one ubiquitin receptor to a polyubiquitin chain sterically blocks 
another ubiquitin binding protein. Some ubiquitin receptors exhibit linkage 
specificity, as noted in Chapter 4, that may bind non-K48 linked polyubiquitin. 
Thus it is possible that other linkage ubiquitin dimers exist, but are bound by in 
vivo ubiquitin receptors that inhibit that Znf_A20 domain from binding at the D58 
surface, thus preventing capture of other linkage polyubiquitin chains via our 
purification strategy. 
 
 5.6.7. The Znf_UBP domain of isopeptidase T binds the free C-terminus of 
unanchored polyubiquitin 
Identification of K48-Ub2 in our Znf_A20 domain-purified fractions and evidence 
of longer chains present after limited USP2 treatment drew our attention to the 
existence of unanchored polyubiquitin in tissue samples; however, the Znf_A20 
domain binds both unanchored and anchored polyubiquitin, which led us to 
consider an alternative method for selective purification of free chains. To 
determine the complement of unanchored polyubiquitin chains which exist in 
vivo, including ubiquitin dimers, we reasoned that a common property of 
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Figure 5.14 
 
 
 
Figure 5.14 Endogenous p62 co-purifies with ubiquitinated proteins purified from U20S 
cells captured on rZNF216 WT Sepharose, but not on the double cysteine C30/33A 
rZNF216 mutant which does not bind polyubiquitin. U20S cells (~6mg protein) were 
homogenised (in 8ml of 50mM Tris, 150mM NaCl, 0.5% NP-40, 5mM N-ethylmaleimide, 
20 M MG132, 0.1% mammalian protease inhibitor cocktail (Sigma), pH 7.5) and 
centrifuged. DTT added to the supernatant to a final concentration of 10mM, and mixed at 
4oC for 15 minutes. Supernatant split between 50 l of WT or mutant Sepharose and 
incubated overnight at 4oC. Beads were washed three times in wash buffer (50mM Tris, 
150mM NaCl, 0.5% NP-40, 1mM DTT, pH 7.5), and 50% probed with anti-ubiquitin or 
anti-p62. Load= 1/80th protein loaded onto beads. 
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unanchored ubiquitin chains is a free C-terminus. As an alternative route to 
purifying diubiquitin and possibly longer unanchored polyubiquitin chains, we 
cloned a ubiquitin-binding domain (Znf_UBP or BUZ domain) of isoT. IsoT is the 
human homologue of S. cerevisiae deubiquitinating enzyme UBP14, that 
disassembles the majority of unanchored polyubiquitin [134] and the Znf_UBP 
domain is responsible for binding the free C-terminus of ubiquitin but contains 
no intrinsic catalytic activity [141]. Purification and immobilisation of the 
Znf_UBP domain provides a route to the capture of unanchored polyubiquitin 
regardless of its chain linkage, and binding of the previously characterised K48-
Ub2 would further confirm the existence and integrity of this protein. This UBD 
was recently utilised as part of a protein standard absolute quantification (PSAQ) 
method, used to selectively capture and quantify unanchored polyubiquitin 
[176]. We cloned the Znf_UBP domain of human isoT from U20S cDNA (Fig 
5.15a), and inserted it into the pGEX-4T-1 plasmid. GST-tagged protein was 
purified using glutathione-Sepharose and the GST-tag was cleaved with 
thrombin, as previously described for purification of FL rZNF216, the C30/33A 
mutant and the Znf_A20 domain (Fig 5.15b). 
 
5.6.8. Specificity of the Znf_UBP domain for unanchored polyubiquitin 
Purified Znf_UBP domain was coupled to CNBr Seph 4B (at 10mg/ml) and found 
to bind to commercial unanchored K48 or K63-linked polyubiquitin chains, 
whereas control Sepharose did not (Fig 5.16a). Ub5+1 is a ubiquitin polymer 
which contains K48-linked Ub4 with a proximal Ub+1 moiety. This Ub+1 lacks a 
free C-terminus, with Gly76 replaced with 20 residues of nonsense sequence, and 
was originally identified as a frame shift ubiquitin mutant associated with ǯs disease [70]. The Znf_A20 domain binds polyubiquitin via the D58  
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Figure 5.15 
a)            b) 
 
 
 
 
Figure 5.15 Cloning and expression of the Znf_UBP domain of isopeptidase T. a) PCR 
reactions were set up using primers targeted to bases 487-873 of the full length 
isopeptidase T mRNA sequence, +/- U20S cDNA. Samples were resolved by 1% agarose 
gel electrophoresis and stained with ethidium bromide. A band of the correct size (386 
bp) was detected in the + cDNA sample only. * Represents non-specific primer dimers. b) 
Capture and purification of recombinant GST-Znf_UBP expressed in IPTG-induced E. coli, 
captured on glutathione Sepharose beads and thrombin cleaved overnight (Beads +), as 
described in Figure 4.5. The Znf_UBP domain was eluted into solution (Sol), and the GST-
tag remained attached to glutathione Sepharose beads. 
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 Figure 5.16 
a)                b) 
 
 
Figure 5.16 The Znf_UBP domain binds specifically to unanchored polyubiquitin. a) 
Znf_UBP-Sepharose (I) or control-Sepharose (C) was incubated with 0.25 g of K48-linked 
or K63-linked polyubiquitin chains. b) Znf_UBP-Sepharose (I), Znf_A20-Sepharose (A) or 
control-Sepharose (C) was incubated with 0.125 g of Ub5+1. Binding of a) and b) was in 
binding buffer (50mM Tris, 150mM NaCl, 0.5% NP-40, 0.1% bovine serum albumin (BSA) 
(Sigma) 1mM DTT, pH 7.5) for 30 minutes at 4oC. Beads were washed twice in binding 
buffer, bound proteins were eluted with gel application buffer, resolved by SDS PAGE and 
immunoblotted with anti-ubiquitin. Control Sepharose failed to bind any ubiquitin, but ǯ ? only unanchored polyubiquitin and not the Ub5+1 mutant, unlike 	 ? ? ?ǯ ? ? ?Ǥ ? ?Ȁ ? ?ȋȌ ? ? ? ?Ǥ5+1 Load 
(L) represents 50% of the polyubiquitin load. 
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interaction surface and does not require a free C-terminus for binding, thus is 
capable of binding to Ub5+1 (Fig 5.16b). However, the Znf_UBP domain failed to 
bind Ub5+1, consistent with its strong preference for a ubiquitin chain with a free 
C-terminus. 
 
5.6.9. Skeletal muscle diubiquitin binds to the Znf_UBP domain 
To further characterise the diubiquitin species previously purified from skeletal 
muscle, which (based on its intact mass) should have a free C-terminus on the 
proximal ubiquitin, we used immobilised Znf_UBP domain to purify proteins from 
rat skeletal muscle. In parallel, proteins were also purified using the Znf_A20 
domain, at an equimolar concentration. Beads with captured ubiquitinated 
muscle proteins were treated +/-USP2 for 2 hours, as previously, and a sample 
was tested by ubiquitin immunoblotting (Fig 5.17). 
 
Monoubiquitin is present as high concentrations in the cell and has a free C-
terminus. Unlike binding with immobilised Znf_A20 domain, in which multiple 
Znf_A20 proteins interact with multiple ubiquitins within a polyubiquitin chain, 
the Znf_UBP domain binds only at the C-terminus of ubiquitin. Thus not only are 
free (unanchored) dimers and longer polyubiquitin chains captured using the 
Znf_UBP domain, but monoubiquitin is also purified and due to the high 
concentration of the latter, it is omitted from the blot in Figure 5.17. An 
immunoreactive band comigrating with commercial K48- and K63-linked 
diubiquitin was, again, purified from skeletal muscle using the Znf_UBP domain 
and notably this species was again spared from deubiquitination by USP2 (Fig 
5.17). 
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Figure 5.17 
 
 
 
 
Figure 5.17 Znf_UBP-Sepharose bound ubiquitinated proteins co-migrated with 
commercial K48-linked polyubiquitin chains. Znf_UBP- and Znf_A20-Sepharose were 
incubated with rat muscle (~15g), under conditions as described in Figure 4.14, but 
incubated +/- 10 g USP2 core overnight at 37oC. Again, 1/40th of proteins bound to beads 
(B) in the absence (-DUB) and presence (+DUB) of USP2 core, and their respective 
solutions (S) were resolved by SDS PAGE and immunoblotted with anti-ubiquitin. 
Monoubiquitin avidly bound to the Znf_UBP domain, so were omitted from the blot for 
clarity. Both the Znf_A20 and Znf_UBP bound ubiquitin dimer was spared from 
deubiquitination, and unanchored polyubiquitin chains as long as Ub8 were detected 
binding to the Znf_UBP domain. (K48)=0.25 g K48-linked polyubiquitin, (K63)=0.25 g 
K63-linked polyubiquitin. 
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5.6.10. Existence of longer chains of unanchored polyubiquitin in the 
Znf_UBP domain-purified fractions 
Previously, in Section 5.6.3.1, we probed partially USP2-deubiquitinated Znf_A20 
Sepharose with antibodies that detect ubiquitin and the K48-linkage. We noted 
the presence of a ladder containing discrete bands that remained bound to 
Znf_A20 after limited deubiquitination, longer than Ub2, providing evidence that 
polyubiquitin chains up to 13 ubiquitin moieties in length may have been 
captured. Their prominent presence after partial deubiquitination implies that 
they may be protected, possibly by co-purifying ubiquitin receptors (such as p62, 
see Section 5.6.6), or that polyubiquitinated substrates are deubiquitinated by 
USP2 core preferentially. Znf_UBP captured proteins in Figure 5.17 appeared to 
include also the unanchored ubiquitin dimer, captured previously on Znf_A20 
Sepharose, but strikingly also contained polyubiquitin chains of up to eight 
ubiquitin moieties in length (detected with anti-ubiquitin). In contrast to binding 
to the Znf_A20 domain, ubiquitin positive binding proteins in the Znf_UBP 
fraction form a discrete ladder rather than a smear (Fig 5.17). Interestingly, the in 
vivo purified unanchored polyubiquitin chain mixture migrates in what appears 
to be an identical pattern to commercial K48-as opposed to K63-linked 
polyubiquitin chains, which migrate differently for reasons discussed in Section 
5.6.1. We probed the same Znf_UBP-purified fractions with the anti-K48 ubiquitin 
specific antibody, which preferentially bound to epitopes in longer chains, 
revealing for the first time purified endogenous K48-linked unanchored 
polyubiquitin chains containing as many as 15 ubiquitin moieties (Fig 5.18). 
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Figure 5.18 
 
 
 
 
Figure 5.18 Znf_UBP-Sepharose bound K48-linked ubiquitinated proteins that co-
migrated with commercial K48-linked Ub5 and Ub6, and chains as long as Ub15 were 
detected. The same volume of samples that were probed for ubiquitin from Figure 5.17 
was immunoblotted with anti-K48. (K48)=0.25 g K48-linked polyubiquitin, 
(K63)=0.25 g K63-linked polyubiquitin. 
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5.6.11. Increase in unanchored polyubiquitin chains following MG132 
treatment of cultured cells  
Previously, we captured polyubiquitinated proteins from cultured cells using 
Znf_A20 Sepharose, and noted an enrichment of polyubiquitinated substrates 
upon proteasomal inhibition relative to untreated cells (Figure 5.1b). The 
polyubiquitinated material presumably also included unanchored polyubiquitin, 
as the Ub2 species was captured, and this and a number of other lower molecular 
weight ubiquitin species were noted to increase after proteasomal inhibition. To 
confirm the existence of unanchored polyubiquitin chains in cultured cells and to 
ascertain whether unanchored polyubiquitin levels changed under conditions 
where the total polyubiquitin pool is known to alter, human U20S cells were 
treated +/- 1 M MG132 overnight to inhibit proteasomes. Cells were 
homogenised and incubated with Znf_UBP Sepharose, in an identical protocol to 
the MG132 treatment of cells used for Znf_A20 Sepharose binding, and captured 
proteins probed with anti-ubiquitin and anti-K48 (Fig 5.19). Affinity capture with 
the Znf_UBP domain revealed that longer unanchored polyubiquitin chains could 
also be captured from human cells and that levels of Ub2 and longer unanchored 
polyubiquitin chains increased following MG132 treatment, that appeared to 
include the K48-linkage. 
 
5.6.12. Optimisation for purification of unanchored polyubiquitin chains 
Ubiquitin is a small globular protein which has been found to be highly stable 
even when heated. Zeng et al. 2010 were interested in the role of unanchored 
polyubiquitin chains during innate immunity [181]. They found that the 
unanchored chains could not be deubiquitinated by isoT, while protected by 
retinoid-inducible gene 1 (RIG-I) protein. Thus they heated samples for 5 minutes  
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Figure 5.19 
 
 
 
Figure 5.19 +/- MG132 treated U20S cell proteins (cells treated with 1 M MG132 for 16 
hours) bound to Znf_UBP beads. Samples (containing ~4mg protein) were homogenised 
in 4ml homogenising buffer (50mM Tris, 150mM NaCl, 0.5% NP-40, 5mM N-
ethylmaleimide, pH 7.5), centrifuged, and the supernatant collected. DTT was added to 
the lysate to a final concentration of 10mM and mixed at 4oC for 15 minutes. 50% of the 
lysate was passed twice through 80 l Znf_UBP-Sepharose at 4oC. Beads were washed 
three times in wash buffer (50mM Tris, 150mM NaCl, 0.5% NP-40, 1mM DTT, pH 7.5). 
Bound proteins were eluted in gel application buffer; 50% probed with anti-ubiquitin and 
50% with anti-K48. (K48)=0.25 g K48-linked polyubiquitin, (K63)=0.25 g K63-linked 
polyubiquitin, (L)= 1/80th lysate loaded onto beads, (I)=Znf_UBP bound proteins. Arrows 
denote an increase in ubiquitin species presumed to be unanchored chains after MG132 
treatment, from Ub2 and above. Monoubiquitin is omitted from the blot for clarity. 
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at 70oC -80oC, reasoning this would denature RIG-I without affecting the more 
stable unanchored polyubiquitin. We adopted this method and heated muscle to 
denature and precipitate non-ubiquitinated proteins prior to affinity purification, 
reasoning that unanchored polyubiquitin would be heat stable. This not only 
prevents non-specific interactors from binding to the Znf_UBP domain but may 
have an additional advantage; we previously established how in vivo 
deubiquitinating enzymes and other ubiquitin receptors such as p62 can co-
purify along with ubiquitinated proteins. Such proteins may also bind to 
unanchored ubiquitin via the C-terminus and sterically hinder binding to the 
Znf_UBP domain. Thus, we heated muscle protein extracts at 75oC for 20 minutes 
prior to purification and compared heated to non-heated muscle for binding to 
the Znf_UBP domain. Not only can fewer bands (presumed to be non-specific 
interactors and/or ubiquitin receptors) be visualised in purified fractions derived 
from the heat-treated samples by Coomassie staining (Figure 5.20), but 
immunoblotting revealed an intensification of the ladder of unanchored chains 
containing the K48 linkage (Figures 5.21 and 5.22) as long as 15 ubiquitin 
moieties. It is interesting that despite all of the recent literature regarding 
unanchored polyubiquitin chains recognising the involvement of K63-linked 
polyubiquitin chains [179-181], to date we have failed to detect K63-linked 
unanchored polyubiquitin, by MS of the ubiquitin dimer bound to Znf_A20 or by 
immunoblotting of Znf_UBP captured polyubiquitin species with K63-linkage 
specific antibodies (not shown). This offers a highly useful protocol for the future 
purification, and determination in molecular detail, of unanchored polyubiquitin 
from an in vivo source under different physiological and pathological conditions.  
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Figure 5.20 
 
 
 
Figure 5.20 Rat muscle (~20g) was homogenised in 100ml homogenising buffer (50mM 
Tris, 150mM NaCl, 0.5% NP-40, 5mM N-ethylmaleimide, pH 7.5), centrifuged, and the 
supernatant collected. DTT was added to the lysate to a final concentration of 10mM and 
mixed at 4oC for 15 minutes. 50% of the lysate was heated at 75oC for 20 minutes and 
centrifuged. +/- Heated rat muscle supernatant was then passed twice through 400 l 
Znf_UBP-Sepharose at 4oC. Beads were washed three times in wash buffer (50mM Tris, 
150mM NaCl, 0.5% NP-40, 1mM DTT, pH 7.5). Bound proteins were eluted in gel 
application buffer, and ¼ of beads loaded. (K48)=3 g K48-linked polyubiquitin. 
Monoubiquitin (Ȍǲǳȋ ?ȌǤ 
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Figure 5.21 
 
 
 
 
 
Figure 5.21 Anti-ubiquitin Western blot of +/- heated muscle bound to Znf_UBP, under 
conditions described in Figure 5.20. Bound proteins were eluted in gel application buffer, 
and 1/40th loaded. (L) = 1/150th lysate loaded onto beads, (I)=Znf_UBP bound proteins, 
(K48)=0.25 g K48-linked polyubiquitin, (K63)=0.25 g K63-linked polyubiquitin. 
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Figure 5.22 
 
 
 
 
Figure 5.22 Anti-K48 ubiquitin linkage Western blot of +/- heated muscle bound to 
Znf_UBP, under conditions described in Figure 5.20. Bound proteins were eluted in gel 
application buffer and 1/20th loaded. (L) = 1/150th lysate loaded onto beads, (I)=Znf_UBP 
bound proteins, (K48)=0.25 g K48-linked polyubiquitin, (K63)=0.25 g K63-linked 
polyubiquitin. 
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5.7 Discussion 
 
5.7.1. Evidence that the skeletal muscle ubiquitin dimer is an endogenous 
species 
Diubiquitin has been detected in rat muscle, human U20S cells and mouse brain, 
after enrichment of polyubiquitinated proteins using our purification strategy 
with the Znf_A20 domain. Samples were treated with NEM to irreversibly inhibit 
in vivo DUBs, but rat muscle and mouse brain samples cannot be removed and 
frozen for subsequent analysis instantly. Thus the ubiquitin dimer may 
conceivably be produced via endogenous processing post-mortem. However, we 
further purified ubiquitinated proteins from human muscle biopsies from five 
healthy volunteers using the Znf_A20 domain. These samples were snap-frozen in 
liquid nitrogen immediately after removal, and subsequently rapidly 
homogenised in the presence of NEM and protease/proteasome inhibitors 
(Figure 5.23). Despite the relatively small mass of muscle used (10mg of human 
muscle compared to several grams of rat muscle), rapid freezing after sample 
removal and immediate treatment with a number of inhibitors of cellular 
processing, the ubiquitin dimer is still present in human muscle. Human derived 
U20S cells are also instantly lysed into homogenising buffer and, again, the 
ubiquitin dimer is detected. This strongly supports the notion of an endogenous 
diubiquitin species existing in vivo, as opposed to artifactually arising from 
proteolysis during sample preparation and importantly suggests the dimer is 
relevant in a human context. In addition, we noted that upon USP2 treatment 
there is no apparent increase in the dimer, simply it is spared, further supporting 
it to be endogenous rather than a transient intermediate of DUB-catalysed 
polyubiquitin processing. Thus we can assume that conjugated polyubiquitin was  
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 Figure 5.23 
 
 
Figure 5.23 Ubiquitin dimer can be detected in human muscle, captured on Znf_A20 
Sepharose. Human muscle biopsy samples (~10mg each), taken from 5 healthy 
volunteers, were homogenised in 1ml homogenising buffer (50mM Tris, 150mM NaCl, 
0.5% NP-40, 5mM N-ethylmaleimide, 20 M MG132, 0.1% mammalian protease inhibitor 
cocktail (Sigma), pH 7.5). Homogenate was centrifuged and DTT added to the supernatant 
to a final concentration of 10mM, and mixed at 4oC for 15 minutes. Supernatant was 
incubated with 50 l Znf_A20-Sepharose for 1 hour at 4oC. Beads were washed three 
times in wash buffer (50mM Tris, 150mM NaCl, 0.5% NP-40, 1mM DTT, pH 7.5) and 
100% bound proteins eluted with gel application buffer and immunoblotted with anti-
ubiquitin. (K48)=0.25 g K48-linked polyubiquitin, (K63)=0.25 g K63-linked 
polyubiquitin. 
204 
  
processed straight to free monoubiquitin by USP2. Importantly, Ub2 has not only 
been detected in rat EDL muscle, but also increases after 24 hours of LPS infusion 
relative to saline control rats, connecting diubiquitin to a disease state and 
further validating it as an in vivo species. 
 
5.7.2. Proposed biological roles of unanchored polyubiquitin 
Ubiquitin has traditionally been considered for its role in modifying other 
proteins post-translationally. However, previous in vitro experiments as far back 
as 1997 supported a potential role for unanchored polyubiquitin chains as a 
regulator of proteolysis, in which free K48-linked chains synthesised in vitro 
were found to compete with polyubiquitinated substrates for binding to the 
proteasome [68]. Proteasomal binding affinity of unanchored polyubiquitin 
chains of eight ubiquitins in length was 90-fold higher than that of diubiquitin, 
indicative that longer chains may compete more effectively with 
polyubiquitinated substrates for binding to the proteasome and may reduce 
protein degradation rates. Interestingly, recent studies have identified the 
presence of an unstructured region within proteasome targeted substrates that ǲǳ [126]. Should this 
region be too close to or far from the proteasomal tag (i.e. polyubiquitin chain), 
the substrates degradation is inhibited. Therefore proteasomal regulation and 
degradation is more complex than originally considered and competition 
between unanchored and conjugated species may not be straight forward. 
However, accumulated unanchored polyubiquitin chains, produced in a cellular 
context upon isoT suppression in mammalian cells [177], have been shown to act 
as competitive inhibitors of degradation of ubiquitinated p53 by the 26S 
proteasome. This mammalian model validates earlier studies in yeast, where 
205 
  
deletion of the UBP14 gene, a functional homolog of isoT, results in accumulation 
of unanchored polyubiquitin that inhibits ubiquitin dependent proteolysis [134]. 
Additionally free chains have been demonstrated to have other biological roles in 
vivo, activating ubiquitin-dependent kinases I- B kinase (IKK) and transforming ȾȂactivated kinase 1 (TAK1) (the latter via unanchored 
polyubiquitin binding to the accessory protein TAB2) [179]. Interestingly, TNF-
receptor associated factor 6 (TRAF6), an E3 ubiquitin ligase essential for NF- B 
activation, produced unanchored K63-linked polyubiquitin chains in an in vitro 
reconstituted system that subsequently activated TAK1. Additionally, alternative 
linkages to K48- and K63-isopeptide linked unanchored polyubiquitin chains 
were implicated in activating the IKK complex. More recently the same group 
noted a further role for unanchored K63-linked polyubiquitin in signalling during 
innate immunity via binding to RIG-I at its caspase activation and recruitment 
domains (CARD) domains and resulting activation of the IRF3 signalling cascade 
[181]. These studies identified unanchored polyubiquitin indirectly, the former 
by the use of deubiquitinating enzymes, that specifically disassemble free chains 
(isoT) [179] and the latter by the ability of co-precipitated ubiquitin chains to 
form thiolester intermediates with the E1 ubiquitin-activating enzyme [181]. 
Zeng et al. 2010 provided evidence that CYLD could deubiquitinate RIG-I-
activating polyubiquitin chains (a DUB that specifically cleaves K63-linked 
polyubiquitin chains). In combination with data that these polyubiquitin chains 
could be detected by K63-specific antibodies, this confirmed that RIG-I-activating 
polyubiquitin chains were K63-linked. This paper approximated that as many as 
6000 molecules of K63-linked free Ub6 chains may exist in human cells under 
non-stimulated conditions, and yet reported that RIG-I signalling may be 
activated with a EC50 of as little as 50pM (equivalent to only 15 chains per cell), 
implicating them as potent regulators of RIG-I. Studies into a tripartite motif 
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containing 5 (TRIM5)-mediated innate immunity signalling pathway has recently 
provided further evidence supporting the role of unanchored K63-linked chains 
in TAK1 activation [180]. In vitro polyubiquitin conjugation mediated by E3 
ubiquitin ligase TRIM5 produced unanchored chains that were detected by K63-
linkage specific immunoblotting. MS/MS analysis of tryptic peptides detected the 
K63-linkage and the absence of alternative linkage signature peptides or peptides 
corresponding to TRIM5. These free chains activated TAK1 and downstream AP-
1 and NF- B signalling pathways. Notably, we have failed to detect K63-linked 
unanchored polyubiquitin by immunoblotting or MS of the Znf_A20 ubiquitin 
dimer from skeletal muscle. However, it is unclear whether this is a MS sensitivity ǡǲǳǡ
immunity signalling or IL-1  stimulation, there may be an increase in K63-linked 
unanchored polyubiquitin chains within a detectable range. 
 
The importance of a free C-terminal di-glycine of ubiquitin was revealed by the ǯǡ
polyubiquitin chains and results in proteasomal inhibition [69]. The severe 
consequences of ubiquitin gene knockout studies have highlighted that 
maintaining sufficient levels of free ubiquitin is essential; Ubb knockout inhibits 
meiotic progression, inducing infertility [244] as well as neurodegeneration 
[244], while Ubc deletion results in embryonic lethality [245]. Levels of free 
unanchored chains are reduced under heat stress conditions in S. cerevisiae, 
mediated in part by deubiquitinating enzyme Doa4 and its inhibitor Rfu1 [178]. 
Free chains were proposed to act as a source of monoubiquitin, which is depleted 
by increased polyubiquitination under heat stress conditions. Short unanchored 
chains accumulated when Rfu1 was overexpressed, which presumably spared 
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free chains from Doa4 mediated deubiquitination, whereas Rfu1 deletion 
prevented Doa4 inhibition, simultaneously increasing monoubiquitin levels and 
depleting unanchored chains. The authors noted that this correlated with a 
potential role of unanchored chains as a ubiquitin reservoir, perhaps parallel to 
the intracellular system that permits storage of glucose as glycogen [178]. Our 
optimised strategy for capturing specifically free chains was to exploit the 
Znf_UBP domain of isoT, which contains no intrinsic catalytic activity, but binds 
with high affinity to the C-terminal di-glycine of unanchored polyubiquitin [141]. 
The existence of enzymes such as isoT and Rfu1 that regulate existing 
unanchored polyubiquitin species, together with evidence of the ubiquitin 
conjugating enzyme E225K regulating synthesis of unanchored polyubiquitin 
chains [246] supports the notion that free chains have a biological role and 
require regulation. Observations of unanchored chains regulating kinase 
activation, innate immunity signalling, proteasomal inhibition and monoubiquitin 
levels provides convincing evidence of free polyubiquitin regulating a wide 
variety of processes. 
 
5.7.3. Biological role of shorter unanchored polyubiquitin 
Our MS analysis of the Znf_A20 captured Ub2 has exclusively detected K48-linked 
diubiquitin. Studies into the biological relevance of shorter diubiquitin chains is 
somewhat more limited, as in vitro observations note that K48-linked Ub2 was a 
considerably weaker inhibitor of the proteasome, relative to longer chains (see 
previous Section 5.7.2). However, Ub2 has been detected in other studies in 
mammalian cells [241] and wheat germ; the latter was confirmed to contain the 
K48-linkage by Edman degradation [247]. It is interesting to note that our data 
corresponds with previous observations of an endogenous K48-linked ubiquitin 
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dimer [247], which was suggested to provide a pre-formed short ubiquitin chain, 
that was observed to successfully conjugate to other target proteins in vitro. A 
K48-linked ubiquitin dimer was also specifically reported to reduce the 
hydrolase activity of the deubiquitinating enzyme UCH-L3 in vitro [241]. 
Although it is improbable that the purified ubiquitin dimer resulted from 
processing during sample preparation, this does not exclude the possibility of its 
formation during endogenous deubiquitination of longer free chains in a 
physiologically relevant context, as Ub2 is detected during deubiquitination with 
a wide variety of DUBs [187].  
 
5.7.4. Characterisation of unanchored polyubiquitin chains purified via the 
Znf_UBP domain 
Results of anti-ubiquitin immunoblotting of longer chains from skeletal muscle 
and U20S cells bound to Znf_UBP hint that these may be K48-linked, as evidenced 
by their co-migration with the commercially produced K48-linked polyubiquitin 
chains, and further supported by detection with anti-K48 antibody. As discussed 
previously, K48- and K63-linked ubiquitin dimers co-migrate, unlike longer 
chains, thus migration of the Znf_UBP bound dimer provides no information on 
possible linkage. Interestingly, the anti-K48 antibody does not even weakly 
detect this dimer. However, currently we lack detailed MS analysis of the Znf_UBP 
captured Ub2 and longer chains, which is required to identify the linkage of 
purified dimers bound to Znf_UBP and validate anti-K48 immunoblotting 
evidence of longer K48-linked chains. MS can be used to investigate whether 
alternative linkages, other than K48, of longer free chains can be detected via MS 
techniques, including K63-linked unanchored chains, of which there is mounting 
evidence of a role during innate immunity signalling. It is notable that 
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unanchored chain levels increase during the innate immunity response [180, 
181] and upon Il1  treatment [179]. Future Znf_UBP purification of free chains 
from stimulated cells may provide a previously undetectable source of 
unanchored K63-linked polyubiquitin and other linkages. A similar Znf_UBP 
domain affinity capture approach has been recently applied to different biological 
samples and captured unanchored polyubiquitin, but was not optimised for bulk 
capture and only detected low levels of free polyubiquitin chains [176]. However, 
unanchored polyubiquitin chains are yet to be comprehensively characterised by 
linkage types and chain lengths.  
 
5.7.5. Stability of unanchored polyubiquitin chains 
Although we have yet to purify ubiquitin proteins from signalling-stimulated 
cells, we have captured polyubiquitinated proteins from MG132-mediated 
proteasome-inhibited cells. We observed increased polyubiquitinated proteins 
binding to both the Znf_A20 (Figure 5.1b) and Znf_UBP domain (Figure 5.19). The 
increased ubiquitin smear of proteins bound to the Znf_A20 domain are 
unprocessed polyubiquitinated proteins that have accumulated as a result of 
proteasome inhibition. Interestingly, proteasomal inhibition also resulted in 
accumulation of unanchored polyubiquitin, revealed by binding to the Znf_UBP 
domain. Recent studies has identified two distinct deubiquitinating activities 
associated with the proteasome, acting to either amputate chains whole (RPN11) 
or to progressively cleave polyubiquitin from the distal end (UCH37 and USP14) 
[122, 248]. Studies have previously detected coupling of proteasomal 
degradation with deubiquitination [249], and correspondingly Zhang et al. 2011 
noted that inhibition of the proteasome not only blocks degradation, but also 
deubiquitination [122]. Since DUB activities are still active during proteasomal 
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inhibition, and given that these processes are not independent of each other, it is 
possible that MG132 treatment forces irregular deubiquitination. The 
accumulation of free chains implicates possible blocking of the ubiquitin chain 
trimming activities, which are believed to remove lingering unanchored chains 
bound to the proteasome, that may otherwise compete with polyubiquitinated 
substrates for binding. 
 
5.7.6. Predominance of K48-linked unanchored polyubiquitin 
Whilst there are no studies to date that have exclusively analysed the abundance 
of different linkage ubiquitin dimers, studies have looked into the abundance of 
different linkage polyubiquitin chains [176]. Kaiser et al. 2011 assessed the 
composition of various cell and tissue samples for K48, K63 and K11-linkages, 
but excluded other linkages from their analysis which altogether comprised less 
than 1% of their samples. However, other studies have detected the less ǲǳ[155] and 
mouse brains [174]. Therefore it is interesting to consider the presence of what 
appears to be exclusively K48-linked polyubiquitin using our purification 
strategy, considering the apparent abundance of other linkages. Observations of 
increased unanchored K63-linked polyubiquitin have been made under rapid 
signalling events. This may account for not observing free chains co-migrating 
with K63-linked commercial chains, as our primary source of tissue is from 
muscle under basal conditions. Whilst unanchored K63 chains are associated 
with a rapid/acute physiological events, K48-linked chains (whether considered 
anchored/unanchored) are mostly associated with chronic events, such as 
proteasomal degradation. Multiple roles have been suggested for unanchored 
K48-linked chains, the longer chains associated with competition for proteasomal 
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binding, as rapid sources of free ubiquitin, or as pre-ǲǳ
rapid polyubiquitination of targets. What is of particular interest, is that we have 
captured polyubiquitin up to 15 monomers in length, according to 
immunoblotting with anti-K48. To date, the function of polyubiquitin chains in 
binding to the proteasome has been observed to increase with chain length. 
However, no increased binding is detected for polyubiquitin chains of longer than 
8 monomers, which raises the question of why free chains of 15 monomers in 
length are detected in rat muscle. Even if unanchored polyubiquitin chains prove ǲǳǡ-product of proteasomal degradation, 
purification and analysis of unanchored polyubiquitin may give us an insight into 
the topology, composition and length of chains that were previously conjugated, 
and improve our understanding of the regulators of the unanchored 
polyubiquitin pool. Analysis of free chains may even provide information on 
previously unknown biological roles of unanchored polyubiquitin, which is 
supported by mounting evidence of functions from regulating deubiquitinating 
activity to signalling during the innate immune response. 
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CHAPTER 6 
General discussion 
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6.1. Summary 
Our initial interest in zinc finger protein 216 (ZNF216) was attributable to its 
involvement in the skeletal muscle atrophy programme [56]. In Chapter 3 we 
measured increased ZNF216 mRNA expression under septic conditions in rats 
(continuous lipopolysaccharide (LPS) infusion), which mirrored muscle atrophy 
F-box protein (MAFbx) and muscle RING-finger 1 (MuRF1) responses in the same 
model and was consistent with ZNF216 expression changes observed in other 
models of muscle atrophy (induced via denervation and starvation [56]). A low 
dose of dexamethasone (Dex) infused simultaneously with LPS spared muscle 
from the LPS-induced atrophy response. However, LPS-induced elevated ZNF216 
mRNA levels were not blunted by Dex, mirroring another groups observations 
that MAFbx and MuRF1 expression also remained elevated in the same Dex+LPS 
model, relative to LPS alone [208]. A statin model of myopathy, in which severe 
muscle damage and atrophy occurs, also significantly elevated ZNF216 mRNA 
levels further, mimicking MAFbx and MuRF1 increased responses relative to less 
severe models [209]. In Chapter 4, we verified that recombinant ZNF216 protein 
was functional in its ability to bind polyubiquitin chains. Subsequently, using an 
affinity capture method, we purified polyubiquitinated proteins from rat skeletal 
muscle using recombinant ZNF216 or its N-terminal ubiquitin-binding Znf_A20 
domain and committed purified material to proteomic analysis, in an attempt to 
identify ZNF216ǯǤǡlimitations of the liquid 
chromatography tandem mass spectrometry (LC-MS/MS) approach, which only 
calculated ion scores below the significance threshold, combined with a lack of 
validation via immunoblotting, prompted us to apply affinity capture to looking 
more generally at global changes in ubiquitination, detailed in Chapter 5. The role 
of unanchored polyubiquitin is a question increasing in interest in the scientific 
community with the revelation that unanchored K63-linked polyubiquitin has a 
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role in activating protein kinases tȾȂactivated kinase 
1 (TAK1) and I- B kinase (IKK) [179] and may have a role in signalling during 
innate immunity [180, 181]. Unexpectedly, we detected a ubiquitin dimer from 
skeletal muscle, mouse brain and human U20S cells, consistently binding 
immobilised ZNF216 and/or the Znf_A20 domain. Ubiquitin dimers have not 
previously been characterised as biologically active species in vivo. However, our 
observations that levels of this presumed ubiquitin dimer are elevated in skeletal 
muscle after 24 hours of LPS infusion (Figure 5.2) suggest it may have a 
physiological relevance. In Section 6.4, we speculate about possible novel roles 
for ZNF216 and unanchored polyubiquitin during muscle atrophy. 
 
6.2. The Znf_A20 domain does not bind monoubiquitin in pulldowns 
and shows no linkage specificity 
Preferential binding of the Znf_A20 domain to polyubiquitin over monoubiquitin 
has been previously attributed (in the previous chapter) to avidity effects 
(Figures 4.2c and 4.11). Some ubiquitin binding proteins bind polyubiquitin but 
not monoubiquitin for alternative reasons, which may confer polyubiquitin 
linkage specificity. For example, proteins that bind to specific ubiquitin linkages 
preferentially to monoubiquitin/other linkages may be because the ubiquitin 
binding domain is incomplete; for example TAB2/TAB3 specifically binds to K63-
linked ubiquitin, but does not bind to the K63-isopeptide linkage directly. 
Instead, there is simultaneous binding to the proximal and distal ubiquitin within 
a K63-linked chain, but the affinity of a single binding domain within TAB2/TAB3 
is not high enough alone to bind to monoubiquitin [237]. Our Znf_A20 captured 
ubiquitin dimer has been shown to be exclusively K48-linked, which may 
implicate linkage specific binding. However, our structural studies do not support 
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a model where a single Znf_A20 can form any additional contacts with polymeric 
ubiquitin to provide linkage specificity (see Figure 5.11), and MS analyses in the 
gas phase did not detect preferential binding to the ubiquitin dimer over the 
monomer, nor between K48- and K63 ubiquitin dimers (Chapter 5.8.3). Together, 
these observations strongly indicate that the purification of the K48-linked dimer 
is reflective of its predominance in vivo as opposed to Znf_A20 specificity and 
binding is likely achieved by two separate domains each interacting 
independently with a single ubiquitin moiety in the dimer, producing a higher 
affinity interaction than that of the Znf_A20 to monoubiquitin (~8uM), which is 
presumably below the limits of what can be detected in the pull-down. Notably, 
ZNF216 is reported to be dimeric [196] suggesting a mechanism by which Ub2 
binding could potentially be achieved in vivo, although related studies from our 
own group found no evidence for ZNF216 dimerisation (Tom Garner; personal 
communication).  
 
6.3. Sparing of diubiquitin during USP2 deubiquitination 
Our observation that diubiquitin is spared from ubiquitin carboxyl-terminal 
hydrolase 2 (USP2)-mediated deubiquitination (of which only the catalytic core is 
used to remove USP2-specificity) occurred regardless of whether it bound to the 
Znf_A20 or the Znf_UBP domain, which bind at the D58 surface and C-terminal di-
glycine, respectively. We have previously established that the Znf_A20 domain 
was unable to spare commercial diubiquitin from USP2 treatment (Figure 4.6), 
implicating it is spared through an alternative mechanism than steric hindrance. 
The ability to co-precipitate p62 upon purification of polyubiquitin (Figure 5.14) 
supports a hypothesis in which an unidentified binding protein(s) is/are co-
purified during capture on both the Znf_A20 domain and the Znf_UBP domain 
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that blocks USP2 core access, although the lack of protection of longer 
polyubiquitin species implies that it is the simultaneously binding of the 
Znf_A20/Znf_UBP with this unidentified co-precipitating protein that confers 
protection.  
  
6.4. Possible novel roles of ZNF216 and unanchored polyubiquitin 
chains during skeletal muscle atrophy 
Polyubiquitination is generally assumed to occur by the addition of a single 
ubiquitin at a time to a substrate by an E3 ubiquitin ligase. However, there is 
evidence that polyubiquitin chains may be preformed and the chain attached en 
bloc to a target protein. This is demonstrated by mouse E2 enzyme Ube2g2 which 
can form K48-linked polyubiquitin in the absence of a substrate [146]. This may 
provide a rapid method of polyubiquitination, in which the benefit of diubiquitin 
may be that it is short enough to not inhibit the proteasome but is longer than 
monoubiquitin to accelerate polyubiquitination of substrates. A K48-linked 
ubiquitin dimer was purified on immobilised ZNF216 or its Znf_A20 domain, 
which was spared from USP2 core mediated ubiquitination. In our LPS-induced 
atrophy model, in which there is notable upregulation of the UPS and hence 
increased polyubiquitination, we observed both an increase in a Znf_A20 
captured ubiquitin dimer after 24 hours (Figure 5.2) and upregulated ZNF216 
mRNA levels (Figure 3.4). We speculate that dimeric ZNF216 (as evidenced by 
Huang et al. 2004 [196]) may bind to diubiquitin in vivo, that is simultaneously 
bound to E2 enzymes (that according to Li et al. 2007 are likely to be dimers to 
facilitate ubiquitin transfer [146]) and sterically hinders deubiquitination of the 
preformed polyubiquitin chains to aid polyubiquitination without having a direct 
role in the process (Figure 6.1). ZNF216 may remain associated with
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Figure 6.1 
a) 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
Figure 6.1 Model of ZNF216 binding to E2 enzyme-associated diubiquitin, in which a) 
ZNF216 may dimerise and bind diubiquitin, sterically hindering access of 
deubiquitinating enzymes (DUBs) that may otherwise cleave polyubiquitin chains, as 
demonstrated in b). Note that E2 enzymes are modelled as a dimer, which has been 
suggested to assist the formation of preformed polyubiquitin chains for en bloc 
polyubiquitination of substrates; ZNF216 binding would promote this model of substrate 
polyubiquitination. 
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polyubiquitin after the formation of longer chains, and then shuttle 
polyubiquitinated proteins to the proteasome, perhaps having a role in 
preventing deubiquitination of substrate-attached polyubiquitin chains. It is 
interesting to consider studies of the deubiquitinating enzyme ubiquitin 
carboxyl-terminal hydrolase isozyme L3 (UCH-L3) in light of our connection of 
diubiquitin to LPS-induced atrophy. Setsuie et al. 2009 observed that UCH- ?ǯ
deubiquitinating activity was impaired in the presence of K48-linked diubiquitin 
[241]. The same group published evidence that UCH-L3 had a role indirectly 
phosphorylating the transcription factor forkhead box, class O 1 (FOXO1) [250]. 
Phosphorylation of FOXO1 retains it within the cytosol, and prevents FOXO1 
dependent transcription. This is particularly interesting, in light of various 
studies that have observed LPS-induced upregulation of FOXO1, and its 
subsequent transcriptional activation of key proteins required for muscle 
atrophy. Our observation that diubiquitin is increased after 24 hours of LPS 
infusion suggests a potential mechanism of positive feedback during muscle 
wasting, demonstrated in Figure 6.2. 
 
6.5. Final conclusions and future work 
ZNF216 expression increased after 24 hours of LPS-infusion in a sepsis model of 
atrophy in rats, supporting previous evidence that denervation- and  fasting- 
induced atrophy upregulated ZNF216 expression [56]Ǥ	 ? ? ?ǯ
to bind polyubiquitinated proteins did not permit identification of elusive 
atrophy substrates, affinity capture has highlighted the presence of a K48-linked 
ubiquitin dimer, increased expression in extensor digitorum longus (EDL) muscle 
under LPS-induced atrophy conditions in rats at the 24 hour time point. These 
results, together with mounting evidence of the importance and abundance of 
 Figure 6.2 
 
 
 
 
 
 
 
 
Figure 6.2 Model of positive feedback during LPS-induced atrophy. Deubiquitinating enzyme UCH-L3 deconjugates polyubiquitinated proteins. It also indirectly 
leads to phosphorylation, and thus cellular retention, of transcription factor FOXO1. LPS induces FOXO1 dephosphorylation and subsequent activation, resulting in 
atrogene transcription and onset of atrophy. A K48-linked ubiquitin dimer has been shown to inhibit the deubiquitinating activity of UCH-L3 in vitro, and thus may 
impair FOXO1 inactivation. K48-linked ubiquitin dimer levels appear to increase after 24 hours of LPS infusion, that may induce positive feedback by reducing UCH-
L3 mediated FOXO1 inhibition, and inducing further atrophy symptoms and further ubiquitin dimers.
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unanchored polyubiquitin chains in recent literature, advocates the need for 
further research into the role of unanchored polyubiquitin. Our optimised affinity 
capture method affords the opportunity to enrich unanchored polyubiquitin and 
characterise it using MS techniques. Unanchored polyubiquitin affinity capture 
can be applied to different physiological conditions to identify changes in the 
unanchored polyubiquitin pool. ZNF216 knockout (KO) mice has been previously 
associated with accumulation of polyubiquitinated proteins under denervation-
induced atrophy relative to wild type [56]. Future experiments of interest include 
generating a ZNF216 KO model and comparing unanchored polyubiquitin levels 
between atrophying wild type and ZNF216 KO samples, or inducing unanchored 
polyubiquitin via interleukin-1 beta (IL-1  stimulation of cells, as indirectly 
noted by Xia et al. 2009 [179], for purification and subsequent MS analysis.  
 
Our method for purifying unanchored polyubiquitin is timely, considering 
growing interest in this field, and provides an opportunity to investigate this 
novel area and discover previously unidentified physiological conditions and 
diseases associated with free polyubiquitin chains. 
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 Appendix I 
Category Primer name ͷǯ-͵ǯ Sequence 
Taqman® primers AWP1 forward primer AAGACCTGCAAGGACCCAGA 
and probe AWP1 reverse primer GAGACTTGCTTTGCTCTTCAGATG 
 AWP1 mRNA MGB probe CCTTGTTCCTCTTGAATGTGATCCTCCATCT 
Site-directed mutagenesis  ZNF216 C30A_C33A sense GGAATCCTAGGACAAATGGAATGGCTTCTGTTGCCTACAAAGAACATCTTCAGAGAC 
primers ZNF216 C30A_C33A antisense GTCTCTGAAGATGTTCTTTGTAGGCAACAGAAGCCATTCCATTTGTCCTAGGATTCC 
 ZNF216 (1-60) sense (Znf_A20) GTTCCAACAGTCCTACCTAAGACTCTGCGTCTGTA 
 ZNF216 (1-60) antisense (Znf_A20) TACAGACGCAGAGTCTTAGGTAGGACTGTTGGAAC 
Znf_UBP primers Znf_UBP forward primer ACAGGATCCAAGCAGGAGGTGCAGGCATG 
 Znf_UBP reverse primer GCTCGAGTTACTTGTCTGTCTTCTGCATCTTCAGC 
 
 Appendix II 
Antibody Wash buffer Blocking buffer/conditions Antibody conditions 2o Antibody conditions1 
Ubiquitin2 
(in house) 
TBS3 
4% Marvel, TBS 
RT4, 1hr 
1o anti-ubiquitin 
1/1000, RT, 1 hr 
2o anti-rabbit 
1/2000, RT, 1 hr 
Lys48 (K48) 
(Millipore) 
TBS-0.05% 
Tween 
5% Marvel, TBS-0.05% Tween 
RT, 1hr 
1o anti-K48 
1/1000, 4oC, overnight 
2o anti-rabbit 
1/2000, RT, 1 hr 
GST 
(Bethyl) 
TBS-0.05% 
Tween 
5% Marvel, TBS-0.05% Tween 
RT, 1hr 
HRP5-conjugated anti-GST 
1/1000, RT, 1 hr 
N/A 
p62 
lck ligand (BD 
Biosciences) 
TBS 
5% Marvel, TBS 
RT, 1hr 
1o anti-p62 
1/5000, RT, 1 hr 
2o anti-mouse 
1/2000, RT, 1 hr 
Adenylate Kinase 1 
(Genetex) 
TBS 5% Marvel, RT, 1hr 
1o anti-adenylate kinase I 
1/1000, RT, 1 hr 
2o anti-mouse 
1/2000, RT, 1 hr 
Note: All blots are blocked, incubated with antibody (1o or HRP-conjugated), washed 3 x 5 min in wash buffer, incubated with 2o antibody where relevant, washed 3 
x 5 min in wash buffer and then developed. 
 
1 2o Antibodies sourced from Dako 
2 Blots probed with anti-ubiquitin are first autoclaved prior to blocking, to enhance the immunoreactivity of ubiquitin 
3 Tris buffered saline 
4 Room temperature 
5 Horseradish peroxidase 
